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1.1 Pluripotent Stem Cell-derived Cardiomyocytes: Opportunities and 
Translational Applications.
The derivation of human embryonic stem cells (hESCs) (1998)[1] and ground-breaking 
discovery of human induced pluripotent stem cells (hiPSCs) (2007)[2] initiated an era with 
exciting opportunities for the development of cell-based therapies, disease models and 
in vitro drug discovery and toxicity screening. In addition, human pluripotent stem cells 
(hPSCs) offer advantages over conventional methods for studying human biological and 
developmental processes. HESCs are derived from the inner cell mass of blastocyst stage 
embryos and proliferate indefinitely in vitro, while maintaining their undifferentiated 
state when cultured under appropriate conditions. hiPSCs have a similar indefinite growth 
capacity, but are of less ethical concern as they can be derived through the reprogramming 
of a variety of human somatic cells, such as skin fibroblasts, blood cells, teeth, or even 
epithelial cells from urine samples[3-5]. Both hESCs and hiPSCs are hPSCs and have the 
potential to differentiate into derivatives of all three primary germ layers: ectoderm, 
endoderm, and mesoderm [6, 7]. The heart, skeletal muscle, mesenteries, kidney, ovary, 
and testis are mostly derived from mesoderm so that deriving these cell types requires first 
that mesoderm is formed (Fig. 1). The ability to differentiate hPSCs in vitro to any cell-type 
of the human body, including cardiomyocytes, prompted researchers to investigate new 
translational opportunities, such as cellular therapy of the damaged heart (Fig. 2)[8].
Cellular Therapy
Ischemic heart disease is one of the leading causes of death worldwide and is increasing due 
to population ageing[9]. Because postnatal cardiomyocytes have little or no regenerative 
capacity[10], the adult heart is unable to restore the large numbers of cardiomyocytes lost 
after infarct, resulting in adaptation mechanisms, such as scar formation and cardiomyocyte 
hypertrophy, followed by decrease in cardiac function. This was the basis of the initial interest 
in deriving cardiomyocytes from hESCs. However, many obstacles have been encountered 
during transplantation of hPSC cardiomyocytes in both rodents and primates[8, 11]. These 
challenges included the method of cell delivery, the cell type to be injected, the risk of 
arrhythmias induced by engrafted beating cardiomyocytes, electrical coupling between 
donor and host cells, immune rejection, poor donor cell survival and the large number of 
cells required for complete cell replacement. These challenges contributed to failure to 
achieve long-term cardiac functional improvements[8, 12]. 
Drug Discovery and Development
An alternative opportunity that emerged is the use of hPSC-derived CMs in human drug 
discovery and safety assessment, as well as modelling human cardiac disease [13, 14]. 
Unanticipated drug-induced cardiotoxicity is a major problem with life-threatening 
consequences; all newly developed drugs need to be screened for potential cardiotoxic 
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effects before they reach the market. Since human primary cardiomyocyte cultures are 
difficult to obtain and maintain in culture, other alternatives, such as Chinese hamster 
ovary (CHO) cells, human embryonic kidney cells overexpressing the hERG channel, or 
in vivo animal models are currently used by pharmaceutical industry[15]. Interspecies 
differences related to heart function and characterization, such as heart rate, ion currents, 
and expression of genes encoding signaling, membrane and structural proteins[16], point 
out the importance of developing human-based models for drug discovery and disease 
modeling.  Human PSC-CMs represent a promising in vitro model since they resemble native 
human cardiomyocytes[17]. hPSC-CMs have been shown to respond to clinically relevant 
drugs and are able to predict cardiotoxic and pro-arrythmic side effects[18]. hPSC-CMs-
based assay technology is gaining interest from the pharmaceutical industry, and a variety 
of screening assays are currently being developed at scalable levels for cost-effective and 
efficient high throughput level compound screenings. Moreover, more complex assays, such 
as co-culture or 3D- tissue engineered assays, which may even more faithfully recapitulate 
cardiac physiology and function, are underway [19, 20].
Developmental Biology and Cell Differentiation
Besides the applicability of hPSC-derived CMs for in vivo and in vitro translational purposes, 
another prospect that emerged with the realization of in vitro hPSC-CMs cultures is their use 
as in vitro model for studying human heart development and the onset of congenital heart 
disease, explained in more detail in the section below. Vice versa, a better understanding 
of molecular pathways involved in the formation of the developing heart, may contribute 
to the development and further improvements of protocols that generate efficient directed 
differentiations of hPSCs towards specific cell-types of the heart. Clearly, this is advantageous 
for therapeutic and pharmaceutical applications, including assay development on the field 
of drug discovery and disease modelling.
1.2     Heart Development: A Blueprint for in vitro Cardiomyocyte Differentiation
Anatomy 
The heart is the first organ to form during human embryonic development, at around 
the third week of gestation[21]. Our current detailed understanding of early heart 
development has been based on numerous studies in model organisms including rodents 
(Fig. 3), zebrafish, chick, and amphibian and a limited number of studies in the early human 
embryo[22-24]. During human development, prior to gastrulation, the bilaminar embryonic 
disc is almost flat and consists of two layers: the epiblast and hypoblast. The epiblast will 
give rise to the embryo and extra-embryonic structures, while the hypoblast will contribute 
to the extra-embryonic membranes. Upon early gastrulation, epiblast cells ingress through 
the primitive node and the primitive streak to form the ectodermal layer, and undergoes 
epithelial-to-mesenchymal transition (EMT) to form the mesodermal and endodermal layer 
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(Fig. 4a).  The mesodermal population, marked by the expression of key transcription factor 
Brachyury T arise from the posterior mesoderm, and migrate to the anterior-lateral regions 
of the embryo, at both sides of the midline. This is followed by formation of the earliest 
mesodermal pre-cardiac progenitor cells, marked by expressing of key transcription factor 
MESP1. Myocardial markers are first detected at this stage, where two molecularly distinct 
progenitor populations are identified, referred to the First Heart Field (FHF) and the Second 
Heart Field (SHF). The cells then extend across the midline to form a crescent-shaped 
epithelium, the cardiac crescent. The FHF differentiates within the cardiac crescent, fuses 
at the midline, and forms the early heart tube, responsible for the distribution of nutrients 
and oxygen in the embryo[25, 26]. The SHF is widely marked by LIM homeobox transcription 
factor 1 (ISL1), and is located medially to the cardiac crescent and at later stages behind 
the forming heart tube. The SHF, contributes to the venous as well as the arterial pole of 
the heart tube. The tube undergoes rightward looping, with its posterior region moving 
anteriorly. Derivatives from the FHF form the entire left ventricle as well as other parts of 
the heart, where SHF derivatives contribute to the right ventricle and atria, and the entire 
outflow tract. The heart is shaped by the looping process, expansion of the myocardium, 
which leads to the formation of the cardiac chambers, septation and further maturation.
Cardiovascular Progenitor Lineages
As mentioned above, the mesoderm transcription factor MESP1 is one of the earliest key (pre-
) cardiac transcription factors, activating the expression of downstream cardiac transcription 
factors, including NKX2-5, GATA-4, HAND2, MYOCARDIN, and MEF2C[27]. Although MESP1 
progenitors have a broader contribution to the embryo than only the heart[28-30], lineage 
tracing in mice demonstrated that almost all the cells of the heart are derived from MESP1 
progenitors[30, 31] (Fig. 4b). A more specified subset of MESP1 progenitor derivatives 
was recently suggested by their expression of Smarcd3[32]. However, also from these 
progenitors, extra-embryonic derivatives outside the heart could be identified. The earliest 
molecularly distinct cardiac progenitor populations are the FHF and the SHF, of which the 
latter is marked by enriched Isl1 expression[25, 32-34]. The earliest transcription factors 
that start to be expressed in the cardiac crescent are NKX2-5 and GATA-4, both identified as 
downstream target genes of transcription factor MESP1[35]. 
Transcription factor NKX2-5, the vertebrate tinman homologue of the Drosophila fruitfly, 
is essential for heart formation and marks definitive multipotent cardiac progenitors.  The 
multi-chambered septated heart consists of several subtypes of cardiac cells, including 
working myocardium cardiomyocytes (atrial and ventricular cardiomyocytes), smooth 
muscle cells, endothelial cells, fibroblasts and cardiomyocytes from the cardiac conduction 
system (CCS), consisting of the sinoatrial node (SAN), the atrioventricular node (AVN), 
bundle of His and Purkinje fibers. 
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Molecular Signalling
The endoderm germ layer plays an important role for the formation of the heart by exerting 
both stimulatory as well as inhibitory signals. Early cardiogenesis is modulated by four major 
signalling pathways of which the ligands originate in the endoderm:  bone morphogenetic 
protein (BMP), nodal/activin, Wnt/β-catenin, and fibroblast growth factor (FGF). Both 
the BMP and WNT/β-catenin pathways have a biphasic role during cardiogenesis. BMPs 
and Wnts, are required for mesoderm specification[36]. In contrast, subsequent cardiac 
progenitor differentiation and activation of key myocardial regulatory genes, such as Nkx2-5 
and Gata-4, are repressed by BMP and WNT/β catenin signalling[37, 38]. Moreover, prior 
to their addition to the primary heart tube, SHF progenitors are exposed to increasing BMP 
and non-canonical Wnt signals, which are thought to be the primary drivers for myocardial 
differentiation[39]. During all phases of the developing heart, WNT ligands, Frizzled 
receptors, or extracellular WNT inhibitors are expressed in relevant tissues, with an aberrant 
role for high WNT signalling in mesoderm formation and CPC proliferation. Furthermore, 
WNT signalling also plays a prominent role in morphogenetic processes, valve formation, and 
establishment of the conduction system (Fig. 5)[38]. An in-depth knowledge of molecular 
signalling during early heart development is crucial for developing and optimizing protocols 
for the derivation of in vitro PSC-CMs and/or in vitro CPC proliferation.
In this thesis, we describe the use of fluorescent reporters in hPSC lines for a better 
understanding of the molecular mechanisms underlying early human cardiac lineage 
commitment and cardiac progenitor dynamics
1.3   Directed Differentiation of Pluripotent Stem Cells towards the Cardiac 
Lineage 
In vitro Cardiac Differentiation Protocols
For defined, robust and controlled differentiation of specific cardiac lineages from hPSCs, 
lessons from early cardiac development have proven invaluable. They have supported the 
development of ways for hPSCs to provide an unlimited supply of cardiomyocytes from a 
single clonal source. 
In recent years, various robust protocols have been established for efficient differentiation 
to cardiomyocytes from hPSCs[40-42]. The two principle approaches for differentiation are 
through aggregate formation or monolayer culture (Fig. 6)[41, 43]. For aggregate formation, 
dissociated hPSCs are seeded and aggregated by centrifugation in V-bottomed 96-well 
plates, leading to the formation of uniformly sized aggregates. The inclusion of polyvinyl 
alcohol is essential for initial aggregation of the cells.  For simplicity, commercially available 
li-APEL or BPEL are often used[44]. Monolayer differentiation is carried out in culture 
media such as RPMI/B27. This is specially used for hESCs maintained in feeder-free culture 
systems, such as mTeSR or E8 (Stem Cell Technologies), as these do not easily form spin EBs 
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by centrifugation, but it is also applicable for hPSCs cultured on feeder layers.
Recently developed methods are based on serum-free culture conditions, involving the 
sequential activation or inhibition of signalling pathways involved in heart development: 
BMP4, Activin-A, and Wnt3a (or a GSK3 inhibitor, such as small molecule Chir99201) are 
added to monolayer hPSC cultures for 3 days, resulting in the temporal expression of 
MESP1+ progenitors, which are subsequently exposed to a Wnt signalling inhibitor, such 
as small molecule Xav939, to further differentiate to NKX2-5 expressing progenitors 
and cardiomyocytes (Fig. 7)[44-47]. Recently, Lian et al. and Burridge et al. published 
defined, growth factor–free monolayer protocols for differentiating feeder-free hPSCs to 
cardiomyocytes[41, 42]. These protocols involve the exposure of PSCs to GSK3 inhibitor 
Chir99201 for 1 or 2 days, followed by the treatment with Wnt inhibitor IWP2 for 2 days. 
These protocols yielded ±90% cTnT+ cells, with numbers of greater than 106 cardiomyocytes/
cm2 in multiple hESC and iPSC lines .
hPSC-derived cardiomyocytes express sarcomeric proteins, such as cardiac Troponin T 
(cTnT), and cardiac transcription factors, including TBX5, TBX20, GATA4, MEF2C, and ISL1, 
chamber-specific proteins, including MLC2V and MLC2A, and ion channels (such as sodium, 
potassium, and calcium channels). To note, transcription factors mentioned above can also 
be expressed in tissue other than the heart. Therefore, defining the combinatorial expression 
of sets of transcription factors is always important in such studies.
In general, these cardiomyocyte differentiation protocols lead to a mixture of 
cardiomyocytes, consisting mostly of ventricular cardiomyocytes. In order to develop new 
therapeutic strategies treating diseases affecting specific cardiac cell subtypes, such as 
atrial or ventricular fibrillation or dysfunctions of the pacemaker and conduction tissues, or 
replacing ventricular cardiomyocytes following myocardial infarction, it is of importance to 
develop cardiomyocyte subtype-directed differentiation protocols[23, 48, 49]. 
In vitro PSC-derived Cardiac Progenitor Populations
hPSCs offer the opportunity to develop in vitro derived cardiac progenitor populations. 
These could be useful for understanding of how progenitor cells can be maintained, 
expanded, and differentiated to specific cardiac subtypes under defined and controlled 
differentiation conditions[39]. One such progenitor population is marked by the expression 
of MESP1, from which almost all cells of the heart are derived, as described before [30]. 
In a mouse study, using fluorescent labelling, ESC-derived pre-cardiac MESP1+ progenitors 
were isolated and characterized[50]. Here, they showed how these progenitors could be 
isolated based on Flk1+CXCR4+PDGFRα+ surface marker expression, and were expressing 
early cardiac transcription factors of both FHF and SHF progenitors.
Several studies have described co-expression of PDGFRα and low KDR (Flk1) expression, 
marking a tri-potent cardiac mesoderm progenitor population, which may allow monitoring 
of proper cardiomyocyte differentiations[46, 51, 52]. Moreover, Ardehali et al. showed 
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that a PDGFRα+/KDR-low/ROR2+/CD13+ population could give rise to cardiomyocytes, 
endothelial cells, and vascular smooth muscle cells in vitro at a clonal level[53]. However, it 
is thought that these markers more broadly describe mesoderm and not specifically cardiac 
progenitors[32, 47]. Another early in vitro human CPC population that has been identified 
includes a tri-potent Isl1+ progenitor, which gives rise to mostly smooth muscle cells and only 
low numbers of cardiomyocytes[54]. These progenitors showed limited expansion in the 
presence of Wnt3a-producing feeders, indicating that canonical Wnt ligands can promote 
the expansion and maintenance of multipotent human ES- cell-derived ISL1 progenitors. 
Studies focussed on PSC-derived NKX2-5 expressing cardiac progenitors have shown that 
these were mostly bi-potent, and only rarely differentiated to endothelial cells, indicating a 
preceded segregation of endothelial progenitors[44, 55].
SCOPE AND OBJECTIVES OF THIS THESIS
Taken together, hPSC derived cardiac progenitor cells and cardiomyocytes offer an 
excellent opportunity for studying human heart development in vitro, and for translational 
applications, including the development of cardiovascular screening assays for drug 
discovery, cardiac disease modelling and safety pharmacology. However, despite high 
cardiomyocyte yields (up to 80-90% purity), these hPSC-derived cultures are heterogeneous 
cell populations. Congenital and acquired heart diseases mostly affect specific cell types, 
as in atrial fibrillation or dilated cardiomyopathy of the ventricles. Therefore, for disease 
modelling or drug discovery, it is of interest to develop protocols that specifically direct the 
differentiation of hPSCs towards subtypes of cardiac cells. In this thesis, we show a role for 
fluorescent PSC reporter lines in improving our understanding of molecular mechanisms 
that play a role in lineage commitment from early cardiac progenitor cells 
The main objective in this thesis is: to dissect molecular mechanisms playing a role in cardiac 
lineage commitment, cardiac progenitor proliferation, and cardiac subtype derivation.
Chapter 2 gives a broad and detailed overview of all recent fluorescent PSC reporter lines 
that have been used to visualize the derivation of hPSC-derived cardiac cells, including early 
cardiac progenitors and subtypes of cardiomyocytes. We further explain their potential for 
assay development in the field of drug discovery and toxicity, and disease modelling, and we 
summarize their applications in the field of cellular therapy of the heart.
In Chapter 3 we describe the generation of the dual cardiac reporter MESP1mCherry/wNKX2-
5eGFP/w hESC line, which allows the study of early cardiac lineage commitment. Upon cardiac 
differentiation, MESP1-mCherry expressing could be isolated and characterized. We identify 
their pre-cardiac mesodermal character and show how their further differentiation is 
enriched for cardiomyocytes. We further characterize how established cardiac progenitor 
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markers are expressed in MESP1 derivatives.
Whole transcriptome analysis of MESP1-cardiac progenitor derivatives at later stages are 
described in Chapter 4. Here, we identified the sequential expression of key established cardiac 
transcription factors during different stages of cardiac differentiation, including early cardiac 
commitment (d5), early cardiac progenitor (d7), cardiac progenitor (d10), and cardiomyocyte 
stage (d14). We describe the identification of putative cardiac key (co)-regulators, based on their 
temporal expression pattern and their predicted protein-protein interactions using network-
based analysis.
In Chapter 5 we describe the generation of a dual TBX3e-mCherry-NKX2-5eGFP/w hESC 
reporter line. Here, we aimed to obtain nodal-like cardiomyocytes from hESCs through the 
use of an atrioventricular-specific enhancer and a pan-cardiac enhancer that were previously 
identified to synergistically activate TBX3 expression in the atrioventricular conduction system 
of the developing mouse embryo. A TBX3e-mCherry reporter was randomly integrated into 
the genome of NKX2-5eGFP/w hESCs through lentiviral delivery. We discuss both technical and 
biological hurdles that need to be overcome.
Chapter 6 describes the generation of a dual cardiac reporter MYL2-T2A-mCherry-NKX2-5eGFP/w 
hESC line. Here, we aimed to monitor and isolate hESC-derived ventricular cardiomyocytes, and 
to study the molecular mechanisms involved in their formation. We made use of the small viral 
T2A peptide, which, upon activation of the MYL2 promoter, results in the generation of one 
transcript, containing both MYL2 and mCherry coding sequences, which is translated into two 
separate proteins. Upon cardiac differentiation we could identify MYL2-mCherry expression 
cardiomyocytes, albeit at low levels. The number of MYL2 expressing ventricular cardiomyocytes 
could be enhanced by their dissociation and/or culture in optimized maturation medium.
In Chapter 7, we study the proliferative capacity of MESP1-mCherry expressing pre-cardiac 
progenitors. The proliferation marker cassette CAG-eGFP-Anillin was randomly integrated into 
the genome of MESP1mCherry/wNKX2-5eGFP/w hESCs through lentiviral delivery, allowing us to study 
the proliferation of early cardiac progenitors up to day 5 of differentiation, prior to NKX2-5-
eGFP expression. Here, we showed through time-lapse imaging how eGFP-Anillin can reflect 
cell division of cardiac progenitors that derive from hESCs upon directed cardiac differentiation, 
and we propose an algorithm-based automated image analysis set-up for small molecular and/
or cytokine screenings to identify enhancing effects on cardiac progenitor and cardiomyocyte 
proliferation capacity.
Finally, the findings of the experimental chapters are considered as a whole in the concluding 




Figure 1. Human embryonic stem cells (hESCs) are derived from the inner cell mass of a blastocyst stage embryo. 
Human induced pluripotent stem cells (hiPSCs) are derived from human somatic cells, such as skin fibroblasts, 
through gene-mediated reprogramming. Both human pluripotent stem cell (hPSC) types can differentiate towards 




Figure 2. Pluripotent stem cell (PSC) derived cardiomyocytes can be used to study early human heart development 
(A), but can also be applied in cardiac therapies, such as regeneration of the damaged heart (B), or for experimental 
assay development on the field of drug discovery and toxicity screening (C). Birket et al. Developmental Biology 
2015
Figure 3. Morphogenesis of the mouse heart.  A: Myocardial progenitor cells originate in the primitive streak 
(PS), from where they migrate to the anterior of the embryo at about embryonic day E6.5. B: These cells come 
to lie under the head folds (HF) and form the cardiac crescent, where differentiated myocardial cells are now 
observed (E7.5). C: The early cardiac tube forms through fusion of the cardiac crescent at the midline (ML) (E8). 
D: It subsequently undergoes looping (E8.5). E: By E10.5 the heart has acquired well-defined chambers, but is still 
a tube (upper panel, ventral view; lower panel, dorsal view). FF In the fetal heart (E14.5) the chambers are now 
separated as a result of septation and are connected to the pulmonary trunk (PT) and aorta (Ao), which ensure the 
separate pulmonary and systemic circulation of the blood, respectively, after birth. Deoxygenated blood enters the 
heart through the right atrium (RA) and is pumped to the lungs through the pulmonary trunk by the right ventricle 
(RV). Oxygenated blood returns to the left atrium (LA) and is pumped by the left ventricle (LV), through the aorta, 
to the systemic circulation that serves the whole body. Anterior (A)–posterior (P) and right (R)–left (L) axes are 
indicated. AA, aortic arch; AVC, atrioventricular canal; IFT, inflow tract; IVC, inferior vena cava; IVS, interventricular 
septum; OFT, outflow tract; PLA primitive left atrium; PRA, primitive right atrium; PV, pulmonary vein; SVC, superior 













































Figure 4.Figure 4. Early Heart Development in the Mouse. A: Upon early gastrulation, epiblast cells ingress through the 
primitive node and the primitive streak to form the ectodermal layer, and undergo epithelial-to-mesenchymal 
transition (EMT) to form the mesodermal and endodermal layer. The mesodermal population is marked by the 
expression of key transcription factor Brachyury T, from which the earliest pre-cardiac progenitor cells, expressing 
key transcription factor MESP1, arise from the posterior mesoderm, and migrate to the anterior-lateral regions of 
the embryo, at both sides of the midline. Myocardial markers are first detected at this stage. VE, visceral endoderm; 
DE, definitive endoderm. B: Time course and pattern of expression of MesP1 in early mouse embryo monitored by 
in situ hybridization (left panel). MesP1 Cell lineage tracing in embryos obtained from breeding MesP1-Cre with 
Rosa26lacZ (R26R) mice (right panel). MesP1+ cells give rise to the whole heart, as well as head and tail muscles. C: 
cardiac crescent. Ht: heart. A: anterior. P: posterior. Pr: proximal. D: distal. Adapted from van Vliet et al. Circulation 
Research 2012.
Figure 5. The role of Wnt signalling in heart development.
Adapted from Gessert et al. Circulation Research.
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Figure 6. Principle methods of Cardiac Differentiation from human Pluripotent Stem Cells. END2 co-culture with 
mechanically passaged hPSCs, or spinEB or monolayer differentiation from enzymatically passaged hPSC cultures. 
Adapted from Mummery et al. Circ Res 2012
Figure 7. A: Time course of a standard monolayer differentiation protocol, based on defined factors, with the 
sequential expression of key cardiac genes. B: Example of the formation of a beating NKX2-5-eGFP expressing 
embryoid body (EB) at day 10 of differentiation. C: Staining of the sarcomeric structures Troponin I and alpha-
actinin of a hPSC-derived cardiomyocyte. CHIR99021: GSK3-inhibitor; XAV939: Wnt pathway inhibitor. Birket et al. 
Developmental Biology 2015
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ABSTRACT
In the last decade, since the first report of induced pluripotent stem cells, the stem cell field 
has made remarkable progress in differentiation to specialized cell-types of various tissues 
and organs, including the heart. Cardiac lineage- and tissue-specific human pluripotent stem 
cell (hPSC) reporter lines have been valuable for the identification, selection and expansion 
of cardiac progenitor cells and their derivatives, and for our current understanding of the 
underlying molecular mechanisms. In order to further advance the use of hPSCs in the 
fields of regenerative medicine, disease modeling and preclinical drug development in 
cardiovascular research, it is crucial to identify functionally distinct cardiac subtypes and 
to study their biological signalling events and functional aspects in healthy and diseased 
conditions. In this review, we discuss the various strategies that have been followed to 
generate and study fluorescent reporter lines in human pluripotent stem cells and provide 
insights how these reporter lines contribute to a better understanding and improvement of 
cell-based therapies and pre-clinical drug and toxicity screenings in the cardiac field.
INTRODUCTION
Human pluripotent stem cells (hPSCs), i.e. embryonic stem cells (ESCs) and induced 
pluripotent stem cells (iPSCs), can be maintained in culture indefinitely and since they 
have the potential to differentiate into any cell type of the human body, these cells offer an 
unlimited source of differentiated cell types, including cardiomyocytes (CMs). The promise 
of hPSC-derived CMs for treatment of heart disease has grown rapidly since the ability to 
reprogram somatic cells into iPSCs, discovered for the first time by Yamanaka et al. in 2006 
[1]. IPSCs are very similar to embryonic stem cells (ESCs), but are of a less ethical concern, 
as they do not require donated embryos for derivation. Further, they can be generated from 
patients with genetic disease to create in vitro human disease models. In recent years, the 
differentiation efficiency from hPSCs to cardiac cells has increased considerately, yielding 60-
90% cardiomyocyte cultures[2]. Efficient directed differentiation of CMs from hPSCs is of high 
interest for multiple fields of research, including cardiogenesis, in vitro disease modeling, 
drug discovery, safety pharmacology and regenerative medicine. Fluorescent reporter lines 
offer the opportunity to monitor cell subtype specification and to investigate underlying 
molecular mechanisms during differentiation of hPSCs towards cardiac cells, and to track 
cells in cell-based therapies.  In order to generate fluorescent reporter lines, hPSCs need to 
be genetically modified, which can be performed through different approaches. A variety 
of fluorescent proteins that cover a broad range of the wavelength spectrum, including 
eGFP, mCherry and mVenus, enable imaging and tracking of specific cell populations and 
mapping their cell fate. Here, we will summarize the different fluorescent reporter lines 
that have been described so far, how these were generated, and how they have contributed 







specification. Further, we describe their importance for applications in regenerative 
medicine (e.g. replacing damaged or non-viable heart tissue) and further advancing in vitro 
systems for disease modeling and drug discovery and safety testing (Figure 1).
1   Methods for Generating PSC Reporter Lines
For selection and purification of specific cell types, non-genetic approaches such as 
metabolic selection or sorting using cell type-specific antibodies are preferred. However, 
these approaches are not always available or fail to yield sufficient purity, and therefore, the 
use of cell-type specific fluorescent reporter lines offers an excellent alternative. Generation 
of these reporter lines require genetic engineering in hPSCs, for which several successful 
approaches have been described. Each genetic engineering approach knows its own 
advantages and disadvantages, which we will discuss here briefly (Table 1). More specific 
details can be found elsewhere[3-5].
1.1   Promoter-driven Reporter Lines
Introducing exogenous regulatory fragments that are coupled to a fluorescent reporter 
gene can generate cell-specific promoter reporter lines. These elements can be introduced 
randomly into the genome through viral-mediated transduction[6], electroporation, 
nucleofection, or chemical-based transfection. However, important shortcomings exist in 
using these methods. First, integration events are random and there is no control over copy 
number, site of integration, and gene expression level. Moreover, chromatin dynamics and 
epigenetic regulators may change upon lineage differentiation, resulting in the chance of 
transgene silencing disabling gene reporter expression[7-9]. Second, endogenous regulatory 
elements may interfere with the incorporated promoter/enhancer elements, so that the 
fluorescent reporter may not faithfully recapitulate endogenous activation of the target 
gene during differentiation. The use of strong insulator elements flanking the enhancer 
and its reporter gene could be a way to overcome transgene silencing[9, 10]. Moreover, 
endogenous elements themselves could be influenced by the integration of new regulatory 
elements, which may affect the differentiation process, cellular behavior and function. 
Several loci have been described to be ubiquitously expressed in hESCs and progeny, 
including sequences highly homologous to the mouse Rosa26 locus and the AAVS1 locus, 
which could be targeted through homologous recombination[11-13]. However, it should be 
noted that transgene silencing can be lineage-specific and the effect of gene expression 
following gene insertion in these loci have not been described for all mature cell-types. 
Third, these strategies are always based on restricted regulatory elements, often based 
on conserved elements between species. However, gene regulation is complex and can 
be regulated through combinatorial distal and proximal elements that control the precise 
expression pattern of a gene during development[14], and therefore detailed knowledge of 
specific regulatory elements and their effect on gene regulation is required. The best way to 
overcome these limitations is the development of a knock-in PSC line.
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1.2  Targeted Genome Editing
With targeted genome editing, a reporter gene is inserted into a specific site at the gene of 
interest through homologous recombination[15]. In recent studies using cardiac reporter 
lines in hESCs, sequences following the translation start codon of the gene of interest 
were replaced in frame with the coding sequence of a fluorescent reporter gene, in the 
presence of adjacent to a positive selection cassette. A targeting vector containing these 
sequences are flanked by sequences homologous to the genomic regions at the 5’ and 
3’ ends of the targeting site, required for homologous recombination[16, 17]. Sequential 
excision of the selection cassette is recommended in order to prevent interfering regulatory 
events at the targeted site[18]. One major disadvantages of this strategy is the generation 
of haploinsufficient hPSC lines, since in one allele the targeted gene of interest has been 
replaced with a fluorescent encoding protein. Therefore, it is important to have additional 
information on whether heterozygote expression of the target gene may affect differentiation 
and cellular functions. For example, studies in knockout mice or comparable strategies 
in other species may provide this information. Alternatively, an internal ribosomal entry 
site (IRES) or viral 2A peptide may be incorporated in the targeting construct in order to 
allow expression and translation of both the endogenous as well as the reporter genes[19]. 
However, in case of the use of IRES, it has been shown by many researchers that transcription 
of the second gene is less efficient than the first, which also depends on the strength of the 
endogenous promoter[20, 21]. Viral 2A could be a superior alternative to the widely used 
IRES. By using a short sequence, multiple proteins can be co-expressed from a single mRNA. 
However, the disadvantage is that due to ribosomal cleavage of the 2A sequence, several 
amino acids are added to the C terminus of the endogenous protein, and one amino acid is 
added to the N-terminus of the reporter protein, which may have an effect on the function 
or turnover of proteins[19, 22].
1.3  The Promise of Engineered Nucleases
Other site-specific genetic engineering methods that have raised interest in recent years 
are engineered nucleases, including zinc-finger nucleases (ZFNs)[23, 24], transcription 
activator-like effector nucleases (TALENS), or the most recently described clustered regularly 
interspaced short palindromic repeats (CRISPR) technology[4]. Important considerations to 
take into account when choosing a specific technology, include the size of the insertion 
sequence, the risk for off-target modifications[25], and the prospected efficiency of the 
targeting. CRISPR technology has shown high efficiency (up to 51-79% in hPSCs[26] and 
reliability (low off target effects) in site-specific amino acid replacement, and is considered a 
promising technique for disease modeling or for genetic repair. Moreover, compared to ZFNs 
or TALENs, it only requires the generation of a single guidance RNA (sgRNA) molecule, CAS 









intensive[5]. Jaenisch et al. have shown that the use of CRISPR/Cas9 can be successfully used 
for the efficient generation of fluorescent gene reporters in mice[27]. Here, Cas9 mRNA, 
sgRNA, and a donor vector containing a 3 Kb transgene cassette were injected into zygotes. 
From the blastocyst stage-derived mESCs, 33% were correctly targeted. However, limitations 
still exist and may be different in hPSCs; here, the insertion of large DNA constructs into the 
genome has not been described yet.  For CRISPR/CAS9 technology, limitations include the 
variance in targeting efficiency, which depends on the size of the epitope or fluorescent 
tag, the amount of targeting vector to be injected, cell type, cell cycle phase[28], and the 
target locus, and will require model-specific optimization. More specific details are reviewed 
elsewhere[4, 29].
In summary, several aspects are important to take into account for generating fluorescent 
reporter lines, such as the amount of time and labor it takes to generate a line, the efficiency 
of targeting, the choice for a replacement or a fusion strategy, random gene insertions from 
lentiviral particles, the risk of silencing, the risk for off-target effects from nucleases, and the 
size of the DNA construct (a fluorescent protein and/or selection cassette). An overview of 
the genetic engineering methods that have been used to introduce reporter constructs in 
PSCs for cardiac development/differentiation and transplantation studies can be found in 
Table 1. So far, most cardiac fluorescent reporter PSCs have been generated through the 
use of lentiviral or homologous recombination approach, although it is expected that future 
studies will increasingly report generation of fluorescent reporter lines through the use of 
engineered nucleases[4, 28].
2.1   Fluorescent Reporters to Study Segregation of Early Cardiac Progenitors
In Vivo Cardiac Development
Since differentiation of hPSCs to the cardiac lineage recapitulate the early steps of in vivo 
heart development[30], a thorough understanding of the molecular cues and signaling 
pathways of this developmental process is essential. The earliest precursors for heart-
forming cells are derived upon ingression of epiblast cells through the vertebrate primitive 
streak. During this event, called gastrulation, cells undergo epithelial-to-mesenchymal-
transition (EMT) and form mesendoderm. They are marked by activation of transcription 
factors, including T-box transcription factor brachyury T (BryT) and homeodomain 
transcription factor MIXL1[31-33]. Another transcription factor, Eomesodermin (EOMES) is 
restricted to the anterior region of the primitive streak[34],  and together with BryT they 
act upstream of bHLH transcription factor MESP1. In combination with low Nodal signaling, 
this results in the transition from a mesendodermal stage to a more defined pre-cardiac 
subpopulation, marked by MESP1[35-37]. Almost all cells of the final developing heart, but 
also hematopoietic and skeletal myogenic lineages, are derived from MESP1-expressing 
early progenitors[38, 39]. Recently, a more restricted cardiac progenitor cell population, 
derived from Mesp1, and marked by Smarcd3 was described[40]. However, information 
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on the segregation and existence of intermediate cardiac progenitors is sparse. Based on 
recent clonal analysis studies in mice, early cardiovascular lineage specification is described 
to occur prior to, or during, Mesp1 expression[40, 41], which distinguishes the so-called first 
heart field (FHF, which forms the initial heart tube, and later the left ventricle (LV) and some 
of the right ventricle and atria) from the second heart field (SHF, marked by ISL1 expression, 
which forms the right ventricle  (RV), atria, and outflow tract[42]. FHF progenitors are 
located within the so-called cardiac crescent, and following migration and fusion at the 
midline, a primitive heart tube is formed. SHF cells are located medially and posteriorly 
to the cardiac crescent and contribute to the formation of the heart at a later stage. In 
the developing human heart, ISL1-expressing progenitors are described to differentiate to 
different downstream multipotent heart progenitors that contribute to SHF-derivatives[43, 
44]. In contrast, the highly conserved cardiac transcription factor NKX2-5 is first expressed 
in the cardiac crescent, but later as well in SHF-derived cardiac cells. Expression of NKX2-5 is 
maintained throughout the developing and adult heart[45].
In Vitro Cardiac Reporter Lines
A genetically modified mouse ES cell line, in which Mesp1 regulatory regions were 
coupled to a GFP reporter, showed the ability to isolate and study early Mesp1-GFP cells 
upon cardiac differentiation[46]. They identified the cell surface markers CXCR4, Flk1, and 
PDGFRa to be specifically expressed in Mesp1-progenitors in mice. Single cell clone analysis 
demonstrated the heterogeneous expression of early cardiac genes, including Isl1, indicating 
early segregation of Mesp1 progenitors into different downstream multi-potent cardiac 
progenitors. This was confirmed by an in vivo study in mouse, where they showed early 
segregation of the FHF and SHF, during MESP1 expression[41]. Recently, we characterized 
for the first time human pre-cardiac MESP1-progenitors differentiating to the cardiac 
lineage[16]. We performed targeting of the genomic locus of MESP1 through homologous 
recombination by replacing one allele with a DNA sequence encoding for the fluorescent 
protein mCherry. Microarray analysis of MESP1-mCherry positive cells largely revealed 
similar transcriptional characteristics to those in mice. However, a clear difference between 
mouse and human cardiac cell differentiations is that human MESP1 progenitors appear 
to have a more demarcated mesodermal character, as only a small subset of early cardiac 
genes is expressed in this population, including GATA4, MYL4, and MYL7. Interestingly, we 
also identified the absence of surface markers that were previously identified on mouse 
Mesp1-GFP progenitors[46]. Human MESP1 progenitors do highly express PDGFRa protein, 
but not CXCR4, and only a low percentage expresses KDR, indicating the presence of a 
PDGFRa+KDR- cardiac progenitor population, besides the previously described human 
KDR+PDGFR+ cardiac progenitor[47].
As described above, the LIM-homeodomain transcription factor Isl1 is enriched in the 
secondary heart field[42]. Mouse multipotent Isl1+ cardiac progenitors contribute to 









atrial cardiomyocytes[43, 48]. By generating an in vitro Isl1-Cre Knock-in DsRed reporter 
line in hESCs for lineage tracing construct it was found that human ISL1+ progenitors can 
give rise to cardiomyocytes (cTnT), endothelial cells (PECAM1), and smooth muscle cells 
(SM-MHC)[44]. Furthermore, this study, and several others, showed expansion of Isl1+ 
progenitors under activation of the Wnt/B-catenin-pathway[44, 49, 50]. More insight in the 
ability to maintain and expand cardiac progenitors may provide an unlimited source of cells 
committed to form cardiovascular cells.
As mentioned previously, NKX2-5 is a key cardiac transcription factor and is expressed in 
heart precursor cells in the FHF, which are committed to the cardiac lineage[51]. Elliott 
et al. designed a NKX2-5 fluorescent reporter line in hESCs, by targeting a DNA sequence 
encoding for eGFP into the NKX2-5 genomic locus through homologous recombination[17]. 
Since NKX2-5 is activated in cardiac progenitors and expression is maintained in functional 
cardiomyocytes at later stages, this reporter line is very suitable for studying the effect 
of small molecules and growth factors during cardiac lineage differentiation from hESCs. 
Indeed, following this approach, a more efficient, robust and defined differentiation protocol 
was attained. In addition, Birket et al. recently showed in a MYC-inducible system expansion 
of hESC-derived NKX2-5-eGFP+ progenitors for many passages through IGF-1 and hedgehog 
signaling, from which different cardiac subpopulations, including nodal-like cells, could be 
obtained[52]. Furthermore, using antibody arrays and gene-expression arrays, a cell surface 
protein signal regulatory protein (SIRPA/CD172a) was identified as a marker for early 
cardiac progenitor cells. Upon further differentiation, co-expression of SIRPA with VCAM1 
was identified to specifically enrich for cardiomyocytes[17, 53]. Interestingly, SIRPA is not 
expressed in the developing mouse heart, in contrast to the human heart, which highlights 
the need to define markers in the human system. The previously described MESP1-mCherry 
targeting was performed in this NKX2-5-eGFP hESC line, yielding a dual cardiac reporter 
line (Figure 2)[16], which facilitates studying molecular pathways that are involved in 
the early switch from hESCs to pre-cardiac mesoderm, and its subsequent differentiation 
towards the cardiac lineage and specification into different cardiac subtypes. This could also 
provide opportunities for monitoring cardiac-committed progenitors (MESP1+) to NKX2-5+ 
cardiomyocytes following transplantation in infarcted hearts (see section 3.1. Fluorescent 
Reporters to Track Cells after Transplantation).
2.2   Fluorescent Reporters to Study Cardiomyocyte Derivation
The major cell types of the heart include ventricular and atrial cardiomyocytes, cardiac 
conduction cells, vascular smooth muscle cells, endothelial cells (myocardium and 
endocardium), and cardiac fibroblasts. Both for cardiac regeneration therapies and 
biomedical applications it is important to establish defined scalable culture systems or tissue 
constructs consisting either of pure cardiac cell populations or a well-balanced and controlled 
mixture of cardiac cells resembling the composition and architecture of the human heart. 
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However, current cardiac differentiation protocols result in a mixture of cardiac and non-
cardiac cell-types. Approaches to purify cell populations using fluorescent reporter lines 
under the control of cardiac- and/or subtype-specific promoters have been first performed 
in mESCs[54-57]. In hESC an alpha-MHC or NCX-1 promoter, coupled to either a fluorescent 
protein (eGFP, mCherry), or the antibiotioc resistance gene, puromycin has been introduced 
into the genome [6, 58-60]. In the study of Kita-Matsuo et al., α-MHC positive CMs were 
selected in the presence of puromycin for 36 hours (day 12 to day 13.5), which yielded 
92-96% pure CMs (based on quantifications of cardiac Troponin I immunostainings)[6]. 
Differentiation of NCX1-eGFP hESCs resulted in a maximum of ±50% of NCX-1-eGFP+ CMs, 
highly enriched for early and late cardiac genes, including NKX2-5, TBX5, cardiac troponin 
T, MYH6, and MYH7[59]. However, as alpha-MHC and NCX-1 are both expressed in all types 
of CMs, this results in a mixture of nodal, atrial-, and ventricular-like CMs. However, Both 
NCX-1 (Na+/Ca2+exchanger) and alpha-MHC are widely expressed in all subtypes, resulting 
in a mixture of nodal, atrial-, and ventricular-like CMs [6, 59].
2.2.1  Ventricular Cardiomyocytes
In order to select ventricular cardiomyocytes, promoter/enhancer elements of ventricular-
specific (or –enriched) genes, such as ventricular myosin light chain 2v (MLC2V) or IRX4 
could be appropriate candidates for generating subtype-specific reporter lines[61]. MLC2V 
expression is restricted to the ventricular segment of the developing human heart, followed 
by expressed in the entire ventricular compartment in the adult heart[62]. It is noteworthy 
that different cis-acting regulatory elements may be responsible for MLC2V expression in 
either the left or right ventricle, indicating differences in the regulation of their derivation 
and the possibility to identify and purify left (predominantly FHF- derived) or right ventricular 
(predominantly SHF-derived) cardiomyocytes[45, 63]. Huber and colleagues generated 
hESCs stable lines, using lentiviral vectors that expressed fluorescent protein eGFP under 
the transcriptional control of a highly conserved 250 bp MLC2V promoter element[64]. 
This enabled a highly enriched population of ventricular-like cells, purified by FACS[65]. It 
should be noted that the used promoter is dominantly active in right ventricular CMs[64]. 
Alternatively, the use of a drug resistance gene under the control of a ventricular-specific 
promoter may be another strategy. A disadvantage of selecting ventricular CMs through 
the MLC2V promoter is its low expression level in early stage hPSC-CMs. Substantial 
MLC2V expression levels are displayed only after long-term cultures for approximately a 
month, which is correlated to a higher degree of maturation [66]. Interestingly, most CM 
differentiation protocols that exist show a preferred differentiation to the ventricular 
lineage. However, it is not known whether these ventricular cells are derived from the same 
or from different cardiac progenitor cells, and whether it is important for development of 
directed differentiation protocols. The use of dual or multi-reporter hPSC lines may provide 










2.2.2   Atrial Cardiomyocytes
Factors that determine fate specification of atrial cardiomyocytes are largely unknown[67], 
although several atrial-specific or –enriched genes have been identified previously in different 
species. For example, myosin light chain 2A (MLC2A) is initially expressed throughout the 
tubular heart in the mouse embryo, and becomes only confined to the atrial segment during 
chamber formation[45]. This is in contrast with human cardiac development, where MLC2A 
transcript was found in both atria and ventricles at even later stages of development[62], 
signifying the importance to understand the molecular mechanisms that are involved at the 
different stages of human cardiac development in order to serve as a blueprint for directed 
step-wise cardiac differentiation of hPSCs. Recently, the orphan nuclear receptor COUPTFII 
was identified as an important regulator of atrial development in mice[67]. Upon in vitro 
cardiac differentiation from hPSCs in the presence of retinoic acid, we recently demonstrated 
that both COUPTFI and COUPTFII are involved in atrial cardiomyocyte derivation[68]. 
Moreover, both transcription factors were highly enriched in human atria at RNA and protein 
levels during cardiac development and both genes may represent interesting candidates for 
generating atrial-specific reporter hPSC lines. However, expression of COUPTFII can also be 
found in venous/lymphatic endothelium, vascular smooth muscle cells, the endocardium, 
and the epicardium[69].
2.2.3   Nodal-like Cardiomyocytes
For understanding molecular pathways leading to differentiation of nodal-like hESC-CMs 
and to allow their isolation, promoter-enhancer elements of several genes involved in the 
development of nodal tissue have been used so far. Previously, in vivo studies in mice showed 
selective activation of a chicken GATA6 (cGATA6) proximal promoter-enhancer element in 
the atrioventricular (AV) node and the bundle of His of the adult mouse heart[70]. Zhu 
and colleagues coupled this cGATA6 regulatory element to eGFP in a lentiviral construct 
and subsequently transduced hESCs prior to differentiation (with a transduction efficiency 
of only ~50%). By adjusting cardiac differentiation via inhibition of Neuregulin-1/ErbB 
signaling, an increased proportion of nodal-like CMs were identified[71]. cGATA6-eGFP 
positive cells exhibited action potential characteristics of a nodal-phenotype, indicated by 
the increased expression of HCN4, responsible for the funny current If, and transcription 
factor TBX3, important for in vivo specification of nodal tissue. Studies in mouse tested 
Hcn4 promoter/enhancer elements to investigate the derivation of nodal-like CMs, in vitro 
[72, 73]. Differentiating Hcn4-promoter-GFP mESCs resulted in only a small percentage 
of Hcn4 positive cells (±1%) exhibited a pacemaker-like action potential after fluorescent-
based isolation[72]. Direct reprogramming of HCN4-GFP fibroblasts, using a combination 
of four transcription factors (Tbx3, Tbx5, Gata6, and Rxra), robustly activated HCN4p-GFP 
expressing cells, but without displaying electrical activity and no expression of sarcomeric 
proteins[73]. Alternative approaches for directed differentiation including the use of RNA 
molecules, such as modified mRNA, miRNAs, or lncRNAs are currently evaluated. Important 
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to note is that at the cardiac crescent stage, Hcn4 is also expressed in early FHF progenitors 
and immature cardiomyocytes[73-76], and only becomes confined to components of the 
conduction system at later stages of development[77], which is of critical importance to 
realize when studying the derivation of human conduction cells.
3   The Promises and Challenges of hPSC-derived CMs for Cellular Therapy
Initially, researchers focused on the potential of hPSC-derived CMs for cell replacement 
therapy in experimental models of heart disease, such as myocardial infarction[78, 79]. 
In order to restore heart function and maintain long-term beneficial effects, sufficient 
transplanted cells need to engraft at the site of injury, receive blood supply, and need to 
couple and communicate with cardiac cells of the host myocardium in order to ensure 
synchronous electrophysiological and contractile function. CMs derived from human 
iPSCs would even provide an autologous source of cells for future cardiac regenerative 
therapy[80]. However, heart repair by CM replacement appeared to be challenging and 
many hurdles need to be taken. These promises and challenges for hPSC-derived cellular 
therapies for the treatment of heart failures have been reviewed elsewhere[78, 79, 81]. One 
crucial aspect that we would like to emphasize here, is the composition of the transplanted 
cell population. Which cell type(s) or tissue constructs would be most ideal regarding cell 
survival, tissue repair, engraftment, and functional coupling? For the delivery of organized 
cardiac tissue we would require scalable cultures of different cell types, such as endothelial 
cells, smooth muscle cells, cardiac fibroblasts, and cardiomyocytes[82]. Another important 
aspect is the immature phenotype of hPSC-CMs. It is expected that a higher degree of 
maturation of transplanted cardiomyocytes and thus a higher resemblance to the native 
myocardium would pose a less arrhythmogenic risk[83]. For cellular therapy, these major 
basic research challenges are important to be overcome.
3.1   Fluorescent Reporters to Track Cells after Transplantation
In cellular transplantation studies, it is crucial to monitor cell delivery, homing, survival, 
proliferation, and migration of transplanted cells[84]. Another important aspect is 
electrical coupling of transplanted cells with host myocardium at single cell level. 
Impaired communication between transplanted and host cardiomyocytes may lead to 
electrophysiological disturbances and consequently cardiac arrhythmias. In order to study 
both homing and electrical coupling, the use of a dual reporter, combining bioluminescence 
imaging and a fluorescent reporter under the control of a cardiac promoter has been 
suggested[85]. However, most studies have used a single reporter line expressing either 
GFP or LacZ in hPSC-derived cells[80, 83, 86, 87]. Alternatively, direct cell labelling with 
fluorescent probes prior to transplantation, or local or systemic injections using non-invasive 
radionuclide imaging, magnetic labelling, or optical mapping through bioluminescence 
imaging are other options[85, 88]. Limitations for cell tracking that are important to consider 









up of the label by other cells after donor cell death. More details on the advantages and 
disadvantages of different cell tracking techniques are reviewed elsewhere[88].
3.2   Functional Integration
Functional integration of donor cells into host myocardium can be measured by the use of 
fluorescent calcium dyes, such as small molecule fluo-4[86]. Calcium is a vital component 
of cardiac excitation-contraction coupling. A wide range of small molecule calcium dyes 
is available, with different excitation/emission spectra and affinities for calcium. When 
choosing a calcium dye, the affinity for calcium should be taken into account, as low-affinity 
calcium dyes will provide more accurate measurements of calcium dynamics (reviewed 
elsewhere)[89]. Moreover, high affinity dyes may interfere with the physiological calcium 
handling, affecting function of transplanted cells, and thereby not completely reflecting 
the final engraftment conditions. Another option is the use of genetically encoded calcium 
indicator proteins, which allows cell-specific calcium mapping over a long time period[90, 
91]. This approach was recently followed in two studies where hESC-CMs were transplanted 
in infarcted non-human primate hearts or guinea-pigs[83, 92]. Fluorescent calcium indicator 
GCaMP3 was incorporated in hESCs at the adeno-associated virus integration site 1 (AAVS1), 
a region of the genome that is considered to be transcriptionally constitutive active, using 
zinc-finger nuclease (ZFN)-based genome editing. Here, they demonstrated electrical 
coupling between donor cardiomyocytes and host myocardium. However, no significant 
increase in ejection fraction was found and hearts suffered from ventricular arrhythmias. The 
main advantages and drawbacks of the different fluorescent calcium-indicators described in 
this section are reviewed elsewhere[89].
3.3   Cardiomyocyte Proliferation 
For a long period of time, the field of cardiac regeneration has been focussing on exogenous 
cell delivery and endogenous activation of cardiac cells to repair the damaged heart after 
infarction[78, 79]. Many studies have indicated that long-term beneficial improvement of 
cardiac function is an immense challenge. 
Although several studies indicated a low proliferation rate of adult cardiomyocytes[93, 
94], it is clear that mammalian adult cardiomyocytes have lost the capacity to regenerate 
the heart after damage, as opposed to fish, amphibians and fetal or neonatal mammalian 
cardiomyocytes[95, 96], therefore it is of importance to develop strategies that may lead 
to proliferation of cardiac progenitors (followed by differentiation to cardiovascular cells) 
and/or cardiomyocytes. Analysis of cell division could be performed through the use of live 
mitosis markers, such as scaffolding protein anillin, which is a component of the contractile 
ring that localizes to specific subcellular compartments during mitosis and cytokinesis. 
Hesse et al. fused anillin to fluorescent protein eGFP, to visualize high spatiotemporal 
resolution of mitotic phase, and proved a lack of cardiomyocyte division after myocardial 
infarction (MI) in mouse hearts[97]. Similarly, a fluorescent anillin reporter would be very 
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valuable for studying real-time cardiomyocyte cell division in vitro (Figure 3). In addition, 
the fluorescence ubiquitination cell cycle indicator (FUCCI) is another system that enables 
live-imaging of cell division, based on a two-color (red and green) fluorescent proteins fused 
to cell cyle regulators ct1 and geminin, which are differentially expressed and ubiquinated 
dependent on the cell-cycle stage. This leads to a dynamic color change when cells are 
progressing from the G1 to S phase of the cell cycle. In contrast to an anillin reporter, the 
FUCCI system is not suitable for demonstrating cytokinesis[98].
4   The Promises and Challenges of hPSC-derived CMs for Disease Modeling, 
and Drug Discovery and Toxicity Screenings
Besides the opportunity to use human stem cell-derived cardiac cells for cell-based therapies, 
the utility of hPSC-CMs for disease modelling, drug discovery, and toxicity screenings has 
been reported in a growing number of studies, allowing researchers to study patient and/or 
disease-specific drug responses. hPSC-CMs are a promising alternative for animal models, 
as they recapitulate native human cardiomyocytes, indicated by expression of cardiac-
specific genes and proteins, morphology and function. Further, they beat spontaneously, 
they possess calcium transients and they generate action potentials that are specific for 
atrial, ventricular, and nodal cells[99]. However, the use of hPSC-CMs as a platform for drug 
discovery need further optimization and validation and thus requires the development of 
tools to faithfully recapitulate cardiac physiology and function at high throughput level[100, 
101]. One of the major significant challenges that scientists are facing is the mixed population 
of cardiac cells that are obtained from directed differentiation protocols
[100, 102-104]. Therefore, it will be important to generate specific differentiation protocols 
in order to obtain sufficient numbers of disease-relevant subtypes of cells, which is described 
in detail in a previous section. Moreover, for development of advanced 3D cardiac cultures 
with the purpose to increase the predictability of screening assays by mimicking the heart 
more accurately, it is important to understand the cardiac microenvironment, including 
cellular and non-cellular compositions and cell-cell interactions[100].
4.1   Cardiomyocyte Electrophysiology: Voltage and Calcium Dyes
Currently published hPSC-CM disease models, including channelopathies, cardiomyopathies, 
and metabolic cardiac disorders, show affected (drug-induced) action and field potentials, 
calcium signalling, disorganized sarcomeric structures, and metabolic abnormalities such 
as irregular lipid or glycogen levels[105-107]. Intracellular electrophysiological recordings 
of single cell hPSC-CMs by patch-clamp analysis provide detailed information about their 
action potential and the contribution of the ion channel currents. This has gained interest, 
since recent development of automated medium to high-throughput whole-cell patch-
clamp chip recordings[108]. An alternative approach for this labour-intensive technology 
is extracellular non-invasive recordings using microelectrode arrays (MEAs), which is 








screening. This will allow analysis of CM depolarization and repolarization from multicellular 
field potential recordings. In addition, the use of voltage-sensitive dyes represents a 
technology to monitor real-time electrophysiological activity at high temporal and spatial 
resolution[109]. These fluorescent reporters reside within the cell membrane and are able 
to monitor membrane potential, based on fluctuating fluorescent intensities. As these 
measurements can be performed at high throughput level, voltage-sensitive dyes-based 
assays are of high interest for drug screening in conditions that affect electrophysiological 
properties, such as channelopathies or drug-induced cardiotoxicity (see below). In addition, 
calcium handling is another important functional parameter of CM electrophysiology, for 
which fluorescent dyes and reporters are available. Calcium signalling in CMs is crucial for 
excitation-contraction coupling. During the action potential there is a calcium influx into 
the cell through activation of L-type voltage-gated Ca2+ channels. This results in calcium-
induced calcium release from intracellular stores of the sarcoplasmic reticulum leading 
to contraction. Uptake of calcium from the sarcoplasm to the sarcoplasmic reticulum (in 
addition to other mechanisms that lead to reduced sarcoplasmic calcium levels) ends the 
contraction. Fluorescent calcium dyes, also described in a section above, include small 
molecules such as Fluo-4, Fluo-3, or Fura-2, or the more technical challenging Fura-4F, 
which has the advantage of a lower affinity for calcium binding, but requires switching 
between emission filters when calcium concentrations change[110]. Using small molecule 
calcium dyes, several studies have reported affected calcium handling in hPSC-CM disease 
models[107]. In the majority of disease modelling studies, single parameters are measured 
in a sequential manner. However, in order to thoroughly understand the deeper mechanisms 
behind the onset of disease and its phenotype outcome, it will be of interest to measure 
different crucial parameters simultaneously. The combination of fluorescent reporter/dyes 
with non-overlapping spectra, and technological advances in LED illumination and optical 
filters, will make this feasible for future applications.
4.2  Cardiac Toxicity
Drug-induced cardiotoxicity of both cardiac and non-cardiac drugs is a major problem in the 
process of drug development and may lead to unexpected life-threatening situations[111]. 
For the identification of cardiotoxic effects of drugs, it is important to understand the 
underlying mechanisms[112]. Since current animal models and cell lines lack sufficient 
predictability, hPSC-CMs may represent a valuable human-based in vitro model for preclinical 
cardiotoxicity screenings. Cardiomyocyte functional readouts may include calcium and 
voltage levels, sarcomere contraction forces and organization, ion channel functioning, CM 
apoptosis, mitochondrial damage, or other putative affected signalling pathways. Cellular 
mechanisms that have been associated with cardiotoxicity include genotoxicity, oxidative 
stress, apoptosis, and lipid peroxidization[113, 114]. Automated microscopy platforms 
in combination with fluorescent reporters/dyes enable quantification of a variety of 
cardiotoxic effects, such as nuclear fragmentation or caspase 3 activity to detect apoptosis, 
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mitochondrial membrane potentials[115-117], biochemical kinase assays based on FRET 
technology or specific signalling pathway analysis based on reporter assays fluorescent 
probes to measure cellular oxidative stress[118, 119], or fluorescent probes to measure 
superoxide, produced by mitrochondria under ischemic/oxidative stress conditions[120, 
121]. Companies from whom such assays are available include Toxys, LifeTechnologies 
(Cellular Pathway Analysis Assays or CellROX), or Cyprotex. In recent years, the availability 
of disease-specific hPSC-CMs is growing, which allows new opportunities in the field of 
drug development and discovery. The demand for human-based standardized and validated 
cardiotoxicity assays is high and the development of reliable and sensitive pathway-specific-
fluorescent reporter lines in well-characterized hPSCs in the combination with high content 
screening analysis methods, will be promising for medium- or high-throughput screenings 
of cardiotoxic side effects in the field of drug discovery[115, 122].
4.3   Optogenetics
A rapidly emerging field in biotechnology is optogenetics, which allows spatiotemporal 
activation of signalling cascades using green algae-derived light-sensitive cation channels, 
the so-called channelrhodopsins (ChR)[123]. Following activation with blue light these 
ChR allow the inward transfer of ions, leading to depolarization and local induction and 
propagation of action potentials in cardiomyocytes[124, 125]. This optogenetic approach 
can be followed to control electrical stimulation of heart muscle and to study subsequent 
cellular physiological responses under healthy and diseased conditions[123, 125, 126]. 
Moreover, by generating hPSC-derived channelrhodopsin-expressing nodal cardiomyocytes 
the realization of a light-activated bio-pacemaker may be feasible in the future. In addition, 
a recent innovative approach has been developed based on G-protein coupled receptors 
(GPCRs) containing motifs enabling light-induced spatiotemporal activation of GPCR-
dependent pathways[127-129]. This will lead to a more in-depth understanding of specific 
intracellular signalling pathways in development, differentiation, and disease, and allows 
the identification of GPCRs and their downstream intracellular signalling cascades as 
therapeutic drugs target(s). Attributable to its ability to precisely control specific signalling 
pathways, optogenetics is a very promising technology for development of new assays in 
the field of drug development and toxicity, especially in combination with future 3D-disease 
modelling.
5   Cardiomyocyte Maturation and Sarcomeric Structures
One of the biggest challenges for the use of hPSC-CMs for preclinical drug screening is to 
increase the degree of maturity of hPSC-CMs[130]. Although morphological and functional 
aspects of hPSC-CMs resemble those of fetal cardiomyocytes, they still show a lack of 
maturity; hPSC-CMs are smaller in size, their sarcomeres, the smallest contractile units of 
striated muscles, have shown to be less organized when compared to adult CMs, they exhibit a 









is based on glycolysis, whereas adult CMs mainly use fatty acids as metabolic substrate[130, 
131]. The lack of a mature phenotype may affect mechanistic and functional aspects of hPSC-
CMs and consequently may result in a different drug-induced or disease-specific response. 
A higher degree of maturity is therefore most likely important for disease modeling and 
drug screening[100, 132]. Strategies to increase maturation in order to mimic human adult 
cardiomyocytes are followed with much interest. In addition, sarcomeric organization 
can be affected in hPSC-CM disease models and drug-induced cardiotoxicity[107]. It will 
therefore be of interest to study the organization of sarcomeric structures in hPSC-CMs 
with respect to the degree of maturation, and disease- and/or toxicity-induced sarcomeric 
disorganization (Figure 4).  In order to allow live-imaging for detailed analysis, a reporter line 
harbouring a fluorescent protein fused to sarcomeric proteins, may be a valuable additional 
tool, provided that the fusion protein will not affect cardiomyocyte function[133].
6   Conclusions and Future Outlook
Here, we reviewed the role of fluorescent hPSC reporter lines to our growing insights 
into cardiac differentiation, and their applications in the fields of cardiac regeneration, 
drug discovery, and toxicity screening. Fluorescent hPSC reporter lines have shown their 
advantages in the development and optimization of efficient cardiac differentiation protocols 
and will also be of high interest for deciphering the molecular signatures and mechanisms of 
differentiation of cardiac subtypes (Table 2a), using technologies such as epigenetics (histone 
modifications, chromatin dynamics), transcriptomics, proteomics and metabolomics[134]. 
The use of dual- or multi-fluorescent reporter lines will have an additional advantage. In this 
manner, sequential lineage decisions can be visualized in real-time, which can be combined 
with in-depth molecular and functional single cell analysis[135].
 A deeper understanding of the processes that determine maintenance and self-renewal of 
cardiac progenitors and thereby may provide an unlimited source of functional cardiac cells, 
will constitute an important contribution for the advancement of the fields of regenerative 
medicine, drug discovery and safety pharmacology. The identification of cell surface 
markers on specific cardiac cell subtypes allows enrichment of cardiomyocytes through cell 
sorting, which will be advantageous for the development of robust and validated assays 
for cardiomyocyte biology and/or function and for cell-based transplantation studies. In 
addition, improved knowledge on expansion and differentiation of cardiac progenitors may 
have far-reaching implications for the discovery of new therapies with a focus on activation 
of endogenous cardiac progenitors for the treatment of heart failure. In the context of 
heart repair it will also be of importance to visualize other biological processes such as 
cell death (necrosis and apoptosis) and the formation of cell-types following differentiation 
within their own lineage or as a result from switching cellular fate (e.g. via directed 
reprogramming). In this regard, subcellular labeling of cells using fluorescent proteins fused 
to specific localization signals, which target different organelles or compartments of the cell 
(e.g. membrane, cytosol or nucleus), offer an additional advantage for identification and 
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tracking of transplanted cells in complex multicolor labeling experiments.
 We have discussed the advantages of fluorescent reporters in cell-based transplantation 
studies, indicated by the possibility to visualize engrafted cells (i.e. homing and survival) 
and to study functional integration and maturation into the host myocardium (Table 2b). 
Combination of these fluorescent reporter lines with other advanced reporter lines, such 
as those based on optogenetics, enables studying specific signalling pathways in a temporal 
spatial manner. In this context the use of the light-sensitive cation channels, channelrhodopsins 
(ChR), derived from green algae, allow the inward transfer of ions following activation with 
blue light, leading to depolarization of cardiomyocyte and local induction of action potentials 
that are propagated to electrically coupled neighbouring cells[124, 125]. This optogenetic 
approach can be followed to control electrical stimulation of heart muscle and to study 
subsequent cellular physiological responses under healthy and diseased conditions[123, 
125, 126]. Moreover, by generating hPSC-derived channelrhodopsin-expressing nodal 
cardiomyocytes the realization of a light-activated bio-pacemaker is one step closer. Besides 
the in vivo applications, these reporter-based strategies have an important role for the 
further development and optimization of human in vitro assays for drug discovery, safety 
pharmacology and disease modelling.
 Finally, use of reporter-based assays and cardiac cell-types facilitates the development of 
three-dimensional (3D) tissues or organ-like structures for tissue engineering and generation 
of highly advanced models that are more closely resembling the human heart using a 
multidisciplinary approach. It will be intriguing to see how, among others, the emerging 
and widely discussed 3D bioprinting technology may contribute to achieve this goal. In 
addition to cardiomyocyte subtypes, additional cardiac cell-types, including vascular cells 
and fibroblasts and the right composition of extracellular matrix components need to be 
included in order to generate these structures. Clearly, many hurdles need to be overcome, 
but increased interest of academia and industry in the use of human stem cell-based assays 
(Table 2c) will stimulate this field and likely increases the pace of its development, which will 
be a big step forward in improving efficient, cost-effective and safe drug development and 
effective therapies for the treatment of cardiac diseases.
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Figure 1. Schematic overview of Functional Applications of Human Fluorescent Reporter Lines for Cardiac 
differentiation and Cardiac Disease and Toxicity.
Figure 2. Dual Cardiac Fluorescent Reporter Line MESP1-mCherry-NKX2-5-eGFP in hESCs allows visualization and 
isolation of pre-cardiac mesoderm MESP1+ progenitor formation from hESCs, and their further differentiation to 
NKX2-5-eGFP+ derivatives, marking early cardiac progenitors and cardiomyocytes. Den Hartogh et al. Stem Cells, 2015.
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Figure 3. Fluorescent Proliferation Marker eGFP-Anillin. Left panel: Fusion of eGFP to scaffolding protein Anillin, which 
is differentially localized in the cell during specific cell cycle stages, allowing detection of the M-phase, and cytokinesis. 
Right panel: Proliferating α-actinin+ (white) cardiomyocytes in sections from an E18.5 eGFP–anillin heart are identified 
by eGFP labelling (green) of contractile rings or midbodies; Ki-67 staining is red; nuclei are blue. Scale bar, 10 μm. Both 
images were adapted from Hesse et al. Nature Communications, 2012, with permission from dr. Bernd K. Fleischmann.
Figure 4. Sarcomeric organization in hiPS derived Cardiomyocytes improves upon maturation. Left: 30-day-old hiPSC-
derived CMs cultured in standard CM medium. Right: hiPSC-derived CMs after culture in commercial media optimized 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2c. Fluorescent Reporter Lines for Disease Modelling, Drug Discovery, and Toxicity
Assay Measurement
Intracellular calcium mobilization
Calcium dynamics Calcium dyes: Fluo-2/3/4/8,
Fura-2, Fura-4F  (ratiometric)
Transmembrane potential Voltage sensitive dyes
Cell viability assay Hoechst expression / 
DNA binding fluorescent proteins
Apoptosis assay Caspase3/7 activity through substrate luminescence
Oxidative stress Reactive Oxygen Species (ROS)
Ki-67
Cell proliferation eGFP-Anillin localizations
PHH3 stainings
Hypertrophy / Cell size
Sarcomeric organizations Sarcomere staining
Intracellular lipid accumulation/ Quantification of fluorescent intensity in 
Peroxidization cytoplasm (perioxidization assay kits available)
Signalling pathways In vitro fluorescent reporter assays that reveil 
cellular response pathways
Table 2c. Fluorescent reporter lines for disease modeling, drug discovery, and toxicity.
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ABSTRACT
Understanding early differentiation events leading to cardiogenesis is crucial for controlling 
fate of human pluripotent stem cells and developing protocols that yield sufficient cell 
numbers for use in regenerative medicine and drug screening. Here, we develop a new tool 
to visualize patterning of early cardiac mesoderm and cardiomyocyte development in vitro 
by generating a dual MESP1mCherry/w-NKX2-5eGFP/w reporter line in human embryonic stem 
cells (hESCs) and using it to examine signals that lead to formation of cardiac progenitors and 
subsequent differentiation. MESP1 is a pivotal transcription factor for pre-cardiac mesoderm 
in the embryo, from which the majority of cardiovascular cells arise. Transcription factor 
NKX2-5 is expressed upon cardiac crescent formation. Induction of cardiac differentiation 
in this reporter line resulted in transient expression of MESP1-mCherry, followed by 
continuous expression of NKX2-5-eGFP. MESP1-mCherry cells showed increased expression 
of mesodermal and EMT (epithelial-mesenchymal-transition) markers confirming their 
mesodermal identity. Whole-genome microarray profiling and FACS analysis of MESP1-
mCherry cells showed enrichment for mesodermal progenitor cell surface markers PDGFR-α, 
CD13, and ROR2. No enrichment was found for the previously described KDR+PDGFR-α+ 
progenitors. MESP1-mCherry derivatives contained an enriched percentage of NKX2-5-
eGFP and Troponin T expressing cells, indicating preferential cardiac differentiation; this 
was enhanced by inhibition of the Wnt-pathway. Furthermore, MESP1-mCherry derivatives 
harboured smooth muscle cells and endothelial cells, demonstrating their cardiac and 
vascular differentiation potential under appropriate conditions. The MESP1-NKX2-5 hESC 
reporter line allows us to identify molecular cues crucial for specification and expansion 
of human cardiac mesoderm and early progenitors and their differentiation to specific 
cardiovascular derivatives.
INTRODUCTION
Human pluripotent stem cells (hPSCs) offer exceptional opportunities for regenerative 
medicine, drug discovery and toxicity, disease modelling and developmental biology 
because of their ability to differentiate in principle into any cell type of the human body. 
In particular, their differentiation towards cell types that are challenging to obtain and 
maintain as primary cultures from tissues with limited or no self-repair capacity, such as 
the brain and heart, have made them attractive as research models. Previously, we and 
others have shown that cardiomyogenesis of hPSCs in vitro recapitulates signalling events 
and sequential transcriptional activation that occurs during heart development in vivo 
[1, 2]. Moreover, as knowledge of the regulatory mechanisms that govern in vivo cardiac 
development has advanced, it has been possible to translate this to differentiation protocols 
based on stepwise temporal modification of signalling pathways. This has led to a remarkable 
increase in the yield of cardiac cells not only from hESCs but also from human induced 
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pluripotent stem cells (reviewed in [3]).
However, despite these advances, the cardiac derivatives obtained contain heterogeneous 
populations of cardiac cells: not only different subtypes of cardiomyocytes but also 
endothelial cells and smooth muscle cells. This is because the molecular cues underlying 
specification of early human cardiac progenitors towards specific cardiac subtypes have not 
been fully elucidated. For future clinical and pharmaceutical applications, better insight into 
the differentiation of cardiac cell subtypes is necessary. 
Several studies have shown that different cardiac subtypes are derived from multiple 
early cardiac progenitors that segregate soon after gastrulation[4-6]. The molecular 
mechanisms that play a role in the formation of early cardiac progenitors however, remain 
largely unknown[4, 7]. In order to study the onset of cardiac differentiation in human, it is 
necessary to identify early populations from common progenitors at the mesodermal stage 
of development and identify the molecular pathways involved in the further differentiation 
of the cardiac lineage. 
Mesoderm transcription factor MESP1 is important in this context as in vivo lineage tracing 
in mouse has demonstrated that almost all cells of the heart are derived from a common 
MESP1-expressing mesodermal progenitor, including myo-, endo, and epicardium, and cells 
of the conduction system[8-10]. MESP1 is transiently expressed in the anterior mesoderm 
from the onset of gastrulation prior to cardiac crescent formation[8, 11, 12]. Furthermore, 
MESP1 overexpression in mouse ESCs showed that MESP1 induces the expression of 
cardiovascular genes[13-15]. A recent study in mouse illustrated that besides the cardiac 
lineage, MESP1 derivatives also encompass cells of the hematopoietic- and skeletal myogenic 
lineages, which emerge depending on the endogenous and exogenous cues present during 
MESP1 expression[16]. Of note, all these studies have been performed in mice. However, to 
instigate advances in human heart development, regenerative medicine, disease modelling 
and drug testing, it is necessary to understand the earliest steps of cardiac differentiation in 
a human model.
In order to identify, isolate and characterise MESP1 expressing cells during human 
cardiomyogenesis, we introduced the mCherry reporter into the MESP1 locus of the NKX2-
5eGFP hESC reporter line generated previously [17], leading to a dual reporter system for 
these early cardiovascular lineage markers in hESCs. We were able to isolate the MESP1-
expressing mesoderm progenitors in a cardiac-inducing environment and demonstrate 
their ability to differentiate further to a highly enriched NKX2-5eGFP expressing cardiac 
population. We further confirmed the presence of other mesoderm and cardiac progenitor 
populations in MESP1-mCherry expressing-derivatives, including CD13+ROR-2+ and PDGFR-
α+KDR+ populations [18-20]. Although CD13, ROR-2, and PDGFR-α expression were strongly 
enriched, they were not specifically expressed in the MESP1-mCherry derivatives. In 
addition, no enrichment was found for the previously described PDGFR-α+KDR+ population.
Finally, we demonstrate that this MESP1mCherry-NKX2-5eGFP dual reporter hESC line is a 
useful tool to study the differentiation of pre-cardiac mesoderm towards early cardiac 
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progenitor cells and their derivatives. It now provides an opportunity to study the molecular 
mechanisms underlying the onset of progenitor subtypes formation specifically in the 
cardiac lineage in human. This hESC dual reporter will contribute to providing better insights 
into cardiomyocyte determination and form the basis for improved differentiation protocols 
for specifying cardiac subtypes (atrial, ventricular, pacemaker cells). This will be relevant to 
future pharmaceutical and clinical applications of specific cardiac cell subtypes.
METHODS
MESP1 Gene Targeting in hESCs 
To generate the MESP1 targeting vector, the bacterial artificial chromosome (BAC) RP11-
975L13 (Source Bioscience, Lifesciences) was modified by recombineering (Gene Bridges). 
The mCherry cassette and a selection marker replaced the MESP1 exon 1 sequence 
(oligonucleotides used for recombineering: MESP1_5arm_PvuI and MESP1_3_arm, Supp. 
Table S1). The modified MESP1 locus and the surrounding 5′and 3’homology arms were 
subsequently subcloned into the MESP1 targeting vector. The final vector comprised a 
8.6-kilobase (kb) 5′homology arm, mCherry, loxP-flanked G418 resistance cassette and a 
2.3-kb 3′homology arm.
The targeting vector was linearized by PvuI digestion and 20 μg was electroporated into 
9x106 NKX2-5-eGFP reporter hESCs (HES3-NKX2-5eGFP/w)[17] as described previously[21]. 
Targeted clones were identified by PCR using oligonucleotides specific for mCherry (P1) and 
a region immediately 3′of the targeting vector (P2) (Fig. S1, Table S1). 
Targeted clones were clonally derived and transfected with Cre-recombinase to excise the 
loxP-flanked neomycin-resistance cassette as described previously[22]. Neomycin excision 
was confirmed by PCR (Fig. S1, Table S1). Undifferentiated, targeted clones were fixed in 2% 
paraformaldehyde and were used for immunocytochemistry (Nanog, Tra-181, and Oct-4) to 
confirm their pluripotent status. For karyotyping, 20 metaphase chromosome spreads were 
examined for each line.
Single Cell Sorting 
For single cell sorting, hESCs were enzymatically passaged using 1x TrypLE Select (Life 
Technologies). After dissociation, cells were resuspended in FACS sorting buffer (PBS with 
0.5% BSA and 2.5mM EDTA) and filtered through a 40-μm cell strainer (Falcon). Cells were 
sorted using a BD ARIA III flow cytometer into 96 wells flat-bottom low attachment plates, 
live cells were gated on the basis of side scatter, forward scatter and propidium iodide 
exclusion. Flow cytometric gates were set using control cells labelled with the appropriate 
isotype control antibody.
hESC Culture and Cardiac Differentiation
MESP1mCherry/w NKX2-5eGFP/w hESCs were cultured on mouse embryonic fibroblasts on 2.85 cm2 
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organ dishes (Falcon), in 1 mL hESC medium (DMEM F12, Non Essential Amino Acids, Knock 
Out Serum (Gibco by Life Technologies); bFGF (Miltenyi Biotec)) and were mechanically 
passaged[23]. One or two days before differentiation, cells were passaged onto a 12-well 
tissue culture dish coated with Matrigel (BD Biosciences; growth factor reduced, phenol 
red–free), in 1 mL of hESC medium per well. On the first day of differentiation, day 0, hESC 
medium was replaced by the low insulin serum-free medium BPEL (BSA, polyvinyl alcohol, 
essential lipids, as previously described)[17, 24], containing the cytokines BMP4 (30 ng 
ml−1, R&D Systems) and Activin A (30 ng ml−1, Miltenyi Biotec), and Chir99021 (1.5uM, Axon 
Medchem). At day 3 of differentiation, the medium was refreshed with BPEL containing 5uM 
Xav939 (R&D). On day 7 of differentiation, the medium was replaced with BPEL without 
growth factors. 
Isolation and Re-aggregation of MESP1-mCherry cells
On day 3 of differentiation, cells were sorted by flow cytometry as described above, based 
on mCherry expression (both positive and negative populations). Flow cytometric gates 
were set using undifferentiated hESCs. Sorted cells were seeded in a 96-well V-shaped non-
adherent plate (Greiner Bio One) at 20,000 cells per well in 50 μL BPEL in the presence 
of Xav939 (5uM, R&D) to enhance cardiac differentiation. Aggregation was initiated by a 
brief centrifugation step for 3 minutes at 480g. Four days after replating, aggregates were 
refreshed with BPEL without addition of growth factors or inhibitors. 
Analysis of MESP1-mCherry Derivatives
Cardiomyocytes derived from MESP1-mCherry-sorted cells were analyzed by flow cytometry 
and immunohistochemistry (IHC) on day 3, 5 and day 14 of differentiation (0, 2 and 11 days 
after replating). For IHC, MESP1-mCherry-derived aggregates were fixed in 2% PFA at day 
14. For alpha-actinin and SM-HC IHC, MESP1-mCherry-derived aggregates were dissociated 
using 1x TrypLE Select, plated on matrigel in BPEL, and fixed after four days.
For flow cytometric analysis, aggregates were collected, dissociated as described before, 
and resuspended in FACS washing buffer (PBS with 2% FCS and 2.5mM EDTA). For analysis of 
intracellular markers, cells were treated with FIX & PERM® Cell Fixation and Permeabilization 
Kit (Life Technologies). Analyses were carried out using a MACS-Quant VYB flow cytometer 
(Miltenyi Biotec) and FlowJo Software. Antibodies are listed in Supplementary Table S4 
(Table S4). Specimens were analysed with confocal laser microscope (Leica TCS SP8). Images 
were acquired with Leica LAS AF software. MESP1-mCherry expressing cells were visualized 
in monolayer differentiation at day 3, using a Nuance™ Multispectral Imaging System.
RNA isolation, Quantitative Real-time PCR and Microarray Analysis
Total RNA was isolated using either the RNeasy micro (Qiagen) or Nucleospin RNA XS kits 
(Macherey Nagel) according to manufacturer’s protocols, and treated with RNase-free 
DNase. Between 100 ng to 1 ug RNA was reverse transcribed into cDNA with I-scriptTM 
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cDNA synthesis kit (Bio-rad), according to manufacturer’s protocol. Real-time quantitative 
PCR was performed on a CFX96 Real Time System (Biorad). All experiments were carried out 
in triplicate with iTaq™ Universal SYBR® Green Supermix. Expression levels were normalised 
to the housekeeping gene hARP and multiplied by 1000 for the purpose of presentation. 
Primer sequences are listed in Supplementary Table S2 (Table S2). Microarray analysis 
was performed on three biologically independent replicates using Illumina human HT-
12v4 arrays (ServiceXS). Illumina microarray data were processed using the lumi package 
and differentially expressed genes were identified using the limma package, included in R/
Bioconductor[25, 26]. ConsensusPathDB-human (http://cpdb.molgen.mpg.de/) web server 
was used for gene ontology analysis. Additional analysis was performed using Genespring 
(Agilent Technologies).
RESULTS
Generation of a MESP1mCherry-NKX2-5eGFP dual cardiac reporter 
To identify, purify and characterize human pre-cardiac mesodermal progenitors and study 
their further differentiation, we generated a dual fluorescent hESC reporter line by inserting 
the sequence encoding mCherry into the MESP1 locus of an existing NKX2-5eGFP reporter 
line by homologous recombination (Fig 1a, b). A PCR screening strategy was performed 
to identify correctly targeted clones (Fig S1a,b). Twenty correctly targeted clones were 
obtained (11% targeting efficiency) from which four clones showed the loxP-flanked 
neomycin-resistance cassette was excised following transfection with Cre recombinase (not 
shown) [22]. We proceeded with clone 2.20B3 (Fig. S1c). hESCs from clone 2.20B3 displayed 
a high immunoreactivity for NANOG, TRA-181, OCT-4, and EPCAM antibodies, confirming 
no loss of pluripotency during targeting and selection procedures (Fig S2a,b). Furthermore, 
chromosome analysis demonstrated no abnormal karyotypes in these targeted lines (Fig 
S2c).
To demonstrate that the targeted MESP1Mcherry/w-NKX2-5eGFP/w hESC lines faithfully recapitulated 
MESP1 activity, hESCs were differentiated as monolayers to cardiac cells by addition of the 
growth factors BMP4 and Activin-A, as well as GSK-3-β inhibitor Chir99021 from day 0 to day 
3, followed by the Wnt-signalling antagonist pathway inhibitor Xav939 from day 3 to day 7 of 
differentiation (Fig 1c).  Red fluorescence of mCherry was clearly visible in a subset of cells at 
day 3 of differentiation (Fig 1d). Cells expressing mCherry appeared to have undergone EMT, 
based on their mesenchymal-like morphology.
MESP1mCherry-NKX2-5eGFP hESCs differentiate towards mesoderm and the 
cardiac lineage
Quantitative PCR (qPCR) analysis of the targeted cell line during differentiation towards the 
cardiac lineage confirmed transient expression of mCherry, peaking at day 3 of differentiation 
and mirroring endogenous MESP1 expression (Fig 2a). In agreement with previous in 
CHAPTER 3
vitro and in vivo studies, expression levels of mesendodermal genes Brachyury (BRY) and 
Eomesodermin (EOMES) displayed peak values at day 2 of differentiation, before that of 
MESP1. Expression levels of NKX2-5 were clearly detectable from day 9 of differentiation, 
just before the appearance of contractile areas. Expression of NKX2-5 further increased at 
day 12, confirming the ability of the MESP1mCherry-NKX2-5GFP reporter line to differentiate 
towards the cardiac lineage. Flow cytometric analysis showed that MESP1-mCherry 
expressing cells first appeared around day 2, peaking at day 4 (8.0% ± 0.5% (mean ± SEM)), 
and becoming negligible by differentiation day 8 (Fig 2b,c), reflecting the gene expression 
profile. NKX2-5-eGFP protein was detected later, first appearing on day 8 and continuing to 
increase to day 14 of differentiation (28.9% ± 1.7%), reflecting our previous findings[17]. 
These results demonstrated that the MESP1mCherry and the NKX2-5eGFP reporters allowed 
visualization of early MESP1-expressing progenitors, followed by the formation of NKX2-5-
expressing cardiac cells during hESC differentiation. 
Gene Expression Profiling of MESP1-mCherry progenitors
To further characterize the MESP1-mCherry progenitors, we isolated MESP1-mCherry 
positive cells (MESP1-mCherry pos) at day 3 of differentiation and compared their 
gene expression profile with MESP1-mCherry negative cells (MESP1-mCherry neg) and 
undifferentiated hESCs of the same line (Fig 3a). A correlation heatmap between samples is 
shown in supplemental figure 3 (Fig. S3). In three biological replicates, 722 genes showed an 
increase in expression of ≥ 1.5 fold when compared to MESP1-mCherry neg cells (Fig 3b). In 
agreement with their mesodermal character, MESP1-mCherry pos cell fraction was enriched 
for EMT- and mesendodermal related genes, including MESP1 itself, SNAI1, SNAI2, MSX1, 
FOXC1, GSC, MIXL1, EOMES, LHX1, FOXF1, and IRX3. Although the differences were greater 
in MESP1-mCherry pos cells, mesendodermal and EMT-related gene levels were higher in 
both MESP1-mCherry pos and neg fractions compared to undifferentiated hESCs, indicating 
that cells had undergone some form of mesoderm differentiation in the protocol used. 
Furthermore, the enrichment of N-cadherin (CDH-2) and vimentin (VIM), and decrease of 
E-cadherin (CDH-1) and EPCAM are also strongly associated with EMT. As expected, transcripts 
of pluripotency genes, including SOX2, OCT3-4, and NANOG, were significantly decreased. 
Furthermore, early cardiac genes, such as GATA4, TBX3, MYL4, GATA6, and HAND1, were 
enriched indicating the pre-cardiac character of MESP1-mCherry progenitors. In addition, 
genes encoding extracellular matrix proteins were increased, including several collagens, 
integrins, laminins, and fibronectin, as well as extracellular matrix (ECM)-receptors, such 
as integrin α-5 (ITGA5). These proteins could play an important role in stage-dependent 
processes such as mesoderm migration or niche formation of the pre-cardiac mesodermal 
cell population. 
The microarray data also indicated the expression of genes of various signalling pathways 
in the MESP1-mCherry pos population, including Notch ligand DLL3, BMP4, FGF17, the 
BMP-antagonist CER1, Wnt inhibitors DKK1 and DKK4, and other components of (non)
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canonical Wnt signalling, such as the ligand Wnt5a and (co)-receptors FZD2, ROR-2, and 
RSPO3. Protein complex analysis showed 100% enrichment of the non-canonical WNT5a/
FZD2/ROR-2 complex (data not shown). In agreement with this, pathway analysis showed 
significant enrichment (P-value ≤ 0.01) in extracellular matrix organization, Wnt signalling 
pathway, cardiac progenitor differentiation, and heart development (Fig 3c). qPCR analysis 
validated enhanced expression of a selection of the genes upregulated in the microarray 
data (Fig 3d).
Surface Marker Expression Analysis of MESP1-mCherry progenitors
Further microarray analysis identified several genes encoding mesoderm associated cell 
surface proteins, including NCAM1, ROR-2, CD13, CDH-2, CDH-11, and PDGFR-α, which 
showed increased expression in MESP1-mCherry pos cells (Fig 3a). FACS analyses showed that 
large proportions of the MESP1-mCherry pos cells expressed cell surface proteins PDGFR-α 
(approximately 70%), CD13 (approximately 97%), and ROR-2 (approximately 96%) (Fig 4a). 
However, none of these proteins marked the MESP1-mCherry pos population exclusively, 
since expression was also clearly detected in the MESP1-mCherry neg cell populations (Fig 
4b). Further, only a small percentage in both the MESP1-mCherry pos and neg population 
was co-expressing PDGFR-α and KDR, in agreement with the microarray analysis, which 
showed that KDR was not differentially expressed in the MESP1-mCherry pos population.
Generation of Cardiac Cells from Isolated MESP1-mCherry progenitors
To investigate whether MESP1-mCherry pos progenitors were able to differentiate towards 
the cardiac lineage, MESP1-mCherry pos cells were isolated on day 3 of differentiation, 
seeded as aggregates or in monolayer in the presence of Wnt-pathway agonist Xav939 until 
differentiation day 7, and maintained until differentiation day 14 (Fig 5a).  To evaluate how 
mesoderm progenitor populations are represented in MESP1-mCherry sorted derivatives, 
we initially performed FACS analysis on differentiation day 5 (2 days after replating). ROR-
2+CD13+ cells were slightly enriched in the MESP1-mCherry pos population, compared 
to the MESP1-mCherry neg population; approximately 73% ± 9% (mean ± SEM) vs. 39% 
± 16% respectively  (Fig 5b). Furthermore, almost all MESP1-mCherry derivatives on day 
5 expressed PDGFR-α (approximately 98% ± 1% (mean ± SEM)), while only 50% ± 4% of 
the day 5 MESP1-mCherry neg derivatives did. Interestingly, there was no enrichment of 
a KDR+PDGFR-α+ cardiac progenitor population in the MESP1-mCherry pos population, 
compared to the MESP1-mCherry neg derivatives (approximately 22% ± 2% (mean ± SEM) 
vs. 28% ± 12%, respectively) (Fig 5b). Similar results were found at other time points during 
differentiation (day 4-8)  (Fig. S4).
On day 8 and day 14 of differentiation, the expression of several cardiac-associated genes 
was enriched in the MESP1-mCherry pos derivatives compared to the MESP1-mCherry neg 
derivatives, including cardiac genes NKX2-5 and ISL1, smooth muscle cell markers SMA and 
MYH11, and endothelial marker PECAM-1 (Fig 5c,d). Additionally, NKX2-5 expression, as 
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determined by flow cytometric quantification of eGFP expression, was significantly enriched 
in the MESP1-mCherry pos population, treated with Xav939 (80% ± 4% (mean ± SEM)) when 
compared to MESP1-mCherry neg cells under similar differentiation conditions (18% ± 6%) 
(Fig 6a,b,c). The eGFP+ cells detected in the MESP1-mCherry neg day 14 aggregates may 
have been derived from a small percentage of MESP1-mCherry pos cells that subsequently 
appeared in the MESP1-mCherry neg population following sorting. Indeed, low expression 
levels of mCherry and MESP1 could be detected in negative sorted samples at day 3 and day 
4 (one day after reaggregation) (Fig. S5).
The importance of inhibiting Wnt/β-catenin signalling following mesoderm induction to 
generate NKX2-5-expressing cardiac progenitors was highlighted by the low levels of eGFP in 
the untreated MESP1-mCherry pos (23% ± 4%) and MESP1-mCherry neg derivatives (0.50% 
± 0.4%). Furthermore, in all conditions, the NKX2-5eGFP+ derivatives were spontaneously 
contracting on differentiation day 14 (data not shown).
To determine whether other specific signalling pathways could affect cardiac differentiation 
from mesoderm, three other major pathways associated with cardiac differentiation were 
inhibited after MESP1-mCherry sorting and re-aggregation (from day 3 to day 7). Inhibitors 
of these pathways included TGF-β/act/Nodal antagonist SB431542, and BMP inhibitor 
Dorsomorphin. None of these inhibitors led to an increase in GFP expression at day 14 when 
compared to control treatment. In fact, GFP expression showed a tendency to decrease in 
the SB431542-treated cells (Fig S6).
Day 14 MESP1-mCherry pos derivatives treated with Xav939, expressed various cardiac 
lineage markers, including α-Actinin (cardiomyocytes), PECAM-1 (endothelial cells), and 
SMA and SMC-myosin (expressed in immature cardiomyocytes as well as smooth muscle), 
indicating the MESP1-mCherry pos cell population can generate all three different cell types of 
the cardiac lineage (Fig 6d). In addition, flow cytometric analysis showed enrichment of cTNT 
(approximately 51% ± 9% (mean ± SEM)) and PECAM-1 (approximately 2.2% ± 0.2% (mean ± 
SEM)) expressing cells in day 14 MESP1-mCherry pos derivatives, compared to the MESP1-
mCherry neg derivatives (approximately 11% ± 5% and 0.62% ± 0.1%  respectively) (Fig 6e). 
SIRPA+ VCAM1+ co-expression marks NKX2-5-eGFP+ cardiomyocytes
In addition to the characterization and differentiation of MESP1mCherry progenitors and 
their further differentiation to NKX2-5eGFP cardiac cells, we studied whether the previous 
described cell surface proteins SIRPA and VCAM1 are specifically marking hESC-derived-
cardiomyocytes[27, 28]. We analyzed SIRPA-VCAM1 and cTnT expression on cardiac cells at 
day 14 of differentiation of NKX2.5-eGFP-HESCs (Fig S7). We showed that the SIRPA+VCAM1+ 
double positive population was highly enriched for NKX2-5-eGFP+ cells (Fig S7a). In addition, 
the vast majority of NKX2-5-eGFP+ cells were cTnT+ (Fig S7b). Similar results were described 
in a recent study by Skelton et al., in which SIRPA+VCAM1+NKX2-5-eGFP+ cardiomyocytes 
were shown to arise from a SIRPA+NKX2-5-eGFP+ intermediate progenitor population[28].
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DISCUSSION
Genetically modified reporter lines are proving increasingly valuable for developing precise 
protocols for the directed differentiation of various lineages from human PSCs[29-32]. Here 
we increased the degree of complexity of the processes that can be analysed by creating a 
double transgenic reporter hESC line, taking advantage of endogenous activation of the key 
cardiac transcription factors MESP1 and NKX2-5[17]. We introduced the fluorescent protein 
mCherry into the genomic locus of the mesodermal transcription factor MESP1, in NKX2-
5eGFP hESCs. As predicted from mouse developmental biology studies, the MESP1mCherry-NKX2-
5eGFP line firstly expressed mCherry under conditions of mesoderm induction, and later GFP+ 
cardiac progenitors and cardiomyocytes emerged in the cultures, demonstrating the value 
of hESCs as in vitro model of previously inaccessible stages of early human development. 
MESP1-mCherry pos cells were first detected on day 2 of differentiation with peak levels 
between day 3 and 4, which is in agreement with our earlier observations during cardiac 
differentiation of hESCs[1]. We demonstrated that sorted and reaggregated MESP1-
mCherry pos cells on differentiation day 3 have a much higher potential to differentiate 
to cardiovascular derivatives than MESP1-mCherry neg cells, as demonstrated by (i) the 
appearance of functional beating cardiomyocytes and (ii) high numbers of NKX2-5eGFP+ 
cardiac cells in the population on day 14 of differentiation (11 days after sorting). At the same 
stage of differentiation, enriched gene and protein expression were found for PECAM-1, 
SMA, and cTNT, suggesting that MESP1-mCherry cells can differentiate to endothelial cells, 
smooth muscle cells and cardiomyocytes, respectively.
Microarray analysis of MESP1-mCherry pos and MESP1-mCherry neg cells revealed new 
insights into the transcriptional profile of human pre-cardiac mesodermal progenitors. 
In particular, transcription factors and signalling pathways associated with mesoderm 
formation, EMT, early cardiac development and components of the ECM were highly 
enriched in MESP1-mCherry pos cells. This is broadly in accordance with the molecular 
signature of MESP1-GFP expressing mouse cells[33]. However, disparities possibly related 
to interspecies differences, differentiation protocols, or technical variations (i.e. random 
integration of an isolated regulatory sequence of the Mesp1 mouse promoter versus 
homologous recombination in the human MESP1 locus) were evident. For example, the 
expression of cardiac transcription factors such as HAND2, MEIS2, SMARCD3, HEY1, HEY2, 
and TBX2 was increased in MESP1-GFP positive cells, whereas in our study these genes were 
not enriched in the MESP1-mCherry pos population. However, expression of these genes 
was increased at later stages following cardiac differentiation of sorted cells, suggesting that 
human MESP1-mCherry pos cells may be a more restricted mesodermal population.
Transition of undifferentiated epithelial pluripotent stem cells to mesodermal cells 
requires the activation of EMT-associated genes. Indeed, MESP1-mCherry pos cells exhibit 
an obvious increase in levels of EMT-related transcription factors SNAI1 and SNAI2. In 
agreement, increased expression of other EMT-related genes, including Vimentin and CDH-
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2, and decreased levels of epithelial proteins, such as CDH-1 and EPCAM, suggested that 
EMT took place in MESP1-mCherry pos cells. In addition, enrichment of many ECM-related 
transcripts, such as those for collagens, integrins, fibrillin, matrix remodellers, and receptors, 
like the Apelin Receptor (APLNR), suggested formation of an appropriate niche for MESP1-
expressing cells [34, 35]. Alterations in cell-cell and cell-matrix interactions are crucial for 
biological processes such as EMT, intracellular interactions, cell-fate decisions, or migration 
of pre-cardiac MESP1-progenitors from the anterior part of the primitive streak to form the 
bilaterally situated cardiac crescent in vivo [36-39]. Further study is required to identify the 
role of specific ECM components and receptors for expansion and further differentiation of 
MESP1+ cells.
Several signalling pathways were also significantly activated in MESP1-mCherry pos cells. 
In particular, components of the Wnt signalling pathway were affected, including the Wnt-
inhibitors DKK1 and DKK4, the (non)canonical pathway ligands WNT4 and WNT5a, and the 
receptors ROR-2 and FZD2. Previous studies have indicated an important role for activated 
canonical Wnt-signalling during hESC to mesendoderm differentiation[40-43]. Subsequent 
inhibition of this pathway by DKK-1 resulted in improved cardiac differentiation, confirming 
the need to inhibit canonical Wnt-signalling following mesoderm formation for efficient 
cardiac differentiation[14, 40].  Conversely, at the same stage, activated non-canonical 
signalling has been associated with driving cardiac differentiation[44]. Non-canonical 
Wnt signalling has been linked with different molecular mechanisms, including canonical 
Wnt and/or β-catenin signalling inhibition[42, 45, 46], progenitor proliferation[47],  and 
cellular movements and polarity. Here, we confirmed the importance of Wnt-inhibition in 
mesoderm to cardiac progression, as we found a major increase in the percentage of NKX2-
5eGFP expressing cells upon treatment with the chemical Wnt signalling antagonist, Xav939. 
Other pathways that have been shown to play crucial roles in the early stages of mesoderm 
formation, such as the BMP, Notch and FGF pathways, were also present in the MESP1-
mCherry pos population, suggesting cross-talk of components of these pathways during 
these early pre-cardiac mesoderm stages[41].
We also examined expression of cell surface markers of mesodermal and cardiovascular 
progenitors during the differentiation of MESP1mCherry-NKX2-5eGFP cells. Several studies have 
reported that PDGFR-α and Flk1/KDR are expressed on early cardiovascular progenitor cells, 
giving rise to cardiomyocytes, endothelial cells, and vascular smooth muscle cells[5, 19, 20]. 
In recent studies using hESCs, an early mesoderm population co-expressing CD13 (ANPEP) 
and ROR-2 has been identified [18, 48]. This population consists of a KDR+PDGFR-α+ 
subpopulation, which has the potential to give rise to cardiovascular cells. In agreement, we 
demonstrated a significant increase in CD13, ROR-2, and PDGFR-α on day 3 MESP1-mCherry 
pos cells and on day 5 derivatives. However, these surface markers were also expressed 
in a high percentage of the MESP1-mCherry neg populations, indicating that they mark a 
broader population than only pre-cardiac mesoderm[27]. Interestingly, in MESP1-mCherry 
pos derivatives we did not find enrichment of KDR+ cells. These findings indicated that, 
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besides the previously described Flk1/KDR+ PDGFR-α+ cardiac progenitor population, other 
MESP1-derived pre-cardiac mesoderm progenitor populations exist, that (co)express other 
(cell surface) markers, and have the potential to differentiate towards NKX2-5eGFP expressing 
cardiac cells. In previous studies, the cardiac potential of other subpopulations besides the 
Flk1/KDR+ PDGFR-α+, was not tested[18, 20].
One of the major challenges in cardiovascular research is cardiac regeneration and improved 
cardiac function in heart failure patients. Tissue engineering, cellular therapy, endogenous 
activation of cardiac progenitors cells, or a combination of these approaches may lead to 
novel therapeutic strategies[49]. However, a key concern is the selection of the right cell 
type for transplantation or enhanced in situ proliferation, as this will be important for 
survival and engraftment, for safety (risk of tumor formation), and for the ability to form the 
required cell type(s) [50, 51]. A recent study showed the ability of a hESC-derived CD13+ROR-
2+KDR+PDGFR-α+ cardiac progenitor population to migrate, couple, and form cardiac cells 
after being transplanted into ex vivo human fetal ventricular heart tissue, without formation 
of teratomas[18]. As pre-cardiac MESP1-progenitors are able to form almost all cell types of 
the heart, it will be of interest to examine both the developmental and regenerative capacity 
of these cells upon transplantation into both healthy and damaged hearts. Even though 
many hurdles have to be overcome, transplantation studies using cardiac-lineage-restricted 
progenitors may shed more light on future heart regeneration therapies. In addition, 
understanding the molecular cues that are important for expansion of mesodermal cells and 
their specific differentiation to the cardiac lineage may lead to novel therapies which are 
based on the progression of endogenous cardiac progenitor cells to functional specialized 
cardiovascular cells. 
CONCLUSION
We conclude that the MESP1mCherry/w-NKX2-5eGFP/w dual cardiac fluorescent reporter hESC line 
in this study is a useful tool for dissecting the molecular and cellular mechanisms related 
to the earliest steps in cardiac development in live cells. This is novel way to carry out fate 
analysis of this subpopulation. Purified mesodermal MESP1-mCherry pos cells efficiently 
differentiated to beating NKX2-5GFP+ cells by inhibition of the Wnt-pathway. Besides a better 
understanding of underlying mechanisms, this human cardiac dual reporter line will make 
it feasible to identify and specify culture conditions for expansion of a mesodermal cell 
population and their further differentiation towards cardiac progenitor cells and specific 
subtypes of the cardiac lineage in vitro. This is of particular interest for future studies on 
cardiac toxicity, drug screening, tissue engineering, and regenerative medicine.
CHAPTER 3
ACKNOWLEDGEMENTS
We thank Dorien Ward-Van Oostwaard for technical assistance; Kostas Gkatzis for help on 
statistical analysis using R/Bioconductor, the Department of Molecular Cell Biology, LUMC, for 
karyotyping analysis. S.C.D.H was supported by the Rembrandt Institute for Cardiovascular 
Disease. This study was supported by the Rembrandt Institute for Cardiovascular Science 
(S.H.), NHMRC, Australia (D.A.E.), ZonMw-MKMD-40-42600-98-036 (R.P.), ERC Advanced 
STEMCARDIOVASC-323182  (C.L.M.).
FIGURES
Figure 1. Generation of a MESP1mCherry-NKX2-5eGFP dual reporter hESC line. A: Schematic overview of wild-
type MESP1 allele, MESP1 targeting construct, and targeted MESP1 allele. B: Schematic overview of the dual cardiac 
fluorescent reporter line. p: endogenous gene regulatory elements of either MESP1 (MESP1p) or NKX2-5 (NKX2-5p).  C: 
Cardiac monolayer differentiation protocol in BPEL. MG: matrigel. Tg: transgenic. D: MESP1-mCherry expressing cells at 
day 3 of cardiac differentiation, visualized by a Nuance™ Multispectral Imaging System.
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Figure 2. Timecourse of MESP1mCherry-NKX2-5eGFP hESCs differentiating towards the cardiac lineage. A: 
mRNA levels of mesendodermal genes BRACHYURY T (T) and EOMESODERMIN (EOMES), pre-cardiac mesoderm 
gene MESP1, mCherry reporter gene, and early cardiac gene NKX2-5 during monolayer differentiation. Results 
are normalized for the transcript expression at day 0 (undifferentiated hESCs) (n=3, error bars indicate SEM). 
B: Percentages of mCherry and eGFP protein expression upon monolayer differentiation. C: Quantification of 





































































































































































    Figure 3. Characterization of MESP1-mCherry expressing cells at day 
     3 of monolayer differentiation.
    A: Transcriptional profiling of three biological replicates of  
    undifferentiated hESCs (D0), differentiation day 3 MESP1-mCherry pos 
cells (D3+), and MESP1-mCherry neg cells (D3-). D3+ samples were enriched for specific transcription factors, cell 
surface markers, ECM components, EMT-related genes, and signalling pathway ligands and receptors. Clustering 
of the samples is based on hierarchical clustering of microarray gene expression profiling. Shown are a selection of 
transcripts expressed in D3+ with a fold change ≥ 1.5 compared to D3- for three independent paired experiments 
(n=3).* indicates differences in only two independent experiments. GEO accession number: GSE56721. http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56721 B: Number of transcripts that was ≥ 1.5 fold differentially 
expressed (n=3) between D3+ and D0, D3- and D0, and D3+ and D3- samples. C: Signalling pathway analysis of 
enriched genes in MESP1-mCherry expressing cells. P<0.01 for selected pathways. Percentages are based on all 
enriched genes. D: Validating microarray results by qRT-PCR analysis of selected transcripts in purified MESP1-
mCherry pos and MESP1-mCherry neg cell populations at differentiation day 3 (n=3, error bars indicate SEM). 
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Figure 4. Flow cytometry analysis of cell surface markers CD13, ROR-2, KDR, and PDGFR-α on (A) MESP1-mCherry 
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Figure 5. Cardiac differentiation induction from the MESP1-mCherry expressing pre-cardiac mesoderm 
progenitors. A: Schematic overview of the cardiac differentiation protocol for MESP1-mCherry cell fractions sorted 
by flow cytometry at day 3. B: Flow cytometric analysis of co-expression of cell surface proteins at differentiation 
day 5 (2 days after replating). C,D: Enrichment of mRNA transcripts of cardiac progenitor transcription factors at 
day 8 (n=3) and day 14 (n=2) in MESP1-mCherry pos and MESP1-mCherry neg derivatives (5 and 11 days after 
replating).
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Figure 6. A: eGFP expression in MESP1-mCherry aggregates at day 14 of differentiation (11 days after replating), with 
and without treatment of Xav939. Brightfield (BF) overlay with eGFP. B,C: Percentage of cells expressing eGFP in day 
14 MESP1-mCherry aggregates, with and without treatment of XAV939 (+sorted: n=7, -sorted: n=6, unsorted: n=2; 
error bars indicate SEM, ***p<0.001). D: Immunohistochemical stainings on day 14 MESP1-mCherry aggregates 
to analyse the presence of cardiac markers, including PECAM-1, SMA, SM-myosin, and α-actinin (α-ACT). E: Co-
staining of α-ACT and SM-Heavy Chain (SM-HC) at d14 to discriminate smooth muscle cells from cardiomyocytes. 
F,G,H: Flow cytometric analysis of cTNT and PECAM-1 expression on day 14 MESP1-mCherry aggregates treated 
with XAV939 (n=2, error bars indicate SEM).
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Figure S1. Genomic PCR experiments to confirm correct targeting of the MESP1 locus. A: Target screening PCR, 
using a forward primer annealing to the neomycin selection cassette and a reverse primer annealing outside the 
targeted region. Targeted clones show a PCR product of 3.1 kb. Clone 2.20 was used for neomycin cassette excision 
and further experiments. The modified Mesp1-mCherry bacterial artificial chromosome (BAC) was used as positive 
control. B: Neomycin excision of clone 2.20B3 was confirmed by a PCR reaction using a forward primer annealing 




Supplemental figure 1. Genomic PCR experiments to confirm corre t targeting.
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Clone 2.20B3  46,XX
Figu e S2. A: Immunohistochemical staining of MESP1mCherry-NKX2-5eGFP hESCs to confirm the expression of 
pluripotency markers after targeting. DAPI-stained hESCs (blue) with NANOG (red), OCT-4 (red), or TRA1-81 (red). 
B: Flow cytometric analysis of EPCAM expression on undifferentiated targeted hESCs. C: Karyotyping analysis of 
Clone 2.20B3 after targeting and neomycin cassette excision.
Figure S3. Additional information on MESP1-mCherry micro array experiments.  A: Correlation heatmap between 
the three biological replicates of each timepoint: day 0 (D0), MESP1-mCherry positive cells (D3 M+), and MESP1-
mCherry negative cells (D3 M-).
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Figure S5. A: Re-analysis of mCherry expression on MESP1-mCherry 
pos and MESP1-mCherry neg sorted populations at day 3-5 of 
differentiation. B: mRNA expression levels of MESP1 and mCherry in 
MESP1-mCherry pos and MESP1-mCherry neg sorted populations at 
day 3 and 5 of differentiation.
Supplemental Figure 4.
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Figure S4. Expression profile of PDGFR-α and KDR during cardiac differentiation of MESP1-mCherry positive and 
negative sorted populations. 
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Supplemental Figure 6.
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Table S1. Recombineering and screening primers 
  Primer name Primer sequence 
MESP1_5arm_PvuI 5’GGAGAATTGCTTGAACCTGGGAGGTGGAGGCTGCAGTGAG CCGAGATCACGATCGCTCTCCTGAGTAGGACAAATC-3’ 
MESP1_3arm 3’CTTTAGTACATCCACAGAGTTGTGCAAGCATTGCCACTAATT TTAGAACGTTCCGCCTCAGAAGCCATAGAGC –5’ 
Target screen - F (P1) 5′- TCGCCTTCTTGACGAGTTCT -3′ 
Target screen - R (P2) 5′- AGGCAGCATGATGAGCCTTA -3′ 
Neo excision screen - F (P3) 5′- CCCCGTAATGCAGAAGAAGA -3′ 
Neo excision screen - R (P4) 5’-AGTTTCTCCCGCTCACTGG-3’ 
 
Figure S6. Effect of inhibition of specific signalling pathways after MESP1-mCherry sort and re-aggregation.  NKX2-
5-eGFP expression in MESP1-mCherry positive aggregates at day 14 of differentiation (11 days after replating). No 
GF: no addition of growth factors/inhibitors.
Figure S7. SIRPA+ VCAM1+ co-expression marks NKX2-5-eGFP+ cardiomyocytes. A: SIRPA+ VCAM1+  and B: 
intracellular cTnT expression on cardiac cells at day 14 of differentiation of NKX2.5eGFP/w-hESCs. NKX2-5-eGFP+ cells 
are indicated in green.
Supplementary table S1. Recombineering and screening primers.
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Table S2. Quantitative PCR primers for human genes 
   Genes Forward primer Reverse primer 
HARP CACCATTGAAATCCTGAGTGATGT TGACCAGCCCAAAGGAGAAG 
MESP1 CTCTGTTGGAGACCTGGATG CCTGCTTGCCTCAAAGTG 
MCHERRY  CAAGTTGGACATCACCTCCCAC ACTTGTACAGCTCGTCCATGC 
MESP2  TCTCCAGAGCCCTGTCTGTC GTCCCTGGTCCTCTGAGTTG 
E-CADHERIN ATTCTGATTCTGCTGCTCTTG AGTCCTGGTCCTCTTCTCC 
SOX2 AACCCCAAGATGCACAACTC GCTTAGCCTCGTCGATGAAC 
BRACHYURY T ATCACCAGCCACTGCTTC GGGTTCCTCCATCATCTCTT 
EOMES TCTGTCCCATTGAGCTTCTC TCTGTCCCATTGAGCTTCTC 
MIXL1 GGTACCCCGACATCCACTT GAGACTTGGCACGCCTGT 
HAND1 AATCCTCTTCTCGACTGGGC TGAACTCAAGAAGGCGGATG 
GATA6 TCCCCCACAACACAACCTAC TGTAGAGCCCATCTTGACCC 
SNAI2 CAGACCCTGGTTGCTTCAA TGACCTGTCTGCAAATGCTC 
FOXC1 CCTGCTTGCCTCAAAGTG TCCTTCTCCTCCTTGTCCTT 
MEF2C CCACTGGCTCACCCTTCTCTGC ACCCGTTCCCTGCACTAGTG 
NKX2-5 TTCCCGCCGCCCCCGCCTTCTAT CGCTCCGCGTTGTCCGCCTCTGT 
ISL1 TGATGAAGCAACTCCAGCAG  GGACTGGCTACCATGCTGTT  
GATA4 GACAATCTGGTTAGGGGAAGC GAGAGATGCAGTGTGCTCGT 
TBX5 ACATGGAGCTGCACAGAATG TGCTGAAAGGACTGTGGTTG 
SCI AAGGGCACAGCATCTGTAGTCA AAGTCTTCAGCAGAGGGTCACGTA 
HAND2 ACATCGCCTACCTCATGGAC TGGTTTTCTTGTCGTTGCTG 
TBX3 CGGTTCCACATTGTAAGAGC TTCGGGGAACAAGTATGTCC 
TBX18 TTGCTAAAGGCTTCCGAGAC AGGTGGAGGAACTTGCATTG 
WT1 TGTGTGCTTACCCAGGCTGC TGTGTGCTTACCCAGGCTGC 
IRX3 GTGCCTTGGAAGTGGAGAAA TAGGATGAGGAGAGAGCCGA 
MYL4 TCAAAGAGGCCTTTTCATTG CGTCTCAAAGTCCAGCATCT 
CD45 ACTCTTGGCATTTGGCTTTG CACTGGGCATCTTTGCTGTA 
MYOGENIN4 CAGCTCCCTCAACCAGGAG GCTGTGAGAGCTGCATTCG 
Supplementary table S2. Quantitative PCR primers for human genes.
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Table S3. Gene ontology classes overrepresented in day 3 Mesp1-mCherry 
pos cells vs day 3 Mesp1-mCherry neg cells (LogFC>0.5, P<0.01). 
   GO 
Accession GO Term Name P-value 
GO:0048856 anatomical structure development 7,13E-19 
GO:0048731 system development 3,51E-18 
GO:0009653 anatomical structure morphogenesis 5,91E-18 
GO:0007275 multicellular organismal development 7,23E-18 
GO:0044767 single-organism developmental process 1,50E-17 
GO:0009887 organ morphogenesis 4,15E-16 
GO:0001501 skeletal system development 5,47E-16 
GO:0007369 gastrulation 7,80E-16 
GO:0044763 single-organism cellular process 1,75E-15 
GO:0044707 single-multicellular organism process 7,82E-15 
GO:0001704 formation of primary germ layer 1,47E-14 
GO:0048598 embryonic morphogenesis 3,99E-14 
GO:0048513 organ development 2,39E-13 
GO:0048729 tissue morphogenesis 2,42E-13 
GO:0009790 embryo development 2,63E-13 
GO:0030154 cell differentiation 3,81E-13 
GO:0050793 regulation of developmental process 4,65E-13 
GO:2000026 regulation of multicellular organismal development 9,09E-13 
GO:0009888 tissue development 1,02E-12 
GO:0007155 cell adhesion 1,25E-12 
GO:0003002 regionalization 2,33E-12 
GO:0048869 cellular developmental process 3,11E-12 
GO:0048568 embryonic organ development 4,28E-12 
GO:0005578 proteinaceous extracellular matrix 5,21E-12 
GO:0009952 anterior/posterior pattern specification 6,27E-12 
GO:0072358 cardiovascular system development 1,17E-11 
GO:0072359 circulatory system development 1,17E-11 
GO:0048468 cell development 1,51E-11 
GO:0048585 negative regulation of response to stimulus 1,74E-11 
GO:0022603 regulation of anatomical structure morphogenesis 2,07E-11 
GO:0045595 regulation of cell differentiation 2,22E-11 
GO:0007498 mesoderm development 3,07E-11 
GO:0032989 cellular component morphogenesis 3,11E-11 
GO:0048646 anatomical structure formation involved in morphogenesis 3,58E-11 
GO:0007154 cell communication 3,88E-11 
Supplementary table S3. Gene Ontology classes overrepresented in day 3 MESP1-mCherry pos cells vs. day 3 
MESP1-mCherry neg cells (LogFC>+0.5, P<0.01).
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Table S4. Antibodies 
Cell surface antigens 
Vioblue-conjugated-mouse-anti–EPCAM (Miltenyi Biotec, 130-098-092) 
Mouse-anti-SSEA4 (Santa Cruz, SC59368) 
BV421-conjugated-mouse-anti-PDGFRα (BD Biosciences, 562799) 
BV421-conjugated-mouse-anti-CD13 (Biolegend, 301716) 
A488-conjugated-mouse-anti-ROR-2 (R&D, FAB2064G) 
PE-conjugated-mouse-anti-FLK1/VEGFR2/KDR (R&D Systems, FAB357P) 
APC-conjugated-mouse-anti-PECAM-1 (eBiosciences, 17-0319) 
APC-conjugated-anti-SIRPA (Miltenyi Biotec) 
PE-conjugated-anti-VCAM1 (BD Biosciences) 
 
Pluripotency markers  
Mouse-anti-TRA-181 (Millipore, MAB4381) 
Mouse-anti-OCT3/4 (Santa Cruz, sc5279) 
Anti-NANOG (Abcam, Ab21603) 
 
Cardiac markers 
Rabbit-anti-smooth muscle actin (Abcam, Ab5694)  
Mouse-anti-cardiac Troponin T (CT3, Developmental Studies Hybridoma Bank, 
University of Iowa)  
Mouse-anti-PECAM-1 (Dako, JC70A) 
Rabbit-anti-α-actinin (Abcam, Ab11007) 
Rabbit-anti-myosin smooth muscle heavy chain (BTI Biomedical Technologies, BT-
562) 
 
Supplementary table S4. Antibodies.
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SUPPLEMENTAL METHODS
Analysis of MESP1-mCherry Derivatives
MESP1-mCherry-sorted cells were re-analyzed on mCherry expression by flow cytometry on 
day 3 (immediately after sorting), 4  and 5 of differentiation (1 and 2 days after reaggregation 
of days sorted cells, respectively). Analysis on KDR and PDGFR-α expression on day 4, 6, and 
8 of differentiation of MESP1-mCherry-sorted cells was performed as described before.
To measure RNA levels of mCherry and MESP1 at day 3 and day 5 of differentiation (0 and 2 
days after sorting), RNA isolation and qRT- PCR were performed as described before.
Inhibition of specific signalling pathways after MESP1-mCherry sorting and 
re-aggregation.
MESP1-mCherry cells were differentiated, sorted, and re-aggregated as described before. 
Pathway inhibitors assessed were 5uM XAV939, 5uM SB431542 (#1614, R&D), and 1uM 
dorsomorphin (P5499, Sigma Aldrich), from day 3 until day 7. NKX2-5-eGFP expression was 
analysed by flow cytometry at day 14 of differentiation (11 days after sorting), as described 
before.
NKX2-5eGFP/w hESC Culture and Cardiac Differentiation
NKX2-5eGFP/w hESCs were cultured in E8 medium (Life Technologies) according to the 
manufacturer’s protocol. Cells were differentiated in BPEL as described previously, with 
FACS analysis performed at d14, using the conjugated antibodies SIRPA-APC (Miltenyi Biotec) 
and VCAM1-PE (BD Biosciences). Flow cytometric analysis of Troponin T was performed as 
described previously.
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ABSTRACT
In vitro cardiac differentiation of human pluripotent stem cells (hPSCs) closely recapitulates 
in vivo embryonic heart development, and therefore, provides an excellent model to 
study human cardiac development. We recently generated the dual cardiac fluorescent 
reporter MESP1mCherry/wNKX2-5eGFP/w line in human embryonic stem cells (hESCs), allowing 
the visualization of pre-cardiac MESP1+ mesoderm and their further commitment towards 
the cardiac lineage, marked by activation of the cardiac transcription factor NKX2-5. Here, 
we performed a comprehensive whole genome based transcriptome analysis of MESP1-
mCherry derived cardiac-committed cells. In addition to previously described cardiac-
inducing signalling pathways, we identified novel transcriptional and signalling networks 
indicated by transient activation and interactive network analysis. Furthermore, we found 
a highly dynamic regulation of extracellular matrix components, suggesting the importance 
to create a versatile niche, adjusting to various stages of cardiac differentiation. Finally, 
we identified cell surface markers for cardiac progenitors, such as the Leucine-rich repeat-
containing G-protein coupled receptor 4 (LGR4), belonging to the same subfamily of LGR5, 
and LGR6, established tissue/cancer stem cells markers. We provide a comprehensive gene 
expression analysis of cardiac derivatives from pre-cardiac MESP1-progenitors that will 
contribute to a better understanding of the key regulators, pathways and markers involved 
in human cardiac differentiation and development.
INTRODUCTION
HPSCs provide an excellent platform to model human heart development and cardiac 
differentiation in vitro. We and others have previously shown that there are close similarities 
between the temporal and sequential transcriptional activation of genes during human 
cardiac differentiation in vitro and in cardiac development in vivo1,2. Identification of key 
molecular events during cardiac differentiation from human pluripotent stem cells is 
instrumental for a better understanding of human cardiac development, and advancing the 
fields of regenerative medicine, disease modelling, and drug discovery. Although cardiac 
differentiation protocols have been improved significantly over the last years, in-depth 
knowledge of molecular mechanisms involved in cardiac lineage commitment is sparse. 
Specification of hPSCs towards the cardiac lineage is regulated by the precise temporal 
expression of transcriptional networks. Detailed information on these transcriptional 
networks and signalling molecules is essential for understanding the mechanisms underlying 
progression and expansion of progenitors and their differentiation to their specific subtype 
derivatives. When hPSCs differentiate towards the cardiac lineage, they first progress via 
an intermediate mesodermal stage, expressing transcription factor MESP1, before they 
further differentiate into cardiac derivatives, indicated by the increased expression of 
cardiac marker NKX2-53,4. In order to understand how molecular mechanisms play a role in 
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these lineage decisions, we previously generated the dual cardiac human embryonic stem 
cell (hESC) reporter line MESP1mCherry/wNKX2-5eGFP/w4. We characterised MESP1 progenitors 
by gene expression and surface marker analysis, and showed that MESP1 derivatives were 
predominantly enriched for NKX2-5 positive cardiomyocytes. Here, we have defined the 
temporal gene expression changes that occur during the differentiation of isolated MESP1-
progenitors towards their cardiac derivatives. By classifying enriched genes according to 
similar expression patterns, functional pathway analysis, GO terms, sequence-specific 
DNA binding properties, and protein-protein interactions, we provide more insight on 
molecular signals and regulators involved in the sequential stages of mesoderm to cardiac 
differentiation. We confirm the enrichment of previously identified transcriptional regulators 
and cardiac functional genes, indicated by the predominant activation of components of 
the Wnt and TGFβ pathways. Interestingly, we identified novel cardiac networks, signalling 
pathways and markers, which may have an important role in the early cardiac differentiation 
and may be used as blueprint to evaluate or study human cardiac differentiation in vitro.
RESULTS
Collection of time points during cardiac differentiation
To obtain MESP1-mCherry progenitors for further differentiation, we differentiated and 
isolated MESP1mCherry/wNKX2-5eGFP/w hESCs as described before4. Day 3 MESP1-mCherry 
positive and negative cells were replated as aggregates and further differentiated in the 
absence (control) or presence of Wnt-pathway inhibitor Xav939, which has been previously 
shown to enhance cardiomyocyte differentiation, (Fig. 1a). Aggregates were collected 2 
(D5), 4 (D7), 7 (D10) and 11 (D14) days after sorting and RNA was isolated subsequently. 
Experiments were performed in triplicates. To ensure efficient cardiac differentiations in the 
samples that were used for gene expression analysis, flow cytometry analysis was performed 
at day 14 of differentiation from a similar differentiation experiment (Fig 1b). We found 
52.3±10.7 % of NKX2-5-eGFP positive cardiac cells in the MESP1-mCherry positive derived 
population, treated with Xav939, which was, as expected, significantly higher than 4.8 ± 2.0 
% in the MESP1-mCherry negative derived population, treated with Xav939  (Fig. 1c). 
Global gene expression patterns segregate upon cardiac differentiation.
In order to study cardiac-specific enriched genes, we performed statistical analysis between 
replicates and generated gene lists based on a 1.5 fold change of expression level, with a 
gene-specific P-value<0.05, in the MESP1-mCherry positive population, treated with Xav939 
(M+X+), compared to the MESP1-mCherry negative population, treated with Xav939 (M-X+) 
(Fig 2a). With this, we selected genes that displayed both large changes as well as more 
subtle, but consistent, changes5. The number of differentially expressed genes increased 
upon further differentiation (Fig. 2b), indicating a lower correlation between MESP1-
positive and –negative samples upon further differentiation, and thus a more specialized 
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gene expression pattern/phenotype. A top 100 list for both enriched and downregulated 
transcripts at each time point is given in Supplementary Table S1.
Gene Ontology analysis shows a clear shift from global development to heart 
development.
We determined which Gene Ontology (GO) categories were enriched for each specific 
differentiation stage, and could identify a clear shift between early cardiac progenitor stages 
D5 and D7, and the later cardiac-lineage-committed progenitors and cardiomyocytes (D10 
and D14) (Table 1). D7 GO terms were highly similar to those in D5, which included GOs 
that were more broadly developmental related. D10 and D14 were both highly enriched for 
heart-specific regulatory and functional GO terms, including heart development (BP00251), 
and muscle contraction (BP00173). To note, GO analysis of downregulated genes at each 
timepoint (FC>1.5 fold, P<0.05), did not show any tissue-specific terms, and is therefore not 
shown.
Transcriptional regulators during early cardiac commitment (D5)
Firstly, in order to show that sorted MESP1-mCherry progenitors leave the mesoderm 
stage upon further differentiation, we generated an expression heatmap up to day 14 for 
a selection of genes that were previously demonstrated to be enriched in day 3 MESP1-
mCherry positive progenitors4 (Fig. 3a). As expected, the levels of mesoderm transcription 
factors MESP1, MIXL1, Eomesodermin (EOMES), and Goosecoid (GSC) show a transient 
expression with a peak at day 3. In order to identify genes that may play important roles in 
early cardiac differentiation development we selected genes that were upregulated  (FC>1.5 
fold, P<0.05) in the day 5 M+X+ population, when compared to the day 5 M-X+ control. From 
the 281 enriched transcripts, (potential) cardiac (co)-regulatory genes were selected based 
on their predicted transcriptional activity, DNA binding domains, and biological function (Fig. 
3b). Several transcription factors for which their role in early cardiac commitment has been 
shown previously could be identified based on their enrichment at day 5 of differentiation 
in the M+X+ samples (GATA5, MEIS1, MEIS2, HEY1, IRX3, IRX5, GATA4, and nuclear retinoic 
acid receptors RARα and RARβ, and PPARγ). Some of these genes maintained high levels 
of expression at later stages. In order to identify novel cardiac regulators, we focussed on 
proteins with conserved DNA binding motifs, such as homeodomain and zinc-finger domains 
motifs. This list of genes included HOXB2, ZFPM1, ZMBTB16, ZNF503, and RUNX1T1. To 
understand how these genes and their encoded proteins could be involved in networks 
related to early heart development, we performed analysis using the STRING database for 
interactomic connections with established key transcription factors (http://www.string-db.
org/)6 (Fig. 3c). Using STRING, we predicted protein-protein associations based on in vivo and 
in vitro experimental assays, including gene co-occurrence in genomes (i.e. phylogeny), gene 
co-expression, gene fusion events, genomic neighbourhood (i.e. synteny), and experimental 
data such as co-immunoprecipitation and yeast two hybrid6. 
CHAPTER 4
We found a high predicted interaction between MEIS1, MEIS2, PBX3, and HOXB2, based on 
binding complexes of MEIS proteins with other PBX and HOX homologs in drosophila and 
rodent models7-9. Moreover, studies have indicated a crucial role for MEIS1, MEIS2, PBX3 
and HOXB2 in either heart development, including heart looping and chamber septation2,10 
or in vitro cardiac differentiation2,11. Interestingly, PBX3 has shown to induce either skeletal 
muscle in the presence of MyoD, a master regulator of skeletal muscle differentiation12,13, or 
cardiac differentiation, in the presence of the cardiac transcription factor Hand212, indicating 
a crucial role for PBX3 as a cofactor during differentiation towards striated muscle. Moreover, 
MEIS1, MEIS2, HOXB2, and PBX3 were all upregulated upon Mesp1 induction in mouse ESCs, 
indicating that they act downstream of Mesp114. 
The genes ZFPM1 (FOG1; friend of GATA family-1), ZBTB16, and ZNF503 belong to the class 
of zinc finger transcription factors. FOG1 contains nine zinc-finger domains and belongs 
to a family of proteins of which two genes have been identified in mammals: FOG1 and 
FOG2. FOG proteins interact with the N-terminal domain of GATA factors and modulate their 
activity15 and have been shown to recruit nuclear receptor-transcriptional co-repressors 
and histone deacetylases (HDACs). Although the role of FOG1 in heart development is not 
well understood, one study in zebrafish showed  the injection of an antisense morpholino 
directed against the homolog to murine FOG1 resulted in embryos with a large pericardial 
effusion and a deficient looping heart tube16.
Another zinc-finger domain protein that we found highly enriched in MESP1-positive derivatives 
at day 5, and that is also upregulated upon Mesp1 induction in mESCs14, is RUNX1T1 (runt-
related transcription factor 1); a protein that is known to interact with transcription factors 
and to recruit a range of co-repressors to facilitate transcriptional repression17. In the human 
embryonic heart, RUNX1T1 expression is identified in both cardiomyocytes and endocardial 
cells1,2,18. Moreover, chromosome break points in the RUNX1T1 gene are associated with 
congenital heart disease3,4,18. Protein-protein interaction between RUNX1T1 and ZBTB16, 
a growth repressor in hematopoietic progenitor cells through its ability to recruit nuclear 
co-repressors such as histone deacetylases and Polycomb (PcG) family proteins, has been 
previously described4,17 and was therefore also predicted following analysis in the STRING 
database (Fig. 3c). Although no potential interactions in this cluster at day 5 were identified 
in the STRING database for Zinc Finger 503 (ZNF503), it has been previously classified as a 
potential human cardiac developmental regulator, based on its chromatin signature and its 
temporal expression level upon in vitro cardiac differentiation in hESCs2,4.
Transcriptional regulators in early cardiac progenitors (D7)
Upon further differentiation of MESP1-derived cardiac committed cell lineages towards 
early cardiac progenitor stage (day 7 of differentiation), we found 660 differentially 
expressed genes (FC>1.5 fold, P<0.05) in day 7 M+X+ population, when compared to day 7 
M-X+ control. Again, (potential) cardiac (co)-regulatory genes were selected based on their 
transcriptional activity, nucleotide binding domains, and biological function. We identified a 
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subset of known and potential novel cardiac regulatory factors, including GATA4, LHX2, and 
COUP-TF1 (NR2F1), and DNA-binding zinc-finger proteins ZFPM2 (FOG2), TSHZ2, and ZFHX3 
(Fig. 4a).
STRING-based interaction analysis of genes enriched at day 7 showed predictive interactions 
of FOG2 with COUP-TF1 and GATA4 (Fig. 4b). It has been previously shown that FOG2 
represses COUP-TFII dependent synergistic activation of the atrial natriuretic factor promoter, 
suggesting that FOG2 functions as a co-repressor for both GATA and COUP-TF proteins5,19,20, 
although it may also act as a co-activator in combination with other transcription factors4,20,21. 
Zinc finger homeodomain protein 3 (ZFHX3) contains 4 homeobox domains and 22 zinc 
finger domains, and is described as transcriptional repressor for myogenic differentiation 
through repression of the MYF6 gene6,22. Based on chromatin signature and transient 
expression levels during in vitro cardiac differentiation in hESCs a regulatory role for ZFHX3 in 
human cardiac development has been suggested2,6. Moreover, sequence variants of ZFHX3 
are associated with atrial fibrillation7-9,23-25. The zinc finger transcription factor TSHZ2, may 
be a potential transcriptional repressor for MEIS transcription factors (Fig. 4b), based on 
interaction studies between conserved orthologs in drosophila. Its role in heart development 
is currently unknown. 
Expression profile plots of potential regulatory genes show a distinct 
expression pattern throughout cardiac differentiation.
Stage-specific (co)-expression of transcriptional genes could indicate a regulatory role. Here, 
we show how similarities between expression profiles of PBX3, MEIS1, MEIS2, and HOXB2 
throughout cardiac differentiation further strengthen the hypothesis that they act in a 
similar stage-specific molecular role, potentially as co-regulators (Fig 5). In addition, similar 
expression profiles of GATA4 and FOG2 during cardiac differentiation support a potential co-
regulatory role (Fig. 5). Further, we show how expression levels of TSHZ2 distinctly increase 
throughout cardiac differentiation from day 5 onwards, suggesting a role for TSHZ2 in cardiac 
differentiation (Fig. 5).
Gene expression profiling of MESP1-derived cardiac cells (D10/D14)
Upregulated genes at day 10 (952) and day 14 (1062) of differentiated samples from M+X+ 
were classified as described before and expression levels were visualized in heatmaps (Fig. 
6a). Several genes from this list are known to play a key role in cardiac development, such as 
NKX2-5, TBX18, WT1, TCF21, TBX2, HAND2, MEF2C, ISL1, and SMARCD3.  Interaction analysis 
of all transcription factors enriched in day 10 and day 14 samples showed a distinct regulatory 
cluster centred on NKX2-5 and GATA4 (Fig. 6b). The presence of highly enriched levels of 
cardiac genes encoding for structural and sarcomeric proteins and ion channels indicates 
the presence of functional cardiomyocytes (Fig. 6a). Moreover, while most structural genes 
are increased at cardiac progenitor stage day 7, levels of ventricular marker MYL2 could 
only be identified in clusters of upregulated genes at day 14. This is in agreement with 
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previous studies, showing that MYL2 expression is only highly increased after approximately 
one month of cardiac differentiation2,10,26, suggesting that MYL2 may serve as a marker for 
cardiomyocyte maturation. 
Further, we could identify a node cluster of TCF21 and WT1, connected to TBX18; three 
regulatory transcription factors implicated in the formation of epicardial progenitors, 
indicating either the presence of these progenitors in our MESP1-derived cardiac aggregates 
or the potential to further differentiate to epicardial cells2,11,27. Furthermore, we identified 
enriched levels of growth factors VEGFA/B/C and receptor Neuropilin-1 (NRP1), ANGPT1, 
and surface marker CD34, indicating the derivation of vascular endothelial progenitors from 
MESP1 progenitors (Fig. S1).
Merging transcriptional networks sequentially active throughout cardiac 
differentiation
In order to understand how cardiac transcriptional networks may be developed along cardiac 
lineage commitment and differentiation we generated a large interactive network, based on 
transcription factors that are enriched throughout all timepoints of differentiation (obtained 
through Gene Set Enrichment Analysis (GSEA) from Broad Institute) (Fig. 7). Interestingly, 
we could identify the development of three distinct large node clusters, including retinoic 
acid nuclear receptors, containing PPARγ and RAR α/β, and two large interconnected cardiac 
networks centered on either GATA4 or NKX2-5.
Signalling pathways during cardiac differentiation
In order to study the role of specific signalling pathways during cardiac lineage differentiation, 
we performed pathway analysis using the KEGG pathway database source (Fig. 8a, 
Supplementary Table S2)) on the enriched genes at each stage of differentiation (M+X+ 
vs M-X+, FC>1.5 fold, P<0.05). From these results, we could clearly find an important role 
for Wnt-signalling pathway components during early cardiac lineage commitment (Day 5, 
Day 7), corroborating the findings from our previous study, in which we demonstrated non-
canonical enrichment of Wnt pathway molecules, including Wnt5a and Wnt inhibitors DKK1 
and DKK4 in MESP1 expressing progenitors4,12,13. Figure 8b shows an expression heatmap 
for enriched Wnt-pathway related genes across all time points (Fig. 8b), including SFRP5, 
SFRP1, FZD2, FZD4, and WNT5A, TCF4, and EMT-regulators SNAI2, and LEF1 (Fig. 8c). 
Interestingly, we identified significant enrichment of Wnt/β-catenin antagonists, including 
SFRP5, WNT5A, DACT1, and DACT3, in particular temporally peaking at early time points 
of cardiac differentiation, which would lead to downregulation of Wnt/β-catenin signalling, 
necessary for cardiac specification (Fig. 8c)12,28. Furthermore, through pathway analysis and 
protein-protein interaction analysis using STRING, we identified a prominent role for TGF-β 
signalling pathway components in early cardiac progenitor stage and cardiomyocytes (d7-
d14) (Fig. 8b, Supplementary Table S2). TGF-β signalling is important for cardiovascular 
development and plays an important role in epithelial-to-mesenchymal transition (EMT), 
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in order to stimulate endocardial and epicardial transitions to mesenchymal cells of the 
heart14,29. Expression analysis of a selection of these transcripts demonstrates a similar 
profile, suggesting interaction and or co-regulation of Wnt/β-catenin antagonists, Wnt/β-
catenin target element TCF4, and EMT-related transcription factors SNAI2 and LEF1, which 
can be activated by both Wnt/β-catenin and TGF-β signalling (Fig. 8c)30.
Role of ECM proteins during cardiac differentiation
Extracellular matrix (ECM) proteins play an important role in the formation of the 
microenvironment for cells and provide different stimuli leading to activation of numerous 
molecular and cellular mechanisms, including migration, proliferation and differentiation of 
cells, as these events take place during the different stages of cardiac development15,31,32. 
Pathway analysis of enriched genes in the MESP1-derivatives indicated an important role of 
ECM signalling upon formation of the early cardiac progenitor populations and in established 
cardiomyocytes (Fig. 8a). Interestingly, the composition of this cluster showed dynamic 
changes throughout cardiac differentiation (Fig. 9a), suggesting the need for a specific 
composition of proteins forming a microenvironment or niche for cardiac progenitor cells and 
cardiomyocytes for optimal functioning in processes such as self-renewal, differentiation, 
and survival16,32,33. Moreover, we identified also other transiently upregulated levels of ECM 
components and proteases that have been implicated in heart developmental defects14,32 
(Fig. 9a). 
Surface marker expression analysis on MESP1-derived cardiac progenitors
An efficient approach to isolate specific subpopulations for translational applications will be 
the use of antibodies against distinct cell surface markers. For this, we analysed expression 
patterns of a large variety of cell surface markers that were enriched in the MESP1-derived 
cardiac populations at the different time points (Fig. 9b). In our previous study we found that 
cell surface markers N-cadherin (CDH2), CD13 (ANPEP), and ROR24,17 are broadly expressed 
in mesodermal cells and not specifically for MESP1-expressing progenitors. Surface 
proteins that show a transient peak expression at day 5 (M+X+), include TMEM88, CD82, 
TMEM171, LGR4, and CD74. From these, only TMEM88 has been clearly associated with 
heart development and acts downstream of GATA factors in the pre-cardiac mesoderm to 
specify lineage commitment of cardiomyocyte development through inhibition of Wnt/β-
catenin signaling34,35. Interestingly, LGR4 belongs to the Leucine-rich Repeat-containing G 
protein-coupled receptor family with a close relation to LGR5 and 6, known stem cell marker 
for different tissues. LGR4 is expressed in the heart36,37, although not exclusively, but no role 
has been described so far for heart development or cardiac stem cells. Surface markers 
that show high enrichment at day 5 of differentiation, with a continuous enrichment upon 
further cardiac differentiation (up to final cardiomyocyte formation) include GPC2, FZD4, 
PDFGRα, NCAM1, FLRT2, TMEM66, and GPR124. We, and others, have shown that PDFGRα 
and NCAM1 broadly mark mesoderm progenitors4,38. In early embryonic development, Fzd4 
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is highly expressed in the cardiac crescent, head mesenchyme, and later in the developing 
heart tube39. Loss of Fzd4 shows a decrease in density and branching of small arteries in the 
developing mouse heart40. Flrt2 and Gpr124 could both be potential markers for cardiac 
lineage-commitment. Flrt2 is abundantly expressed in developing mouse heart tissue and 
loss of Flrt2 results in in impaired expansion of the compact ventricular myocardium41. 
G-protein coupled receptor GPR124 shows a similar stage-specific expression pattern as 
FLRT2. However, GPR124 is expressed on endothelial cells during blood vessel development, 
but not specifically expressed in the heart42. Transmembrane protein 66 (TMEM66) functions 
as calcium ion transmembrane transporter, and is enriched in MESP1 progenitors and their 
cardiac derivatives up to day 14.  However, in vivo it has been shown that TMEM66 is not 
specific for the developing heart43.
Surface protein transcripts that are specifically enriched in late cardiac progenitors (day 10), 
and cardiomyocytes (day 14) include TMEM151A, VCAM1, TMEM71, TMEM173, and SIRPA. 
VCAM1 and SIRPA have been previously identified to be specific human CM markers3,44,45. 
Mouse embryo expression databases describe TMEM71 in mesoderm tissues, including atria 
and ventricles. Not much is known about TMEM151A and TMEM173 expression in the heart. 
DISCUSSION
For studying the temporal expression of key molecules involved in cardiac lineage 
commitment upon differentiation, we recently generated the dual cardiac fluorescent 
reporter MESP1mCherry/wNKX2-5eGFP/w hESC line, allowing us to isolate early pre-cardiac 
mesoderm progenitors and follow their further differentiation towards NKX2-5 expressing 
cardiomyocytes4. In the current study, we used this dual cardiac reporter line to perform 
molecular profiling during cardiomyocyte differentiation from MESP1-expressing pre-
cardiac progenitors by genome-wide transcriptomic analysis encompassing crucial events 
during cardiac differentiation from hPSCs: early cardiac lineage commitment, early 
cardiac progenitor stage, late cardiac progenitor stage, and functional cardiomyocytes. 
Global gene expression analysis and gene ontology analysis confirmed and visualized that 
expression patterns became more specified towards cardiac differentiation, shifting from 
developmental networks to cardiovascular-specific developmental networks. Throughout 
differentiation, we identified sequential expression patterns of key cardiac transcription 
factors, followed by enriched levels of structural and functional cardiac genes at day 10 and 
day 14 of differentiation, indicating that in the presence of Wnt-pathway inhibitor Xav939, 
isolated MESP1 progenitors have the preference to differentiate to the cardiac lineage. Using 
pathway analysis we identified a prominent role for Wnt-pathway antagonists during early 
cardiac lineage commitment leading to inhibition of Wnt/β-catenin signalling. Furthermore, 
using STRING software6 that builds functional protein-association networks based on 
compiled available experimental evidence, we identified a subset of transcription factors 
during early lineage commitment: HOXB2, ZFPM1, ZBTB16, ZNF503, RUNX1T1, ZFPM2, 
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and ZFHX3. Zinc-finger proteins ZFPM1 (FOG1) and ZFPM2 (FOG2) belong the FOG (friend 
of GATA) gene family, however, their role in heart development has not been elucidated 
yet. Based on previous studies, FOG proteins interact with GATA and COUPTF proteins, key 
transcription factors for early developmental processes, including heart development and 
lineage commitment19-21. FOG1 and FOG2 are indicated as co-activators or co-repressors of 
GATA- and COUPTF-activity on downstream cardiac genes, dependent on the transcriptional 
network that is active, pointing towards a putative role in cardiac lineage commitment. 
Besides their possible role in cardiac differentiation, FOG1 is expressed in blood islands 
of the yolk sac in mice and act as a cofactor with GATA1 to induce transcriptional activity 
of downstream genes in erythroid and megakaryocytic cell differentiation46,47, which may 
indicate the presence of MESP1-derived hematopoietic progenitors in our cultures48,49. 
Interestingly, FOG1 antagonizes GATA-1 activities in other cell lineages46. Repression of other 
lineages may also lead to a preferred induction of the cardiac lineage. Here, we did not found 
an enrichment of GATA-1, nor did we find enrichment of surface receptor KDR, or ETV2 and 
Tal1, transcription factors that are important for a MESP1-progenitor derived hematopoietic 
lineage48. In contrast, we did find increased expression of GATA4, 5 and 6 at this stage of 
development, which could indicate a potential binding of FOG1 to the conserved amino zinc 
finger of these factors15,20. 
Furthermore, homeodomain protein HOXB2 has been previously identified as potential 
cardiac regulator, based on its epigenetic signature2, although a more extensively 
investigated role for HOXB2 in anterior-to-posterior patterning has been described in 
hindbrain development7,11. In our study, we found temporal stage-specific co-expression of 
HOXB2 with PBX3, MEIS1 and MEIS2. STRING software showed binding evidence between 
these genes, based on experimental evidence of heterodimeric transcription complexes 
between PBX, HOX, and MEIS family genes7. Although a role for this predicted complex has 
not yet been described in the heart, both PBX3 and MEIS1 and MEIS2 have been implicated 
in heart development.
Network analysis revealed another cluster of transcription factors, consisting of RUNX1T1 
and ZBTB16, which were first identified at day 5 of differentiation but maintained high 
expression levels throughout the course of cardiac differentiation. RUNX1T1 is described 
as a co-repressor for ZBTB16, important for hematopoietic lineage differentiation17. It is not 
clear whether these factors may also have a role during early cardiac differentiation, since 
increased expression is maintained throughout cardiac differentiation, or whether absence of 
other key regulators of hematopoietic differentiation prevented a hematopoietic molecular 
profile.  Similarly, zinc finger transcription factor ZNF503, described during hindlimb and 
brain development, may also have a role in cardiac differentiation, since peak expression 
was observed at day 5 with continued expression levels throughout differentiation. ZFHX3 
is another zinc finger homeobox domain containing protein that finds enriched levels in 
cardiac progenitors and cardiomyocytes. SNP variants in the coding sequence have been 
correlated to atrial fibrillation, suggesting a role in heart development23,24.
CHAPTER 4
Furthermore, we studied the temporal expression patterns of enrichment cell surface 
markers that could be useful for efficient cardiac progenitor and/or cardiomyocyte isolation 
experiments. Several cell surface markers have been identified including LGR4, which is an 
R-spondin receptor with strong positive effect on Wnt signalling, and could play a role in 
self-renewing capacity of early cardiac progenitors50,51. Its homologs LGR5 and LGR6 are well-
known stem-cell-growth markers in other organ stem cells, including that of the intestine, 
stomach, and hair-follicle52, which makes the role and expression of LGR4 in cardiac 
progenitors of high interest to study. Furthermore, we identified other cell surface markers, 
and found that transmembrane protein transcripts TMEM151A, TMEM71, and TMEM173 
show a stage-specific enrichment similar to that of SIRPA and VCAM1, both human-specific 
cardiomyocyte markers44.
Another key finding in this paper is the importance of ECM components upon cardiac 
differentiation. For example, we find transcripts as COL9A2 and COL23A1 temporal-specific 
enriched at day 5 of differentiation, where a large number of other collagen transcripts are 
enriched throughout complete cardiac differentiation. Similar stage-specific patterns are 
seen for other ECM proteins, such as Laminin gamma-3 subunit (LAMC3, enriched at day 3), 
and Laminin alpha-2 subunit  (LAMA2, enriched at day 14).
A complete understanding of how ECM proteins are involved in heart development is lacking. 
Increasing our knowledge of stage-specific ECM-controlled steps in early heart development 
will be valuable for understanding pathology of diseased hearts.
Furthermore, the variety of enriched cardiovascular transcripts in day 10 and day 14 
M+X+ samples, including HAND2, which is expressed throughout the heart predominantly 
in the right ventricle; epicardial progenitor transcription factors WT1, TCF21, and TBX18; 
and vascular endothelial progenitor surface marker CD34, vascular growth factors VEGFA/
B/C, and cell surface receptor tyrosine kinase (TEK/TIE2), which is required for normal 
angiogenesis and heart development during embryogenesis, indicate the mixture of cell 
populations that derives from MESP1 progenitors, or the requirement of these transcripts 
for optimal cardiomyocyte differentiation cultures.
To conclude, results from our comprehensive gene expression analysis revealed several 
potential novel cardiac regulators, either as (co)-activator, or (co)-repressor, dependent on 
the transcriptional network active. Future studies will clarify the role of these identified 
factors during early cardiac differentiation and whether they have multiple roles during 
lineage. In addition, besides their role in lineage specification, these factors may also play 
additional roles in other cellular processes such as proliferation, differentiation, or cell 
survival. Therefore, to further validate the role of predicted regulatory genes in early human 
heart development and/or in the onset of congenital heart disease, experimental interaction 
analysis, direct downstream gene target analysis, and knockdown studies in vivo and in vitro 
will be of high interest. 
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METHODS
hESC maintenance, cardiac differentiation, and sample collection
MESP1mcherry/wNKX2-5eGFP/w hESCs were cultured and differentiated as described before4. 
In brief, hESCs were induced with BMP4 (30 ng/mL, R&D Systems), Activin A (20 ng/mL, 
Miltenyi Biotec), and Chir99201 (1.5 μM, Axon Medchem). At day 3 of differentiation, 
MESP1-mCherry positive and negative progenitors were isolated by FACS and aggregated for 
further differentiation, in the presence of 5 μM Xav939 (R&D). Total RNA was isolated using 
Nucleospin RNA XS kits (Macherey Nagel), at day 5 (2 days after replating), day 7, day 10, 
and day 14 of differentiation (Fig. 1). At day 14 of differentiation, samples were analysed on 
NKX2-5-eGFP expression by flow cytometry, as described before4.
Gene expression micro array and data analysis
RNA quality control, RNA labeling, hybridization and data extraction were performed 
at ServiceXS B.V. Microarray analysis was performed on three biologically independent 
replicates using Illumina human HT-12v4 arrays (ServiceXS B.V.). Data analysis was performed 
using Genespring (Agilent Technologies). Previously published micro array data that was 
complementary used in this study is numbered as: GSE56721. First, to filter probe sets on 
outlying values, we performed a one-ANOVA significant analysis test. P-values were corrected 
using the Benjamin-Hochberg method (corrected P-value<0.05). In order to select enriched 
genes in MESP1-mCherry positive derivatives compared to MESP1-mCherry negative 
derivatives, we performed statistical analysis, using a moderated T-test, on normalized values 
from three biological replicates. P-values were corrected using the Benjamin-Hochberg 
method. By using a volcano plot view, enriched genes were selected by FC>=1.5 fold value 
difference in MESP1-mCherry positive derivatives compared to MESP1-mCherry negative 
derivatives, with a P-value < 0.05 (Fig. 2). GO analysis was performed on the selected genes, 
with a multiple-GO-term correction using the Benjamini-Yekutieli method, and a P-value cut-
off of P<0.05. For GO analysis we used the DAVID Bioinformatics Recources 6.7 database from 
NIH (https://david.ncifcrf.gov/). Pathway analysis on the FC>=1.5 fold selected genes was 
performed using KEGG pathway databases. Pathways with a P-value cut-off of P<0.05 were 
selected. Heatmaps of selections of enriched genes were generated with Gene-E (http://
www.broadinstitute.org/cancer/software/GENE-E/index.html). Genes were hierarchical 
clustered through the one minus Pearson correlation. In order to be able to predict temporal 
gene networks based on our selection of enriched genes in MESP1-positive derivatives, we 
screened genes on DNA binding domains and transcription factor activity (using Gene Set 
Enrichment Analysis (GSEA) at www.broadinstitute.org), and used the STRING database to 
integrate protein-protein interactions. This online available database provides a prediction 
pipeline for inferring protein-protein associations, covering more than 2000 organisms, with 
scalable algorithms for transferring interaction information between organisms, based on 
prediction, and in vivo and in vitro experimental assays, including gene co-occurrence in 
CHAPTER 4
genomes (i.e. phylogeny), gene co-expression, gene fusion events, genomic neighbourhood 
(i.e. synteny), text mining, and experimental data such as co-immunoprecipitation and 
yeast two hybrid6. STRING extract experimental data from BIND, DIP, GRID, HPRD, IntAct, 
MINT, and PID databases. Cluster positions in the network are determined by an algorithm 
that is based on global confidence binding score (medium >0.4 or high>0.7). Based on this 
score, clustering of gene nodes (visualized by node colours) was determined by applying the 
Markov Cluster Algorithm53. Thus, interacting proteins with a higher global score have more 
chance to end up in the same cluster.
In order to understand how developmental networks are build up throughout cardiac 
differentiation, we extracted STRING data into Cytoscape54 and generated a large interrogating 
network from protein-protein interactions from day 5, day 7, and day 10 (interactions with a 
high confidence > 0.7 are visualized).
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FIGURES
Figure 1. A: hESCs were differentiated as monolayer and were sorted at day 3 on their MESP1-mCherry expression. 
Positive and negative fractions were further differentiated and RNA was collected at sequential timepoints day 5, 
day 7, day 10, and day 14. B,C: The efficiency of the cardiac differentiations was monitored by flow cytometry at 
day 14 of differentiation. NKX2-5-eGFP levels were highly increased in the MESP1-positive derived fraction, treated 
with Wnt-pathway inhibitor Xav939. MESP1-negative fractions, lacking Xav939 treatment, were showing almost no 
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Figure 2. A: Schematic overview of the methodology of gene selection from three biological replicate pairs, and the 
different methods of analysis that contribute to the identification of putative cardiac co-(regulators). A volcano plot 
view allows selection of differentially expressed genes, based on a P-value (P<0.05, moderated  t-test), and a fold 
change > 1.5. B: The number of differentially expressed transcripts at each timepoint (M+X+ vs M-X+), based on a 
FC>1.5 fold difference, and a gene-specific p-value<0.05. N=3.
Figure 2.
B. Differentially expressed transcripts in M+X+ vs M-X+ (FC>1.5fold, P<0.05)
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Figure 3. A. Heatmap visualization of the relative expression levels of mesoderm genes throughout cardiac differ-
entiation, showing a stage-specific enrichment in MESP1-mCherry isolated progenitors at day 3 of differentiation. 
Heatmap shows averaged values from n=3. B. Relative expression levels of DNA binding transcriptional regula-
tors that were enriched at day 5 of differentiation in the MESP1-mCherry positive derivatives. Genes were clus-
tered based on a One Minus Pearson Correlation. Heatmap shows averaged values from n=3.  C. Evidence for 
protein-protein interaction networks of enriched transcription factors at day 5 of differentiation was constructed 
by STRING. Interactions with a medium confidence > 0.4 are visualized. Proteins are clustered using the MCL algo-
rithm. Every color represents a cluster. Inter-cluster edges are represented by dashed lines. 
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Day 7: Early Cardiac Progenitors
Enriched transcription factors
Figure 4. 
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Figure 4. Enriched transcripts at day 7 of differentiation in MESP1-mCherry derivatives. Genes were selected 
based on a P-value> 0.05 and FC>1.5 fold difference in expression, when compared day 7 MESP1-mCherry neg-
ative derivatives. A: Enriched DNA binding transcripts at day 7 of differentiation in MESP1-mCherry derivatives. 
Heatmap shows averaged values from n=3.  B: Evidence for protein-protein interaction networks of the enriched 
transcription factors at day 7 of differentiation was constructed by STRING. Interactions with a medium confidence 
> 0.4 are visualized. Proteins are clustered using the MCL algorithm. Every color represents a cluster. Inter-cluster 
edges are represented by dashed lines.
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Figure 4C. 
Protein-protein interaction network (STRING) - Enriched Transcription Factors Day 5-7
Figure 4C. Protein-protein interaction network (STRING) - Enriched Transcription Factors Day 5-7
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Figure 5. Profile Plots of Day 5 and Day 7 Enriched Transcription Factors. The upper panel shows the expression 
patterns upon cardiac differentiation of a selection of DNA binding transcription factors. The second upper panel 
shows the similarities between the expression patterns of HOXB2, MEIS1, MEIS2, and PBX3. The second last pan-
el shows the expression pattners of GATA factors and ZFPM factors, and shows the similarities between ZFPM2 
and GATA4 from day 7-14 of differentiation. The lower panel shows the expression levels of retinoic acid nuclear 
receptors and their co-activators, peaking at day 5 of differentiation. Normalized alues are visualized on a global 
expression scale and averaged from n=3 at each timepoint.
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A. Figure 6.
B.       
Day 10/14: Cardiac Progenitors / Cardiomyocytes
Day 10/14: Protein-protein interaction network (STRING)
Enriched Transcription Factors Day 10-14
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Figure 6. Enriched transcripts at day 10 and day 14 of differentiation in MESP1-mCherry derivatives. Genes were 
selected based on a P-value> 0.05 and a FC>1.5 fold difference in expression with day 10 and day 14 MESP1-mCher-
ry negative derivatives. A. A selection of regulatory and functional genes that were enriched. Heatmaps show av-
eraged values from n=3. B. Evidence for protein-protein interaction networks of the enriched transcription factors 
at day 10 and 14 of differentiation was constructed by STRING. Interactions with a medium confidence > 0.4 are 
visualized. Proteins are clustered using the MCL algorithm. Every color represents a cluster. Inter-cluster edges are 
represented by dashed lines. 
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Figure 7.
Merged Protein-Protein Interaction Network of Enriched Transcription Factors Day 5-14
2
Figure 7. Merged protein-protein interaction network of the enriched transcription factors from all timepoints (d5, 
d7, d10, d14), obtained from STRING. Interactions with a high confidence > 0.7 are visualized. Proteins are clustered 
using the MCL algorithm. Every color represents a cluster. Inter-cluster edges are represented by dashed lines. 
Non-connected gene nodes are not visualized. We could identify the development of three distinct large node 
clusters, including retinoic acid nuclear receptors, containing PPARγ and RAR α/β, and two large interconnected 
cardiac networks centered on either GATA4 or NKX-5.
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C. Profile plot of Wnt-pathway and EMT-related transcripts
Cell Signalling: Wnt-pathway
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Figure 8. Enriched signalling pathways were identified through KEGG pathway analysis. A: Pathway analysis was 
performed on the enriched genes, selected as described before. Pathways that are visualized have a P<0.05. Gene 
count indicates the number of genes that could be identified for each enriched pathway. % indicates the percentile 
of the gene count from the total number of genes in the specific pathway. Numbers indicate the pathway-specific 
p-value. A comprehensive list of pathways can be found in Table S2. B: Heatmap visualization of the enriched tran-
scripts belonging to the Wnt signalling pathway, which is enriched in early cardiac committed progenitors, and the 
TGF-β signalling pathway, enriched in cardiac progenitors and cardiomyocytes. Heatmaps show averaged values 
from n=3. C: Profile Plots of enriched Wnt-pathway-related and EMT-related gene expression levels throughout 
cardiac differentiation. Normalized values are visualized on a global expression scale and averaged on n=3.
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Figure 9.
Cell Surface Proteins / Markers
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Figure 9. A: Heatmap visualizes the temporal enrichment of extracellular matrix proteins throughout cardiac differ-
entiation.  B: Visualization of temporal expressed cell membrane proteins to identify potential cell surface markers 
for subsets of cardiac progenitors or cardiomyocytes. Heatmaps show averaged values from n=3.
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Table	  1A.	  Gene	  Ontology	  Analysis	  of	  enriched	  transcripts	  at	  sequential	  stages	  of	  differentiation	  (P<0.05).	  
Day	  5	  (Enriched	  transcripts	  in	  M+	  vs	  M-­‐,	  FC>1.5,	  P<0.05) Benjamini
Category Term Count % Corrected	  P-­‐value
PANTHER_BP BP00193:Developmental	  processes 89 20,60 1,35E-­‐06
PANTHER_BP BP00102:Signal	  transduction 108 25,00 0,011389832
PANTHER_BP BP00274:Cell	  communication 47 10,88 0,018208241
PANTHER_BP BP00248:Mesoderm	  development 27 6,25 0,020433632
PANTHER_BP BP00246:Ectoderm	  development 31 7,18 0,016956308
PANTHER_BP BP00199:Neurogenesis 27 6,25 0,032211571
PANTHER_MF MF00178:Extracellular	  matrix 27 6,25 3,52E-­‐05
PANTHER_MF MF00179:Extracellular	  matrix	  structural	  protein 11 2,55 0,001599702
Day	  7	  (Enriched	  transcripts	  in	  M+	  vs	  M-­‐,	  FC>1.5,	  P<0.05) Benjamini
Category Term Count % Corrected	  P-­‐value
PANTHER_BP BP00193:Developmental	  processes 38 24,36 0,002291487
PANTHER_BP BP00124:Cell	  adhesion 16 10,26 0,015033261
PANTHER_BP BP00281:Oncogenesis 12 7,69 0,059284076
PANTHER_BP BP00274:Cell	  communication 22 14,10 0,046309515
PANTHER_BP BP00102:Signal	  transduction 43 27,56 0,187888803
PANTHER_BP BP00122:Ligand-­‐mediated	  signaling 9 5,77 0,425197991
PANTHER_BP BP00071:Proteolysis 15 9,62 0,405883178
PANTHER_BP BP00109:Receptor	  protein	  serine/threonine	  kinase	  signaling	  pathway 3 1,92 0,531826987
PANTHER_BP BP00248:Mesoderm	  development 10 6,41 0,535902255
PANTHER_BP BP00103:Cell	  surface	  receptor	  mediated	  signal	  transduction 21 13,46 0,653573879
PANTHER_BP BP00267:Homeostasis 5 3,21 0,667475861
PANTHER_MF MF00178:Extracellular	  matrix 18 11,54 1,59E-­‐06
PANTHER_MF MF00282:Aspartic	  protease 4 2,56 0,035633978
PANTHER_MF MF00179:Extracellular	  matrix	  structural	  protein 6 3,85 0,041276498
Table	  1B.	  Gene	  Ontology	  Analysis	  of	  enriched	  transcripts	  at	  sequential	  stages	  of	  differentiation	  (P<0.05).	  
Day	  10	  (Enriched	  transcripts	  in	  M+	  vs	  M-­‐,	  FC>1.5,	  P<0.05) Benjamini
Category Term Count % Corrected	  P-­‐value
PANTHER_BP BP00173:Muscle	  contraction 38 5,65 2,02E-­‐14
PANTHER_BP BP00250:Muscle	  development 25 3,71 9,55E-­‐08
PANTHER_BP BP00248:Mesoderm	  development 51 7,58 1,36E-­‐06
PANTHER_BP BP00193:Developmental	  processes 122 18,13 1,58E-­‐04
PANTHER_BP BP00251:Heart	  development 10 1,49 0,004440264
PANTHER_BP BP00285:Cell	  structure	  and	  motility 65 9,66 0,019756301
PANTHER_BP_ALLBP00287:Cell	  motility 27 4,01 0,018914324
PANTHER_MF MF00261:Actin	  binding	  cytoskeletal	  protein 48 7,13 1,83E-­‐11
PANTHER_MF MF00091:Cytoskeletal	  protein 63 9,36 6,27E-­‐06
PANTHER_MF MF00178:Extracellular	  matrix 34 5,05 2,34E-­‐04
PANTHER_MF MF00230:Actin	  binding	  motor	  protein 9 1,34 0,024317475
Table 1. Gene Ontology Analysis of enriched transcripts at sequential stages of differentiation. Differentially ex-
pressed genes in the MESP1-mCherry positive derived cardiac populations were selected on a FC>1.5 fold dif-
ference with their MESP1-mCherry negative counterpart, and a P-value<0.05, n=3. GO-analysis was performed 
using the Panther Classification System. Multiple-GO-term correction was performed using the Benjamini-Yekutieli 
method. GO-terms hold a corrected p-value <0.05.
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ABSTRACT
Human pluripotent stem cell (hPSC)-derived cardiovascular cells hold great expectations 
for the field of regenerative therapy of the heart, disease modelling, drug development, 
and toxicity screenings. Recent optimized cardiomyocyte differentiation protocols yield 
high percentage of either atrial or ventricular cardiomyocytes, whereas only a small subset 
of cardiomyocytes poses a pacemaker-like identity. Although studies indicate a role for 
Neuregulin/ErB and Notch signalling in the formation of specialized conduction-like cells, 
detailed insights into the regulation of cardiac conduction cell formation is largely unknown. 
In the mammalian heart, TBX3 is expressed specifically in cells from the cardiac conduction 
system (CCS), which initiate and propagate the electric impulse required for the coordinated 
contraction of the chambers. Previously it was shown that two enhancer elements are 
responsible for atrioventricular TBX3 expression in vivo. Here, we incorporated these 
enhancer elements in a reporter construct, coupled to a minimal promoter, and driving 
mCherry expression. Transgenic lines were generated in the background of the previously 
described NKX2-5-eGFP reporter hESC line. Subsequently, we screened this double reporter 
line with cytokines/molecules in order to identify factors/pathways that may be important 
for activating TBX3-positive pacemaker-like cardiomyocytes. 
 
Introduction
The heart is comprised of cardiomyocytes, which can be subdivided in two classes: 
working myocardium (atrial and ventricular), and conductive tissue. In higher vertebrates 
the conduction system consists of a central and a peripheral component. In the central 
conduction system (CCS), the sinoatrial node (SAN) initiates electrical impulses, that are 
propagated through the atria, and delayed in the atrioventricular node (AVN). This is followed 
by rapid propagation through the interventricular ring, the right atrioventricular ring bundle, 
the atrioventricular bundle, and the proximal bundle branches (BBs). The impulses then 
enter the peripheral conduction: the distal part of the BBs and the peripheral ventricular 
conduction network. Cardiomyocytes of the conduction system are highly specialized 
cells. Their development is tightly controlled by specific regulatory pathways [1]. Several 
transcription factors play crucial roles in the differentiation of cells of the CCS, including 
T-box transcription factors. Alterations in transcriptional networks during formation of 
the conduction system cause electrical disturbances, such as sinus node dysfunction or 
atrioventricular block[2-4] may lead to life-threatening cardiac arrhythmias. Insights into the 
molecular control of the developing conduction system will give us more understanding into 
the onset of congenital and acquired conductive abnormalities. The T-box factor TBX3 is 
specifically expressed in the developing and mature CCS in mammals. During development, 
TBX3 is expressed in the cardiac inflow and outflow tract, the SAN, the AVN, internodal 
regions, atrioventricular regions, the AV bundle, and in the BBs[5]. TBX3 is a repressor of 
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working myocardial genes, such as NPPA (ANF) and Connexin40 (CX40), and is described as 
critical factor in the formation of the SAN by repressing the atrial working myocardial gene 
expression, and by activating SAN genes, such as LBH, HCN family members, and Connexin 
30.2[6]. Horsthuis et al. showed how a transgenic mouse reporter line, harbouring a 160Kb-
BAC sequence spanning the Tbx3 locus, displayed gene expression only in a subdomain of 
TBX3 positive cardiac cells, including the primordial AVN, ventral/cranial, and right side of 
the AVC. This implies that the activity of specific regulatory DNA elements are responsible 
for a precise pattern of TBX3 expression in the CCS[7]. In a recent study by the same group, 
incorporation of upstream sequences of this TBX3 locus complementary expression was 
found in the complete AV rings and in the prospective AV bundle[8]. They identified two 
enhancer regions eA and eB to be responsible for the AVN-TBX3 expression, which were 
activated by both BMP signalling and GATA4 expression. 
For therapeutic and pharmaceutical applications, including cardiac repair and/or drug 
development/discovery, it will be of interest to derive cells from the cardiac conduction 
system in vitro. Therefore, in this project, we studied the in vitro derivation of CCS cells 
from pluripotent stem cells, by generating a TBX3eAeB-Hsp68 (TBX3e)-mCherry reporter 
in the previously generated NKX2-5-eGFP-hESC line[9]. Here, both enhancer regions were 
sequentially coupled to promoter-element Hsp68 and sequences encoding for fluorescent 
reporter protein mCherry. By screening the activation and inhibition of different signalling 
pathways at specific timings during cardiac differentiation, we investigated activation of 
TBX3e-mCherry expressing cells.
MATERIAL AND METHODS
Generation of Lentiviral TBX3eAeB-mCherry Reporter Construct
The TBX3e-mCherry reporter construct was generated through the Gateway® Cloning 
Technology, using the Gateway® LR Clonase® II Enzyme mix (Life Technologies). Two pENTR 
vectors were kindly provided by H. Van Weerd: pENTR4-mCherry-polyA and pENTR5-
TBX3eAeB-Hsp68 (sequences can be found in Supplemental Fig. 1), which were used to 
clone mCherry-polyA and TBX3eAeB-Hsp68 into destination vector pLenti6-R4R2-V5-DEST 
(Fig. 1a).
Enzyme mix:
 pENTR4 – mCherry   100ng  1.5uL
 pENTR5- eAeB   100ng  1.5uL
 pLenti6/R4R2/V5-DEST  150ng  1uL
 TE PH 8.0     4uL
 Total      8uL
+  Enzyme mix     2uL
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The reaction was incubated at RT for 18 hours, and was stopped by addition of 1uL 
Proteinase K. A reaction volume of 2 uL was transformed into E. Coli (One Shot® TOP10 
Chemically Competent E. coli, Life Technologies). Positive bacterial colonies were selected 
on Ampicillin-containing agar plates (100ug/mL). Destination vectors were isolated from 
selected colonies and digested with EcoRV (New England Biolabs). Clones # 1, 2, 5, 7, 9, 
10, 11, 13, 14, 16, and 17 were showing the expected bands (Fig. 1b). This was confirmed 
by a second digestion with PvuI (New England Biolabs) on clones # 7, 9, 10, 11, 13, 14, 16, 
and 17 (Fig. 1c). Clones # 7, 9, and 10 were sent for sequencing, from which clone 7 and 9 
contained correct sequences. Clone 9 was used for further experiments. Lentiviral particles 
were produced by co-transfection with 3rd generation lentiviral packaging vectors (pMD2.G, 
pRRE and pRSV/REV) into HEK293T cells (Thermo Scientific). For transfections, the construct 
DNA was mixed with Lipofectamine 2000 in OptiMEM (Life Technologies) and was added to 
the media (DMEM containing 4% FCS). After 18 hours, cells were refreshed with DMEM-4% 
FCS. Lentiviruses were harvested 72 h after transfection and concentrated in a Beckman 
coulter ultracentrifuge at 20,000 rpm and at 40C for 2 hours. Lentiviruses were resuspended 
in 1% BSA-PBS and stored at -80°C. The titer was determined with a qPCR lentiviral titration 
kit (ABM Inc.).
Lentiviral transfection
To generate the TBX3e-mCherry reporter line, DeltaN3-NKX2-5eGFP/w hESCs were transduced 
with the lentiviral construct containing the TBX3emCherry expression cassette (Fig. 2a). The 
viral titer was estimated by qPCR on 4.2x106 IU/uL (ABM Inc.). We added 0 MOI (control), 10 
MOI (0.25 uL), 20 MOI (0.5uL), and 50 MOI (1.2uL) to 100k hESCs. Incubation was performed 
in an Eppendorf tube for 5 minutes at RT, and after that, cells were plated in a 12 wells plate, 
coated with MEFs. After transduction, single clones were selected using blasticidin for 48 
hours (Invitrogen, 10ug/mL). Clones were screened for the presence of mCherry protein by 
PCR. As positive control, we used a mCherry.pcDNA3.1 plasmid. PCR screening sequences 
were PCR_F1: GCATGGACGAGCTGTACAAG, and PCR_R1: GCATGAACTCCTTGATGATG. From 
the 32 screened colonies, we found 12 colonies positive, which was confirmed by a repeating 
PCR (Fig. 2b, c).
Culture and selection of positive clones
After blasticidin selection and PCR screening, multiple clones were kept as colony growing 
cultures. The cells were cultured on mouse embryonic fibroblasts (MEFs) in 2.85 cm2 organ 
dishes (Falcon), in 1 mL hESC medium (DMEM F12, Non-Essential Amino Acids, Knock Out 
Serum (Gibco by Life Technologies); bFGF (Miltenyi Biotec)) and were mechanically passaged 
once a week. Due to the random integration properties of lentiviral particles, three clones 
(A4, A5, and B5) were differentiated to cardiac cells by a standard cardiac differentiation 
protocol as described below.  At day 14 of differentiation, NKX2-5-eGFP and TBX3e-mCherry 
CHAPTER 5
expression was analysed by flow cytometry.
Cardiac Differentiation Protocol
One day prior to the differentiation, hESCs were passaged onto a 12-well tissue culture plate 
(Greiner CELLSTAR), coated with Matrigel (BD biosciences; growth factor reduced, phenol 
red-free), in 1 mL of hESC medium per well. The first day of differentiation, day 0, hESC 
medium was replaced by low insulin, serum–free medium BPEL (BSA, polyvinyl alcohol, 
essential lipids, as previously described[9, 10], containing the cytokines BMP4 (30 ng/mL, R&D 
Systems), Activin A (30 ng/mL, Miltenyi Biotec) and CHIR99021 (1.5µM, AxonMedchem). At 
day 3 of differentiation, the medium was refreshed with BPEL containing XAV939 (5µM, R&D 
Systems). At day 7, cells were refreshed with plain BPEL and further differentiated. In order 
to direct the differentiation towards the formation of CCS cells, this protocol was altered by 
the addition of several other cytokines in a range of concentrations at different timings as 
indicated. Cytokines that were screened included NRG-1β/ErbB signalling inhibitor AG-1478 
(TEBU), FGFR antagonist SU5402 (Sigma-Aldrich Chemie) and WNT11 (R&D).
Flow Cytometry
To screen for the formation of TBX3e-mCherry expressing cells in the different differentiation 
protocols, fluorescent expression was analysed by flow cytometry at day 14 of differentiation. 
For this, the cells were enzymatically dissociated using 1x TrypLE Select (Life Technologies). 
After dissociation, cells were resuspended in FACS sorting buffer (PBS with 0.5% BSA and 
2.5 mM EDTA) and analysed using a MACS Quant VYB flow cytometer (Miltenyi Biotec) with 
a 488 nm and a 561 nm laser. FACS data was further processed using FlowJo Software v10. 
RESULTS
Generation of a Cardiac Conduction Reporter Line
In order to identify cells from the CCS in current cardiac differentiation protocols, and to 
develop protocols specifically directing towards cardiac conduction system lineages, we 
developed a cardiac conduction reporter construct. Enhancers eA and eB, recently identified 
to regulate TBX3 expression in the developing AV node during mouse embryogenesis, were 
both sequentially coupled to minimal promoter-element Hsp68 and sequences encoding for 
fluorescent reporter protein mCherry. The previously generated NKX2-5-eGFP hESCs[9] were 
transduced with lentiviral particles containing this reporter construct (Fig. 2a), resulting in a 
dual cardiac reporter line (Fig. 2b).
TBX3e-mCherry activation during In vitro cardiac differentiation
After blasticidin selection, 32 clones were picked and screened by PCR for the insertion of the 
mCherry cassette, of which 12 clones were positive (Fig. 2c). Due to the random integration 
properties of lentiviral particles and risk of transgene silencing, three clones (A4, A5, and 
B5) were further used for screening on TBX3e-mCherry expression upon differentiation. 
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As eA and eB were shown to be activated by both BMP signalling and GATA4 expression 
during mouse development[8], we supplemented our standard cardiac differentiation 
protocol with 20 ng/mL BMP4 from day 3 up to day 5, directly after mesoderm formation, 
hypothesising that cardiac conduction progenitors segregate from this early population, and 
taking into account endogenous GATA4 expression during differentiation[11, 12] (Fig. 3a). 
In this preliminary experiment, we identified low TBX3e-mCherry expression in two of the 
three clones (A4 and B5). Unfortunately, when repeating the BMP4 supplemented cardiac 
differentiation several times, we could not identify TBX3e-mCherry+ cells. As we initially 
found mCherry expression in the cardiac differentiation from clone A4, we decided to 
use this clone for further screening analysis, as it shows the best cardiac differentiation in 
presence of Xav939, compared to other clones (Fig. 3b). 
Screening Protocols to Obtain Cardiac Conduction System Cells In Vitro
A number of signalling pathways has been shown, either in vivo or in vitro, to play a role in 
CCS development and/or differentiation[8, 13-17]. Here, we investigated the potential role 
of various factors in cardiac conduction lineage differentiation from hPSCs. First, we tested 
the potential role of neuregulin (NRG)-1β/ErbB signalling in cardiac conduction lineage 
differentiation, as it was previously shown that inhibition of this pathway resulted in enhanced 
differentiation towards a cardiac nodal phenotype[14]. However, addition of AG1478, an 
ErbB antagonist, from day 3-5, or day 5-7 during our standard cardiac differentiation protocol, 
did not result in activation of TBX3e-mCherry positive cells at any time point studied (Fig. 
3c). Furthermore, the presence of non-canonical Wnt-agonist WNT11 was tested during 
differentiation, shortly after mesoderm formation (Fig. 3d). WNT11 is detected in developing 
central conduction structures in mouse, including the right atrioventricular ring[17]. 
Nonetheless, we did not identify TBX3e-mCherry positive cells. However, in a preliminary 
experiment we did observe that WNT11 could possibly enhance cardiac differentiation, 
indicated by increased NKX2-5-GFP+ levels in both conditions (D3-D5 and D5-D7), This is 
in agreement with previous studies[18-21]. Further, we tested a protocol that was recently 
developed by Birket et al.[22], which resulted in differentiation to pacemaker-like CMs in a 
transgenic hESC line. Growth factors involved in the derivation of NKX2-5 negative beating 
CMs from hESCs included SU5402 (an FGF-receptor-inhibitor[22], and BMP4. Additional 
protocols were screened, which also included AG1476. Birket et al. showed how inhibition 
of FGF signalling could potentially play a role in SAN lineage specification[22]. However, in 
our experiments, addition of both FGF-inhibitor SU5402 and BMP4 did not result in TBX3e-
mCherry positive cells, and even inhibited cardiac differentiation, although not significantly, 
in the absence of XAV939 (Fig. 3e). Birket et al. also showed this inhibitory effect of SU5402 
on NKX2-5 expression. In addition, the differentiations that also included AG1476 showed 
total absence of NKX2-5 positive CMs (Fig. 3e), indicating a role for neuregulin (NRG)-1β/
ErbB signalling in cardiac differentiation, which is reviewed elsewhere[23].
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DISCUSSION
In vivo developmental studies from different species are contributing largely to our increased 
understanding of combinatorial actions of regulatory elements on the precise patterned 
expression of specific cardiac genes, such as Tbx3[8]. Moreover, advancements in new 
technologies to understand chromatin organization and epigenetic changes upon lineage 
commitment, contribute to the identification of these critical regulatory elements[24, 25]. 
This increased knowledge on molecular regulation during the different phases of cardiac 
development can be extrapolated and applied in human in vitro differentiation models, 
by the use of fluorescent reporters in combination with medium- up to high-throughput 
screening methods. This will allow culture, identification and characterization of cardiac 
subtype cells of interest. The derivation of these subsets of cells will allow a next step in 
drug development: cardiac subtype-specific and disease-specific drug screenings.
The development of protocols to differentiate towards cells from the CCS will create 
opportunities for their use in the development of safe and effective drugs for the treatment 
of diseases specifically affecting the conductive system, including atrioventricular nodal 
abnormalities and may eventually lead to the production of biopacemakers. In this study, 
we describe the generation of a TBX3-reporter in the previously published NKX2-5-eGFP 
hESC line[9]. TBX3 is a cardiac transcription factor, crucial for the formation of the cardiac 
conduction system in the developing mammalian heart. Recently, the group of Christoffels 
identified, using high-resolution 4C-sequencing and transgenic mice models, 2 highly 
conserved enhancer regions within the Tbx3 domain. Both enhancers synergize with the 
Tbx3 promoter to drive TBX3 expression in the atrioventricular conduction system[8]. Here, 
we coupled these enhancers, eA and eB, to minimal promoter Hsp68 and mCherry coding 
sequences, and transfected hESCs with lentivirus particles containing the generated reporter 
cassette. We hypothesised that activation of both enhancers during induction of cardiac 
differentiation would result in mCherry expression in cell types that are recapitulating the 
TBX3 activity in the AV node in vivo. Subsequently, mCherry-positive, GFP-positive, nodal 
cardiomyocytes could be isolated and further characterized.
Extrapolating developmental processes from in vivo mouse studies to in vitro human 
differentiation models has been shown very useful due to the highly conserved regions 
that are shared between mouse and human. Moreover, comparison to the developmental 
processes and molecular mechanisms in other species is a necessity, since human material at 
early stages of development are extremely difficult, if not impossible, to obtain. However, our 
study appeared to be challenging due to several technical and biological difficulties, including 
the random integration properties of lentiviral particles, and limited information regarding 
the signalling pathways involved in cardiac conduction system lineage development. Upon 
lineage commitment, chromatin dynamics and epigenetic regulators may change, which may 
result in the risk of transgene silencing of the random integrated reporter cassette[26-28]. To 
circumvent this problem in first case, we decided to screen several clones on their potential 
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TBX3e-mCherry expression upon standard cardiac differentiation conditions, and in 
presence of BMP4. However, after an initial positive result, displaying a modest upregulation 
of mCherry expression in two clones, none of the clones showed mCherry expression in 
follow-up experiments. Moreover, this also indicated the lack of active eA and eB in our 
standard cardiac differentiation protocol. This is in line with previous findings on the low 
TBX3 expression levels upon cardiac differentiation[12]. We performed further screening 
differentiations on one clone, that showed the initial positive result (clone A4). 
As van Weerd et al. showed eA and eB activation by the combinatorial presence of 
GATA4 and BMP4, we initially screened on TBX3e-mCherry expression by testing different 
concentrations of BMP4 at different timings of cardiac differentiation. Here, we assumed 
high endogenous expression levels of Gata4, based on previous gene expression array 
results[12]. Our nodal-like CMs are expected to co-express NKX2-5-eGFP and TBX3e-
mCherry levels, as Nkx2-5 is required for the development and maintenance of the AVN[29]. 
Unfortunately, after the initial positive experiment, no TBX3e-mCherry positive cells could 
be identified in any condition. Based on knowledge from in vivo mouse development and 
recent publications on the in vitro derivation of human cardiac conduction cells[14, 22], 
growth factors were screened for their role in TBX3 expressing conduction cell derivation; a 
variety of differentiation protocols were developed. For instance, Birket et al. showed how 
FGF-signalling inhibition by SU5402 could have an inhibitory effect on NKX2-5 expression 
in early cardiac progenitors[22], which further differentiated to CMs with a pacemaker 
identity, based on electrophysiology and gene expression, including increased HCN4 and 
TBX18 levels. However, in our experiments, addition of SU5402 and BMP4 did not result in 
TBX3e-mCherry positive cells, and did even inhibit cardiac differentiation in the absence of 
XAV939. Further, Wnt11 and (NRG)-1β/ErbB signalling were both described to play a role 
in the developing cardiac conduction system[14, 17]. Again, also here, we could not detect 
any TBX3e-mCherry expression. Despite the absent of mCherry expressing cells, we could 
confirm the role of Wnt11 and neuregulin (NRG)-1β/ErbB signalling in heart development, 
as we did find increasing NKX2-5-eGFP expressing CMs when differentiation was induced 
with Wnt11, and decreasing levels after induction with ErbB antagonist AG1478. However, 
important to note is the high variance of biological repeats, which makes it more difficult 
to obtain statistically significant results. In order to make any conclusive statements on 
the effects of cytokine on cardiac differentiation and specification it is crucial to optimize 
and standardize cell culture and differentiations conditions in order to minimize biological 
variation.
Our results regarding the lack of induction of TBX3 activity is in contrast with previous findings 
from the studies of Zhu et al. and Birket et al. This could be due to 1) transgene silencing, or 
2) restricted activity of the highly conserved eA and eB in only a subset of TBX3 expressing 
cardiac conduction cells (primordial AVN, AVC, AV rings, prospective AV bundle). The latter 
explanation is feasible, since both previously mentioned studies showed upregulation of 
TBX3 expression in their PSC-derived nodal cells[14, 22]. Indeed, TBX3 expression is critical 
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for conduction cell specificity and function[6, 30, 31]. To circumvent the risk of transgene 
silencing due to random integration of the reporter cassette, the generation of an endogenous 
TBX3 fluorescent reporter line, using a knockin through replacement or fusion strategy could 
be recommended. However, as TBX3 expression is not specifically expressed in the heart, 
the use of specific regulatory elements, coupled to fluorescent reporters, or in combination 
with another cardiomyocyte reporter, such as a sarcomeric protein, or NKX2-5, such as in 
this study, would still be a preference. Targeted integration of a reporter cassette, such as 
used in our study, at an ubiquitous active genomic region (“a docking station”) should be 
reconsidered and could make it more promising to generate such fluorescent reporter lines. 
Genomic sites that have been described in literature include including sequences highly 
homologous to the mouse Rosa26 locus and the AAVS1 locus[32-34].
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Figure 1. A: Gateway® cloning of the 
two TBX3 enhancers eA and eB and the 
Hsp68 promoter element, and mCherry 
from two separate entry vectors into 
one destination vector (Life Technolo-
gies). B. Digestion with EcoRV of multi-
ple picked destination vectors to define 
correctly cloned vectors. C. Digestion 
with PvuI of a selection of correctly 
cloned destination vectors to confirm its 
correct integrity.
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C. PCR screening after transfection: PCR_F1 + PCR_R1
PCR_F1 PCR_R1
676 bp
   Clone #    A2  A3  A4  A5         A6  A7         B5  B6  B7  B8 B9 B10 B11              + control (mCherry plasmid)
Figure 2. A: Generation of the TBX3e-mCherry hESC reporter line through viral delivery of the TBX3e-mCherry re-
porter construct. Cells were incubated with lentiviral particles for 24 hours followed by selection using blasticidin. 
Resistant clones were picked and screened for mCherry expression upon cardiac differentiation. TBX3e-mCherry 
expressing cardiomyocytes would be characterized on their gene expression profile and action potential pheno-
type, and could be of potential for future translational applications. B: Schematic overview of the genome of the 
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Figure 3. Growth factor screenings during cardiac differentiations in order to direct differentiation towards 
TBX3e-mCherry expressing cardiomyocytes. A: Addition of 20ng/mL BMP4 resulted in a small percentage of 
mCherry expressing cardiomyocytes at day 14 of differentiation in clone A4 and clone B5. B: A standard monolayer 
differentiation protocol results in 34% of NKX2-5-eGFP expressing cardiomyocytes at day 14, in clone A4, versus 
14% without Wnt signalling inhibitor Xav939. C: Addition of  ErbB antagonist AG1478 after mesoderm formation 
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between D3-D5 or D5-D7 did not result in TBX3e-mCherry expressing cardiomyocytes at day 14 , and did even 
inhibit cardiac differentiation. D: Addition of Wnt11 after mesoderm formation did not result in TBX3e-mCher-
ry expressing cardiomyocytes. Addition of Wnt11 between D3-D5 could possible enhance cardiac differentiation, 
but requires repeated experiments. E,F: Screening of a variant of differentiation protocols did not direct towards 
TBX3e-mCherry expressing cardiomyocytes. 
Supplemental Figure 1. Sequences of pEntry vectors containing both TBX3 enhancers eA and eB and Hsp68, and 
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ABSTRACT
In recent years, differentiation of human pluripotent stem cells (PSCs) to the cardiac 
lineage has improved considerably leading to mixtures of cardiomyocyte subtypes.  This 
allowed researchers to study human cardiac development and differentiation, and to 
obtain cardiomyocytes (CMs) for pre-clinical applications, such as drug discovery, safety 
pharmacology, disease modelling and cell-based therapies for cardiac repair. However, in 
order to increase the predictability and the robustness of stem cell based assays and follow-
up experiments, it is essential to obtain pure populations of CM subtypes. Here, we describe 
the generation of a MYL2-T2A-mCherry-NKX2-5-eGFP hESC reporter line in order to study and 
steer in vitro cardiac differentiation to a ventricular cardiomyocyte subtype. MYL2 encodes 
for ventricular myosin light chain-2 (MLC-2v) and is specifically expressed in ventricular 
cardiomyocytes. During cardiac differentiation, MYL2 only becomes markedly expressed 
after 1 month of differentiation. Fluorescent labelling of cells expressing MYL2 will allow 
us to isolate ventricular cardiomyocytes and study their molecular and electrophysiological 
characteristics. Moreover, this may contribute to the identification of regulators that are 
important for the formation of the ventricular-specific-lineage. In this chapter, we focus 
on the technical challenges that we faced upon the generation of this fluorescent reporter 
line and our preliminary results on the identification of MYL2-T2A-mCherry expressing 
cardiomyocytes during cardiac differentiation.
INTRODUCTION
The heart is one of the first organs formed in the developing human embryo, indicating its 
vital importance in supplying oxygen and nutrients to the developing organism and at the 
later adult stage[1]. Formation of the developing heart is complex and requires a balanced 
interplay between specific molecular signalling pathways and transcription factors under 
tight temporal and spatial control. Congenital heart disease encompasses abnormalities in 
the developing heart due to mutations in important regulators of heart development, but 
may also be caused by prenatal environmental influences[2]. It is important to understand 
how these underlying defects result in the onset of congenital heart disease, which requires 
a complete understanding of the developing human heart. Acquired heart diseases, such as 
myocardial infarction, mostly result in a massive loss of ventricular cardiomyocytes (CMs) 
due to an ischemic event, leading to decreased cardiac function[1]. As cardiac disease is 
still a leading cause of morbidity and mortality worldwide, there is an urgent need for a 
better understanding of its onset and progression, and in the end, better treatment 
options[3, 4]. The adult human heart has no or limited regenerative capacity, and is 
therefore unable to restore damaged cardiac cells due to ischemia or cardiomyopathies, 
resulting in progressive heart failure[5]. Replacement of damaged heart tissue with viable 
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hPSC-derived cardiomyocytes may be a possible therapeutic strategy. In particular, the 
possibility to generate human iPSC-derived cardiomyocytes created the opportunity to use 
cardiomyocytes for autologous transplantation, as opposed to the ethically sensitive use of 
human embryonic stem cells (hESCs). Optimized hPSC-CM protocols have been developed 
and result in 50-95% CM differentiation efficiencies[6]. Moreover, the use of hPSC-CMs 
offers an exclusive physiologically relevant human model system for drug discovery and pre-
clinical development strategies. However, current cardiac differentiation protocols result 
in heterogeneous pools of CMs. Although these mixed cultures predominantly consist of 
ventricular-like cells, there is a significant percentage of other cardiomyocyte subtypes, 
such as atrial-like and nodal-like cells[7]. For high reliability in predictive pharmacological 
compound screenings, pure populations of cardiac subtypes are necessary. In particular, 
ventricular cardiomyocytes are of interest, since in the majority of cases, genetic cardiac 
disorders and cardiac injury affect ventricular cardiomyocytes. 
The generation of fluorescent pluripotent stem cell reporter lines offer an excellent 
opportunity to study the derivation of specific cellular subtypes[8, 9]. In order to obtain pure 
populations of ventricular CMs, here, we generated a MYL2 (MLC2V) fluorescent reporter in 
the previously described NKX2-5-eGFP hESC line[9]. In vivo, MLC2V expression is restricted 
to the ventricular segment of the developing human heart, followed by expressed in the 
entire ventricular compartment in the adult heart[10]. Previous studies have described 
the generation of MYL2 reporter lines in mouse ESCs, reporting a specific MYL2 promoter 
element or endogenous MYL2 expression[11, 12]. Here, we reported endogenous MYL2 
expression in hESCs through a fusion strategy, making use of a cleaving 2A peptide sequence 
which is positioned in frame between MYL2 and the coding sequence of mCherry[13]. 
2A-mediated cleavage is a universal phenomenon in all eukaryotic cells. However, it has not 
been observed in prokaryotic cells[14]. Transcriptional activity of the MYL2 transcript leads 
to production of a single messenger RNA encoding both proteins, MYL2 and mCherry. Here, 
we will discuss our technical approach for the generation of a MYL2-fluorescent reporter 
line, preliminary results, and possible future strategies for obtaining pure ventricular CM 
populations.
MATERIAL AND METHODS
Generation of the MYL2 targeting construct
To generate the MYL2 targeting vector, bacterial artificial chromosome RP11-587H5, 
containing the MYL2 sequence (Source Bioscience, Lifesciences, Nottingham, UK), was 
modified by recombineering (Gene Bridges, Heidelberg, Germany) (Fig. 1). An R6k plasmid 
was generated through cloning, containing the T2A sequence[15], followed by mCherry 
(in-frame), and a neomycin selection cassette, flanked by LoxP recombination sites. 20ug 
of the complete cassette of interest was linearized by the two enzymes PvuI and EcorV, 
restricting an upstream PvuI site, and a downstream EcoRV site (Fig. 1a).  Recombineering 
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was performed using the Red/ET recombination technology (Genebridges). Here, we 
introduced the Red/ET plasmid (pSC101-BAD-gbaA-tet) into E. Coli containing BAC RP11-
587H5 through electroporation. Genes from plasmid pRed/ET promote base precise 
exchange of DNA sequences flanked by homology arms. The exonuclease Redα and the DNA 
annealing protein Redβ catalyze the in vivo reaction. Further, two primers were designed, 
containing 40bp that were homologous to the ends of the linearized R6K cassette, and 
containing 50bp homologous to the region of the MYL2 BAC upstream and downstream of 
the MYL2 stopcodon (Fig 1b).  Addition of 10% L-arabinose (to a final concentration of 0.1%) 
for induction of RedET genes, followed by electroporation of the linearized R6k cassette and 
both primers into the MYL2 BAC containing E. Coli, resulted in quadruple recombination of 
the BAC. Oligonucleotide primers oligo1 and oligo2 were used for recombineering (Table 
1). Recombineered BACs were screened by PCR; 7 out of 40 clones displayed a correct 
product size (17.5%)(Fig. 1c). For clone 3, PCR products were generated for the 3’ homology 
arm (HA) and 5’ HA recombined regions, and sent for sequencing (100% correct). The 
modified MYL2 locus, including 5’ and 3’ homology arms, were subsequently subcloned 
into a MYL2 targeting vector. For this, a PCR (Phusion, Thermo Scientific) was performed 
on a linearized minimal vector (digested by XhoI and HindIII), containing a Diphtheria Toxin 
A (DTA) sequence for negative selection, an ampicillin resistance cassette, and an origin 
of replication (ORI) sequence (Fig. 2a). Oligos that are used to generate this PCR product 
contain extra 50bp sequences that are homologous to the BAC sequence that are upstream 
(5’ HA, 8.8kb) and downstream (3’ HA, 2.3kb), so that regions in between these homologous 
regions are subcloned into a final target construct, containing the PCR product as backbone 
(Fig. 2a, Table 1). For subcloning, the pRed/ET plasmid was re-introduced into the E.Coli, 
containing modified BAC clone 3, and activated by L-arabinose prior to electroporation of 
the PCR product of the minimal vector. The newly subcloned minimal vectors were then 
isolated and screened by PCR; 80% of the clones was positive (Fig. 2b). Three clones were 
further verified using Bgl1 and XbaI digestions (Fig. 2c). Clone 3.9 displayed the correct 
sequence and was further used for MYL2 targeting.
Generation of the MYL2-T2A-mCherry Reporter Line
The final targeting vector comprised a 8.8-kb 5_homology arm, T2A-mCherry, loxP-flanked 
G418 resistance cassette, a 2.3-kb 3_homology arm, and a Diphtheria Toxin A (DTA) sequence 
for negative selection (Fig. 2a). The targeting vector was linearized by PvuI digestion and 
20 μg was electroporated into 10x106 NKX2-5-eGFP reporter hESCs (HES3-NKX2-5eGFP/w)
[9] as described previously[16]. Homologous recombination will result in replacement of 
the MYL2 STOP codon, localized in exon 7. Targeted clones were identified by PCR using 
oligonucleotides specific for mCherry (MYL2_screen_F1: CCCCCTGAACCTGAAACATA) and a 
region immediately 3’ of the targeting vector (MYL2_screen_R1: GCATCTCTGTATGTCCCTGTG) 
(Fig. 3a,b). After identification of correctly targeted clones, five hESC clones were maintained 
as single cell cultures, enzymatically passaged, and transfected with a Cre recombinase 
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construct using lipofectamin (Invitrogen) for removal of the neomycin cassette. 24 Hours 
after transfection, cells were cultured in the presence of puromycin (1ug/mL) for 36 hours. 
After puromycin selection, single cells were sorted based on SSEA-4 expression, screened 
for neomycin excision, and further cultured as single cells (Fig. 3a,c). 
By the use of a T2A cleavage peptide to report MYL2 gene activity, endogenous gene 
expression remains normal. Here, we replaced the MYL2 stopcodon with the T2A and 
mCherry sequences (in-frame), and a selection cassette, which is excised after targeting to 
prevent interference with transcriptional activity. Upon MYL2 activation, one RNA transcript 
is generated, followed by ribosomal translation, where T2A is cleaved through ribosomal 
skipping, resulting in the presence of two separate proteins MYL2 and mCherry (Fig. 3e).
Flow Cytometry
For analysis on MYL2-T2A-mCherry and NKX2-5-eGFP expression, cells were dissociated 
using 1x or 10x TrypLe Select (Life Technologies). After dissociation, cells were resuspended 
in FACS Wash buffer (PBS, 2% FCS (Gibco), 2mM EDTA) and filtered through a 40μm cell 
strainer (Falcon). Cells were analyzed using a Miltenyi VYB Flow Cytometer using a 488 nm 
and a 561 nm laser.
Single Cell Sorting:
For single cell sorting, hESCs were enzymatically passaged using 1x TrypLE Select (Life 
Technologies). After dissociation, cells were resuspended in FACS sorting buffer (PBS with 
0.5% BSA and 2.5mM EDTA) and filtered through a 40μm cell strainer (Falcon). Cells were 
sorted using a BD ARIA III flow cytometer into 96 wells flat bottom low attachment plates. 
Live cells were gated on the basis of side scatter, forward scatter and
propidium iodide exclusion. Flow cytometric gates were set using control cells labelled with 
the appropriate isotype control antibody.
Cardiac differentiation
MYL2-mCherry/w-NKX2-5-eGFP/w hESCs were cultured on mouse embryonic fibroblasts 
in 2.85 cm2 organ dishes (Falcon), in 1 mL hESC medium (DMEM F12, Non Essential 
Amino Acids, Knock Out Serum (Gibco by Life Technologies); bFGF (Miltenyi Biotec)) and 
were mechanically passaged. One or two days before differentiation, cells were passaged 
and seeded in a 12-well tissue culture dish coated with Matrigel (BD Biosciences; growth 
factor reduced, phenol red–free), in 1 mL of hESC medium per well. On the first day of 
differentiation, day 0, hESC medium was replaced by low insulin serum-free medium BPEL 
(BSA, polyvinyl alcohol, essential lipids, as previously described[9] containing the cytokines 
BMP4 (30 ng ml−1, R&D Systems) and Activin A (30 ngml−1, Miltenyi Biotec), and Chir99021 
(1.5uM, AxonMedchem). At day 3 of differentiation, the medium was refreshed with BPEL 
containing 5uM Xav939 (R&D). On day 7 of differentiation, the medium was replaced with 
BPEL without growth factors.
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To enhance MYL2 expression, cardiomyocytes were dissociated at day 21 of differentiation 
with 10x TrypLe (Gibco) for 10 minutes at room temperature, and plated as single cells 
in Cardiomyocyte Medium (CM) (Pluriomics BV). After 7 days, medium was changed to 
commercially available maturation medium (MM), containing T3 hormone (Pluricyte 
medium, Pluriomics BV).
RESULTS
Generation of the Dual Cardiac Reporter hESC Line MYL2-T2A-mCherry-NKX2-
5-eGFP
In order to isolate and characterize ventricular-specific cardiomyocytes, derived from hPSCs, 
we generated a MYL2 fluorescent reporter line in the previously generated NKX2-5-eGFP 
hESC line[9]. The MYL2 targeting construct was generated, linearized and electroporated into 
NKX2-5-eGFP hESC line  (Fig3a).  Homologous recombination resulted in the replacement 
of the MYL2 stopcodon with the T2A-mCherry sequences and a selection cassette (Fig3a). 
Correctly targeted clones were identified by PCR screening (Fig 3a, b, c). Five correctly 
targeted clones were obtained (18% targeting efficiency), transfected with Cre recombinase 
for excision of the neomycin-resistance cassette, and after selection of 36 hours, sorted 
as single cells. From these clones, one clone (8.1D1) that showed neomycin excision was 
selected for further experiments in this study (Fig 3c). A schematic overview of the newly 
generated dual reporter line is given in Figure 2a.
 
Ventricular Cardiomyocyte Derivation from hESCs
To study the presence of MYL2-mCherry expressing cells upon cardiac differentiation from 
hESCs, we analysed cardiac cells on mCherry and eGFP expression at different timepoints 
during differentiation (Fig. 4a). In order to increase expression of MYL2 in cardiomyocytes, 
cells were dissociated at day 21 of differentiation and further maintained in physiologically 
optimized CM medium (Pluriomics, BV). 7 Days after dissociation (day 28 since the start of 
differentiation), we analysed MYL2-T2A-mCherry expression by FACS. We observed that ~30% 
of cells expressed NKX2-5-eGFP levels at day 28 of differentiation. However, only about ~3% 
from the total differentiated cell population was expressing MYL2-T2A-mCherry, which was 
±16% from total NKX2-5-eGFP expressing cardiac cells (Fig. 4b). It has been previously shown 
that MYL2 expression is only strongly increased after approximately one month of cardiac 
differentiation[12]. Therefore, we extended cardiomyocyte differentiation in the presence 
of maturation-promoting media (MM). At day 56 of differentiation, cells were analysed by 
FACS (Fig. 4b). When we cultured dissociated CMs in CM medium, or additionally in MM 
medium, we detected a decreased percentage of NKX2-5-eGFP expressing cells (~7-17%), 
which is most likely due to the proliferative capacity of non-cardiomyocytes that are present 
in these differentiation cultures. Nonetheless, we found a clear increase in the percentage 
of MYL2-T2A-mCherry positive cells in the NKX2-5-eGFP positive populations (~27-39%), 
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indicating an increase in the proportion of ventricular cardiomyocytes in prolonged and 
optimized culture conditions (Fig 4b).  In agreement, we could confirm the presence of 
double NKX2-5-eGFP+MYL2-T2A-mCherry+ cardiomyocytes by fluorescent microscopy, 
showing endogenous mCherry expression in day 67 dissociated cardiomyocytes (Fig 4c). 
Interestingly, when we measured NKX2-5-eGFP+MYL2-T2A-mCherry+ levels in undissociated 
cultures at day 56 of differentiation, which were continuously cultured in BPEL medium, 
we could almost not detect any MYL2-T2A-mCherry expressing cells (~0.2%) (Fig. 4b). 
Thus, either by dissociating cardiomyocytes, and thereby inducing mechanical stress, or by 
culturing in medium containing maturation-inducing-components, or both, may result in 
MYL2 upregulation, allowing detection and isolation of MYL2-T2A-mCherry positive cells.
DISCUSSION
Here, we describe the generation of a MYL2-fluorescent reporter line for the identification 
of hESC-derived ventricular CMs, in order to allow isolation and to further study ventricular-
specific CMs. We developed a targeting strategy in which one allele of MYL2 was genetically 
modified into a bicistronic site, by replacing the stop codon of MYL2 for the coding 
sequences for a T2A viral peptide and fluorescent protein mCherry. When transcription 
of MYL2 is activated, one single messenger RNA molecule is transcribed. Upon ribosomal 
translation, T2A is cleaved, resulting in the presence of the two separate proteins MYL2 and 
mCherry. Small peptide T2A is described to be more reliable and efficient than the currently 
used internal ribosomal entry site (IRES) and leads to the expression of multiple cistrons at 
equimolar levels[13, 17-19]. Moreover, the use of a multi-cistronic fusion reporter construct, 
can be superior to a knockin replacement strategy in which one allele of the gene of interest 
is replaced by the fluorescent reporter construct, resulting in haplo-insufficiency and thus 
differential expression levels of the gene. 
Here, we show that upon cardiac differentiation, up to day 28, only low levels of MYL2 
expressing cardiomyocytes could be detected. This is in alignment with previous cardiac 
differentiation studies in mESCs, where also only 0.5 - 1.2 % of MYL2+ expressing cells could 
be identified between day 10 and day 30 of differentiation[11, 12]. 
This is in significant contrast with the presence of high numbers of ventricular CMs in current 
cardiomyocyte cultures, based on electrophysiology data[20], indicating the preference to 
search for an alternative ventricular marker for the efficient isolation of early ventricular 
CMs during differentiation. Only one earlier study in hESCs reports the presence of 67-
98% MYL2-eGFP positive cardiomyocytes, but this has not been repeated[21]. Here, they 
made use of a randomly integrated reporter construct, which expression could have been 
influenced by surrounding genomic regulatory elements.
Further, we show that either dissociation of cardiac monolayers into single cell cultures or 
culturing cardiomyocytes in thyroid hormone-based culture medium additionally enhances 
MYL2 levels. Thyroid hormone is described to be a critical regulator of cardiac growth and 
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development, both in fetal life and postnatally, and induces mature electrophysiological 
properties[12, 22-24]. In our study, it will be of further interest to isolate the double positive 
MYL2-T2A-mCherry-NKX2-5-eGFP cardiomyocytes, and study their electrophysiological and 
molecular properties, including genome wide analysis for the identification of ventricular-
specific cell surface markers and important molecular regulators. The identification of a 
ventricular-specific cell surface marker, would allow ventricular CM isolation from any PSC-
derived cardiac culture, without the need of genetic modifications. Here, we show that, 
although MYL2 could potentially be a proper marker for ventricular CM isolation, due to its 
low expression in early ventricular CMs, the identification of an additional early ventricular-
specific marker would be a preference for the isolation of (early) ventricular CMs. Moreover, 
as MYL2 expression levels increase upon further maturation of our cardiomyocytes, it could 
be a potential maturation marker. 
FIGURES
Figure 1. MYL2 BAC recombineering. 
A: An R6k cloning plasmid containing 
the T2A sequence, in-frame with 
the following mCherry sequence, 
and a eukaryote/bacterial selection 
cassette, was digested with PvuI and 
EcorV to obtain a linearized construct. 
B: A BAC, containing the MYL2 coding 
sequence, was modified through 
Red/ET quadruple recombineering 
(GeneBridges BV) T2A, mCherry, and 
the selection cassette replaced the 
TAG stopcodon sequence of MYL2, 
located in its last exon 7. C: PCR 
screening on BAC clones to identify 
for correctly modified BAC.













B. Quadruple Red/ET Recombineering
BAC MYL2 RP11-587H5 + RED/ET + L-arabinose
MYL2 Exon 7


















A. BAC Subcloning into Targeting Vector through Red/ET Recombineering











C. Integrity screening by digestion with BglI and XbaI




















Figure 2. BAC subcloning into targeting vector. A: Step 1: A minimal vector containing an ampicillin-resistance 
cassette, and a DTA sequence for negative selection, was digested into a linearized construct. A PCR construct was 
generated, using oligos with 50 bp long arms (purple) that were homologous to regions in the modified MYL2 BAC, 
8.8kb upstream of the modified region (Oligo_F), and 2.3kb downstream (Oligo_R). Step 2: The MYL2 modified 
region in the BAC was subcloned into the PCR construct through the homologous regions between BAC and PCR 
construct ends (purple). B: A PCR was performed to screen for correctly recombineered subclones. C: Integrity of 
a selection of subclones was checked by digestion with either BgII or XbaI. Clone 3.9 was used for further MYL2 
genomic targeting in hESCs.
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A. MYL2 Targeting in hESCs Figure 3.
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E. T2A cleavage results in two protein products from one single mRNA transcript






Figure 3. MYL2 targeting in NKX2-5eGFP/w hESCs. A: The MYL2 targeting construct was designed to replace the 
MYL2 stopcodon, located in exon 7. Prior to targeting, the construct was linearized through PvuI digestion, and 
electroporated into NKX2-5eGFP/w hESCs[9]. Targeted cells were selected through their resistance to G418, which 
was added to the culture medium after electroporation (Oligos used: MYL2_screen_F1 + MYL2_screen_R1). Cre-
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mediated excision of the selection cassette (through the presence of two distal loxP sites) resulted in the final 
MYL2-T2A-mCherry reporter line. B: PCR screening of selected clones. Positive control was the modified MYL2 
BAC, showing a 2461 bp band. Negative control was the unmodified NKX2-5eGFP/w hESCs line. C: PCR screening on 
neomycin cassette excision, which would result in a 516 bp band, and the absence of the 2461 bp band. D: Overview 
of the finally generated dual cardiac reporter line. E: Schematic drawing of the ribosomal translation of one mRNA 
transcript containing both MYL2 CDS and mCherry CDS. Cleavage of the T2A sequence during ribosomal translation 
results in two separate proteins.
Figure 4. Directing hESC differentiation towards ventricular cardiomyocytes. A: Overview of cardiac monolayer 
differentiation protocol. hESCs were plated on matrigel, one day prior to induction with BPEL containing BMP4, 
Activin-A, and GSK3-inhibitor Chir99021. After three days, growth factors were replaced with BPEL containing 
Wnt signalling inhibitor Xav939. This was replaced with plain BPEL for further continuous culture. At day 21 of 
differentiation, cells were dissociated and further cultured.
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MYL2 Neomycin Excision Screening
MYL2_screen_F1 CCCCGTAATGCAGAAGAAGA
MYL2_screen_R1 GCAAAGAAGATGGAGGTGGA
Table 1. Oligo sequences
Table 2. Quantitative PCR primers for human genes
Table 2. Quantitative PCR primers for human genes
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ABSTRACT
Production of cardiomyocytes from human pluripotent stem cells (PSCs) provides not only 
promising opportunities for both in vitro as well as in vivo translational applications, but also 
may lead to a better understanding of signalling pathways and biological processes during 
the early phases of cardiac differentiation and development. For translational applications 
in drug development, disease modelling and cell-based therapy, it is important to obtain 
a large amount of highly purified cardiomyocytes from PSCs. Alternatively, controlled and 
defined expansion of cardiac progenitor cells offers additional advantages. Here, we studied 
the proliferative capacity of pre-cardiac MESP1 progenitors through the combinatorial use 
of fluorescent proliferation reporter eGFP-Anillin and the previously generated MESP1-
mCherry cardiac reporter line. Scaffolding protein anillin is localized at distinct locations 
during the cell cycle, and fusion to eGFP enables distinction from cytokinesis with other 
cell cycle stages. It is currently unknown what the proliferative capacity is of MESP-positive 
pre-cardiac progenitors and how they respond to changes in environmental conditions. 
Therefore, we studied the proliferative capacity by analysis of subcellular localization of 
eGFP-Anillin in MESP1-mCherry progenitors under controlled culture conditions and using 
time-lapse microscopy. In addition, we screened several small molecules and growth factors 
on the ability to enhance MESP1 progenitor proliferation. 
INTRODUCTION
Heart disease is the most common cause of death in most Western societies, unlocking 
the potential of regenerative stem cell- and drug therapy[1]. For successful development 
of cell-based therapies, large numbers of human cardiac cells will be necessary. Human 
pluripotent stem cells (hPSCs) can be efficiently differentiated to cardiac cells[2, 3], however, 
the inverse relationship between the degree of differentiation and the proliferation rate 
of cardiomyocytes limits the production of cardiac cells and advocates striving for an 
expandable cardiac progenitor population. When hPSCs, including induced PSCs (hiPSCs) 
and embryonic SCs (hESCs), differentiate towards the cardiac cells they first transit from a 
mesendodermal stage, expressing genes such as Brachyury T, MIXL1, and Eomesodermin, to 
a pre-cardiac mesodermal stage, marked by the expression of transcription factor MESP1[4]. 
These cells then further segregate to distinct multi-potent cardiac progenitor cells (CPCs), 
and start to express cardiac transcription factor NKX2-5[5]. These CPCs are capable of further 
differentiation into several cardiac cell subtypes, including atrial, ventricular, pacemaker-
like cardiomyocytes, but also endothelial, and smooth muscle cells. In order to obtain 
high yields of cardiac subtype populations and to control maintenance and expansion of 
CPCs, it is of interest to understand the underlying mechanisms[6-9]. Several studies have 
demonstrated a crucial role for FGF-, IGF-, Notch1, and Wnt/B-catenin signaling pathways 
for self-renewal/expansion of CPCs. Nevertheless, the self-renewing capacity of specific 
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CPCs and their biological responses may vary between different CPCs and/or developmental 
stages. As we know from in vivo studies in mice, almost all cells of the heart are derived 
from MESP1 expressing progenitors[10]. Therefore, it is for both regenerative and drug 
development studies of interest to understand whether we are able to maintain and expand 
human MESP1 progenitors in culture. 
In order to study the proliferative capacity of MESP1 progenitors, we made use of a in vivo 
reporter system using the scaffolding protein anillin fused to enhanced green fluorescent 
protein (eGFP), to provide high spatiotemporal resolution of the mitotic phase[11]. Anillin 
is localized at specific subcellular locations in the cell during cytokinesis and midbody 
formation, enabling a clear visual separation of the different phases of the cell cycle, including 
cell division (Fig 1). Anillin is localized in the cell nucleus during G1-phase, S-phase, and 
G2-phase, and moves to the cytoplasm when entering the M-phase. Prior to cell division, 
anillin locates in the cytoskeleton ring and becomes restricted to the midbody region upon 
cytokinesis. When cells leave an active cell cycle, anillin gets degraded.
Here, we generated a dual fluorescent reporter line by introducing eGFP-Anillin in the 
MESP1w/mCherry hESC line, allowing live imaging of the different phases of cell division of 
cardiac progenitors and their derivatives[11]. Using time-lapse microscopy we were able to 
visualize the dynamics of MESP1-expressing progenitors. We measured a low proliferative 
capacity of these progenitors during in vitro cardiac differentiation. Further, we optimized 
this model for screening cytokines/small molecules for their ability to enhance MESP1-
progenitor proliferation. We further discuss future development of automated analysis 
of cell proliferation, using the eGFP-Anillin reporter, and we indicate its potential in the 
development of cardiomyocyte-proliferation assays, which will be of interest for the fields 
of regenerative medicine and assay development for drug discovery and toxicity[12-15].
METHODS
Lentiviral transductions in hESCs
To generate the hESC proliferation reporter line, 100k MESP1w/mCherry hESCs[4] were transfected 
with a lentiviral construct containing a CAG–eGFP–anillin expression cassette (0.5uL / 20k 
cells), and plated on a Matrigel (BD Biosciences; growth factor reduced, phenol red–free)-
coated 24 wells plate (Falcon)[11]. Three days after transduction, hESCs were enzymatically 
passaged using 1x TrypLE Select (Life Technologies). After dissociation, cells were stained 
with anti-SSEA-4 in order to select for pluripotent hESCs, followed by resuspension in FACS 
sorting buffer (PBS with 0.5% BSA and 2.5mM EDTA) and filtration through a 40-μm cell 
strainer (Falcon). Cells were sorted using a BD ARIA III flow cytometer into 96 wells flat 
bottom low attachment plates. Live cells were gated on the basis of side scatter, forward 
scatter, anti-SSEA-4-PE, and eGFP-Anillin fluorescency. Flow cytometric gates were set using 
control cells labelled with the appropriate isotype control antibody.
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Clone Selection and Culture
Due to the integration properties of lentiviral particles, five undifferentiated transfected 
clones were analysed for their eGFP-Anillin expression. Clone A4 and C6 were selected, 
based on their eGFP expression intensity, and further cultured as single cells on mouse 
embryonic fibroblasts on 9.96 cm2 6 well format (Falcon), in 3 mL hESC medium (DMEM F12, 
Non Essential Amino Acids, Knock Out Serum (Gibco by Life Technologies); bFGF (Miltenyi 
Biotec)) and were enzymatically passaged. hESCs from clones A4 and C6 were analysed 
for eGFP-Anillin expression. Clone A4 showed a more consistent and robust eGFP-Anillin 
expression and further experiments were performed with this clone. 
Cardiac Differentiation
One day before differentiation, 10k hESCs were passaged onto a 96-well tissue culture dish 
(96 Well Optical CVG, ThermoScientific), coated with Matrigel (BD Biosciences) in 100uL 
of hESC medium per well. On the first day of differentiation, day 0, hESC medium was 
replaced by low insulin serum-free medium BPEL (BSA, polyvinyl alcohol, essential lipids, as 
previously described)[17, 24], containing the cytokines BMP4 (20 ng ml−1, R&D Systems) and 
Activin A (20 ngml−1, Miltenyi Biotec), and Chir99021 (1.5uM, AxonMedchem). At day 3 of 
differentiation, the medium was refreshed with BPEL containing 5uM Xav939 (R&D). To study 
their proliferation, we sorted MESP1-mCherry progenitors at day 2 of differentiation. Cells 
were plated back as monolayers in 96 wells plates (96 Well Optical CVG, ThermoScientific), 
in a density of 50k cells per well, in BPEL with 5uM Xav939 from day 2 until day 7. 
Growth Factor Screening
For the in vitro growth factor screening, cells were differentiated as described before, on 96 
well tissue culture dishes (Falcon). A complete list of the compounds used for screening, and 
the concentrations used, can be found in Supplemental Table 1. Growth factors were added 
to the cell culture at day 2 or day 3 of differentiation. The proliferative effect was assayed 
on day 4 of differentiation using a MACS Quant VYB flow cytometer (Miltenyi Biotec).  The 
percentage of MESP1-mCherry+ cells was assessed for each treatment, and compared to 
control cells without treatment. Each experiment was performed in quadruplicate, and one 
or two independent experiments were performed for each condition.
Flow Cytometry
During cardiac differentiation, eGFP-Anillin and MESP1-mCherry expression were analysed 
every 24 hours. For this, cells were enzymatically dissociated using 1x TrypLE Select (Life 
Technologies).  After dissociation, cells were resuspended in FACS sorting buffer (PBS with 
0.5% BSA and 2.5mM EDTA) and analysed using a MACS Quant VYB flow cytometer (Miltenyi 
Biotec) and FlowJo Software with a 488 nm and a 561 nm laser. Co-expression of eGFP-
Anillin with proliferation marker Ki-67 was analysed by flow cytometry in undifferentiated 
hESCs, and at differentiation day 3 and day 5. For this, dissociated cells were treated with 
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FIX & PERM® Cell Fixation and Permeabilization Kit (Life Technologies) and stained with anti-
Ki-67-PE (Biolegend). 
Immunohistochemistry
eGFP-Anillin transduced MESP1-mCherry-cells were analyzed by immunohistochemistry 
(IHC) when undifferentiated, and at day 3, and 5 of differentiation. For this, cells were fixed 
in 2% PFA and stained for Ki-67 (MIB-1 M7240, DAKO  (1:400)), PHH3 (Ser 10, Millipore 06-
570 (1:100)), and aurora B kinase (SIGMA A5102 (1:200)). Primary antibodies were diluted in 
0.2% TritonX in PBS, supplemented with 5% Donkey serum and incubated with the cells for 
1.5 hour at room temperature (RT). Then, cells were washed 3x 5 minutes with PBS. The 2nd 
antibodies (mouse and rabbit Cy5 Jackson Immuno Research) were directly diluted (1:400) 
in Hoechst 33342 solution (1 µg/ml) in PBS and incubated for 1 hour at RT in dark. Then, 
cells were washed 3x with PBS and embedded in FLUKA mounting medium (Sigma10981) 
on glass-cover slips.
Statistical Methods
A two-tailed Student’s T test was performed using Graphpad Prism software (Graphpad 
Software, La Jolla, CA, USA). Results were considered significant at P values <0.05.
Time Lapse Microscopy
In order to study cellular dynamics of MESP1 progenitors, eGFP-Anillin-MESP1w/mCherry hESCs 
were differentiated as previously described, and sorted at day 3 of differentiation. 50k cells 
were replated as monolayer onto a 96-well glass bottom plate (Thermo Scientific), coated 
with Matrigel. The cells were incubated on a stage-heated fluorescence image acquisition 
station (Leica AF6000). The plate was covered with a CO2 environment cover glass, supplied 
with 8% CO2/O2 inflow to maintain pH balance. Time-lapse imaging was started 5 hours 
after plating. Imaging settings can be found in supplemental table 2 (Supp. Table 2). Cell 
tracking was performed manually using the Fiji ImageJ plugin MTrackJ (E. Meijering, 
Methods in Enzymology 2012).
Automated Quantification of Proliferation
The pipeline of automated quantification of eGFP-Anillin localizations at single cell level 
contains two major parts: image analysis and data analysis. Image analysis procedure 
basically converts raw microscope images into quantified measurements representing 
characteristic biological phenomena. Three steps are elaborated to achieve this purpose: (1) 
image enhancement, (2) image segmentation and  (3) phenotype measurement. Here, image 
enhancement aims at providing a better input for image segmentation by a list of   techniques 
including   background  correction, noise suppression and contrast enhancement. Image 
segmentation partitions an image into multiple regions (single cell regions) with the goal to 
simplify the representation of an image into comprehensive components.  For fluorescence 
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microscopy cell imaging, we utilized seeded propagation cell segmentation method[16]. 
The method segments the single nuclei using watershed segmentation based on Euclidian 
distance map  (EDM) from the DAPI channel.  The segmented single nuclei mask is treated as 
seed and propagate to find the Anillin  positive  cell  area  in  the  GFP  channel.  Phenotype 
measurements including shape and texture features are calculated on both individual nuclei 
and Anillin positive cell area masks. These phenotype measurements are further used as 
feature dataset in the data analysis part. In order to quantify the number of dividing cells 
versus non-dividing cells, a classifier was trained to distinguish the dividing cells  from the 
image.  Supervised classification strategy, which is based on ground truth analysis (dividing 
= 1 versus non-dividing = 0), was used in this study. First, a feature dataset was normalized 
in order to equalize the ranges of the features. 
Second, the feature selection procedure was applied to select a subset of relevant features. 
Four representative feature selection methods were evaluated: the best individual-N 
features, the branch and bound procedure, greedy forward selection and greedy backward 
elimination[17]. Third, four classifiers covering both linear and non-linear categories; i.e. 
the linear classifier (LDC), the quadratic classifier (QDC), k-nearest neighbour classifier 
(KNNC) and support vector machine (SVC) were included for the classification evaluation. 
The final performance of the automated analysis was evaluated using the precision, recall 
and F-score[16, 18].
RESULTS
eGFP–Anillin expression marks proliferating hESCs.
In order to study the proliferative capacity of early pre-cardiac MESP1-mCherry progenitors, 
we transduced previously generated MESP1w/mCherry hESCs[4] with lentiviral particles 
containing a CAG-eGFP-Anillin fusion cassette[11], resulting in random genomic integration 
of the CAG-eGFP-Anillin reporter in actively transcribed genes (Fig. 2). Five targeted clones 
were obtained (showing the brightest eGFP expression in undifferentiated hESCs), from 
which clone A4 showed the most consistent expression (Fig 3a).  In clone A4, eGFP-Anillin 
expression was analyzed for its co-expression with M-phase marker PHH3, proliferation 
marker Ki-67 (S, G1, G2, M phase), and aurora B (midbody expression) (Fig 3b,c). Indeed, 
we found correlating expression patterns of eGFP-Anillin with PHH3, aurora B co-expression 
with eGFP-Anillin in the midbody of dividing cells (telophase), and all cells positive for 
both eGFP-Anillin and Ki-67, indicating how different eGFP-Anillin localizations can distinct 
specific cell cycle stages from eachother.
eGFP-Anillin expression intensity decreases upon cardiac differentiation
To further characterize the MESP1w/mCherry eGFP-Anillin reporter, we differentiated cells (clone 
A4) as described before. We analyzed eGFP and mCherry expression every 24 hours from day 
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0 until day 5 of differentiation (Fig. 4). We found MESP1-mCherry levels peaking around day 
2 and day 3 (12-14%). Furthermore, we observed all cells being positive for eGFP when in 
undifferentiated state, up to day 2 of differentiation. However, we found a rapid decrease in 
eGFP-Anillin intensity upon day 3 of differentiation, where we could only detect 75% of cells 
still positive for eGFP-Anillin. These levels decreased to only 37% at day 5 of differentiation, 
indicating cells entering the G0-phase upon differentiation. An alternative explanation for 
decreased expression of GFP can also attributed to epigenetic silencing of the transgene 
(for example by DNA-methylation and chromatin remodelling). To further investigate this, 
we performed analysis on Ki-67 co-expression at day 3 and day 5 of differentiation and 
compared this to eGFP-Anillin (Fig. 5a,b). Despite decreasing levels of eGFP-Anillin, we could 
still detect maintained expression of Ki-67 in a large population of cells (±80% at day3, and 
±77% at day 5), indicating silencing of the construct upon differentiation at day 5. Moreover, 
at day 5 of differentiation, we could identify cells positively stained for Ki-67, and negative 
for Anillin-eGFP (Fig. 5b). The same image shows high variability of eGFP levels between 
cells, at both day 3 and 5 of differentiation. Based on these results we concluded that from 
day 5 onwards silencing of the transgene would interfere with the experimental outcome. 
Therefore, time-lapse imaging and analysis was performed up to day 4 of cardiomyocyte 
differentiation.
Proliferation of Early Cardiac Progenitors
In order to get insight in the proliferative capacity of early cardiac progenitors in vitro, we 
manually analysed cell division in the first four days of differentiation (Fig. 6a). Based the 
number of cells that was expressing eGFP-Anillin in the cytoplasm, cytoplasmic ring, and 
midbody region, the percentage of proliferating hESCs was measured to be approximately 
4%, which was similar to the findings observed by Hesse et al.[11]. This proliferative capacity 
was largely decreased upon the first days of differentiation, and slightly increased after the 
formation of mesoderm (day 3,4). MESP1 progenitor division could be nicely visualized 
through the co-expression of mCherry with eGFP-Anillin localizations in the cytoplasm, 
cytoskeleton, and midbody. Moreover, dividing cells became rounded and were less 
spread out. They showed to have a proliferative capacity of about 2-3%, with no significant 
difference between early (day 2) and late (day 4) progenitors (Fig 6a,b). In order to get 
more insight in the proliferative capacity of MESP1-mCherry progenitors at single cell level, 
we performed time lapse imaging during cardiac monolayer differentiations, and of sorted 
MESP1-mCherry progenitors.
Induction of MESP1-mCherry proliferation
To identify signalling pathways involved in early cardiac progenitor proliferation, MESP1-
mCherry–eGFP-Anillin hESCs were differentiated as described before and treated with 
growth factors/small molecules on day 2 or day 3 of differentiation. As a preliminary screen 
we measured the yield of MESP1-mCherry+ cells by automated flow cytometry, at day 4 of 
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differentiation (Fig 7). The control treatment did not  contain any GFs (plain BPEL). For all 
growth factors we have added in our screening, we could not find a significant upregulation 
of mCherry+ cells, compared to control, indicating no aberrant role for these pathways in 
MESP1-progenitor proliferation under the tested conditions, which is in contrast to their 
role in proliferation of other early cardiac progenitors[6, 9, 19]. Therefore, we postulate 
that a complex combination and concentration of growth factors and possibly specific 
ECM components, which are highly expressed by MESP1-mCherry progenitors[4], may be 
required.
Real time tracking of MESP1-mCherry progenitors
In order to study the proliferative capacity of CPCs at single cell level, we developed a live 
single cell tracking system during differentiating, to follow division and migration of single 
cell MESP-mCherry expressing progenitors. For this, optimization of culture conditions and 
technical settings were required, which included light intensity of the fluorescent lamp, 
exposure time, autofocusing, heating temperature, objective magnification and objective 
immersion medium (Supp. Table 2). To decrease the effects of photo-bleaching, we used a 
low lamp intensity (4.3) and 2x2 binning (Fig. 8a). Another setting that required optimization 
included Z-position stability, or focal drift. Without autofocus, focal drift would occur, which 
makes long time-lapse experiment impossible. Since eGFP-Anillin signal diminishes easily, 
autofocus was set up in the bright field-DIC channel. This resulted in a consistent error in 
the focal plane of 5-6 µM, which was compensated by making images in multiple Z-planes. 
In order to generate an assay to study the proliferative capacity of MESP1 progenitors live, 
we sorted MESP1-mcherry progenitors at day 3 of differentiation and replated them as 
monolayers at 96 wells plates with glass bottom. We started live-image acquisition after 
cell attachment (about 5 hours later). We used a maximum interval time of 10 minutes to 
be able to track single cells (Fig. 8b). Live cell division could be followed through the distinct 
localizations of the eGFP-Anillin reporter protein (Fig. 8c). We identified how the nucleus 
changes from oval to a more U-shaped form prior to cell division, and how cell shape 
became more rounded when eGFP-Anillin moved to the cytoplasm during the prophase. 
These changes prior to cell division are described as mitotic cell rounding. This was followed 
by the formation of a cytoplasmic ring, and a midbody upon cytokinesis. We estimated that 
the M-phase of early cardiac progenitors would take about 30 minutes, which is consistent 
with previous findings from Hesse et al. who demonstrated a similar time for the M-phase of 
hPSCs[11]. In a similar sort-and-replate experiment, we determined the migrating behaviour 
of MESP1-mCherry expressing progenitors, using a time interval of 15 minutes (Fig. 8d). 
We were able to follow MESP1-mCherry progenitors for up to 15 hours after replating and 
attachment (20 hours after sorting). Some tracked cells were lost, as they migrated out of 
focus. Further, we showed the ability to visualize MESP1-mCherry progenitor proliferation, 
and identified the distinct eGFP-anillin localizations marking the different stages of the 
M-phase and final cytokinesis (Fig. 8e). 
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To understand the dynamics of MESP1-mCherry progenitor proliferation and their further 
differentiation towards cardiomyocytes, it will be of interest to follow their behaviour and 
phenotype changes in time, through time lapse imaging at single cell level. Here, we show 
how sorted and replated MESP1-mCherry progenitors, were further differentiating over 
time, followed for up to 48 hours (Fig. 9). Bright MESP1 expression at day 3 was diminished 
upon further differentiation, and cell shape and behaviour changes could be observed. 
eGFP-anillin signal faded alongside MESP1-mCherry signal and was completely gone at day 
5 of differentiation, possibly due to silencing upon differentiation (Fig. 9).
Automated Quantification of Proliferation
In order to study whether small molecules/growth factors may enhance proliferation of 
cardiac progenitors and/or cardiomyocytes using the eGFP-Anillin cassette, we developed 
a pipeline for automated quantification of eGFP-Anillin localizations at single cell level. 
For the image analysis part, we used a seeded propagation cell segmentation method to 
identify the single cells from the image.  The precision of seeds  (single nucleus) picking is 
crucial for a correct propagation procedure.  The EDM watershed segmentation method 
works best for smooth convex objects that don’t overlap too much.  However, in our case, 
when cells are dividing, the shape of nuclei becomes irregular and dispersed.   Furthermore, 
highly overlapping   nuclei   regions   were observed in our image dataset. Therefore, we 
introduced a merging criterion which is based on the homogeneity of region intensity for 
the over segmented regions of nuclei under division. Since the number of highly overlapped 
nucleus regions is limited, these regions were excluded for the phenotype measurement. 
An example of the final segmentation result is shown in Figure 10. For the data analysis, 
1500 individual cells (291 dividing cells and 1209 non-dividing cells) and 44 features were 
firstly collected as training dataset.  During the classifier training, each combination of a 
feature selection method and a classifier algorithm was repeated for 100 times and the 
performance for each combination was evaluated using weighted classification error, which 
assigns different importance to different classes (www.mathworks.com)[20].
Based on this, we found that the combination of branch and bound feature selection (B&B) 
with k-nearest neighbour classifier (KNNC) has the lowest minimal value of mean weighted 
error and relatively small standard deviation of mean, as can be concluded from Table 1. The 
minimal value was reached when the feature selection method selects 4 features. These 4 
features include smoothness of cell intensity, area of eGFP-Anillin positive cell area region, 
entropy of eGFP-Anillin signal in nuclei region, standard deviation of nuclei intensity. 
Next, to identify the degree of errors in the automated analysis, we compared the results 
from manually quantifications of 22 images with their automated quantified counterpart 
as shown in Figure 11a-d. To demonstrate quantitatively the accuracy of the automated 
classification, we have used the Precision, Recall, and F-score metrics[21] (Fig. 11e). We 
reached a F-score equalling ±0.85, which meets or exceeds the performance of previous cell 
segmentation and/or pattern recognition studies[16, 22].
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DISCUSSION
The availability of large numbers of cardiac committed progenitor populations is of high 
interest for translational purposes, such as cell therapy or drug discovery. An additional 
advantage is that it may provide us with a model for studying cardiac progenitor cells in 
relation to heart development. Although numerous studies have been conducted to unravel 
molecular and morphological aspects of heart development, in-depth knowledge regarding 
formation, proliferation, (subtype) differentiation and self-renewal of cardiac progenitors is 
limited. From in vivo mouse embryo studies it is evident that during gastrulation, cells ingress 
through the primitive streak and start to express mesendodermal transcription factors, 
including Brachyury T and Eomesodermin. From these cells, a posterior subpopulation 
develops that expresses key cardiac transcription factor MESP1. Lineage tracing studies in 
mouse have shown that the vast majority of the cells of the heart are derived from this 
MESP1-expressing population. In order to study the characteristics of these early pre-
cardiac progenitor population in human, we previously developed a dual cardiac reporter 
MESP1mCherry/wNKX-2-5eGFP/w hESC line[4]. This allowed us to isolate MESP1-mCherry 
expressing progenitors and to follow their further differentiation towards NKX2-5-eGFP 
expressing cardiac cells. In our current study, we were interested in the proliferative capacity 
of these MESP1 progenitors, in order to understand their potential as an unlimited source 
of cardiac progenitors. Several methods for measuring cell proliferation exist, on fixed and 
living material. M-phase marker PHH3 and active cell cycle marker Ki-67 are commonly used 
for measuring proliferation at fixed time-points.  However, both markers require fixation 
and staining of samples, and are not appropriate for quantifying live cell division. Moreover, 
they are not specifically marking cytokinesis, and therefore do not distinguish between 
endoreduplication and cell division[11]. To overcome these limitations we made use of 
an in vitro reporter system that was recently developed[11], using the scaffolding protein 
anillin fused to eGFP. Here, we transduced MESP1mCherry/wNKX-2-5eGFP/w hESCs with lentiviral 
particles containing the CAG-eGFP-Anillin cassette, and thereby developed an in vitro 
system to study the proliferation of early cardiac progenitors, up to day 5 of differentiation. 
Since activation of NKX2-5-eGFP occurs at later stages during differentiation (~day 7 and 
later), GFP expression at early stages could be attributed to Anillin-eGFP alone. In hESCs, we 
showed the different stages of the M-phase by distinct localizations of eGFP-Anillin, clearly 
discriminating cytokinesis from other cell cycle stages. We showed that the vast majority 
of eGFP-Anillin+ hESC co-localized with Ki-67 immunostaining, whereas dividing cells co-
localized with PHH3. Upon differentiation of hESCs towards the cardiac lineage, we found 
decreasing eGFP levels, leading to absence of detectable GFP levels at day 6. One possible 
explanation for this decrease in GFP expression could be due to an increasing number of 
cells entering a quiescent cell cycle stage upon differentiation[23], although this is not 
very likely, since we only observed a slight decrease in Ki-67 levels during the first days of 
differentiation. A more plausible explanation is silencing of the gene in which the CAG-eGFP-
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Anillin cassette had integrated[24]. As the Anillin-eGFP signal could still be detected up to 
day 5 of differentiation, the generated reporter line allowed us to study early progenitor 
differentiation. By measuring at fixed timepoints, we found, that approximately 4% of 
undifferentiated hESCs were dividing. MESP1 progenitors show a similar percentage, with no 
difference between early (day 2) and late (day 4) MESP1 progenitors. To fully understand the 
proliferative capacity of MESP1 progenitors at single cell level, and to get insights into the 
dynamics of these progenitors prior their further differentiation towards cardiomyocytes, we 
decided to set up a time-lapse live imaging system. Many hurdles needed to be overcome, 
including photo bleaching of the fluorescent protein upon exposure to high light intensities, 
the ability to track migrating single cells (time interval of image acquisition, autofocus, and 
Z-stacks), and the amount of data generated from a long-term time-lapse study (3-5 days, 
10 minute interval, 3 Z-stacks). Following optimization by adjusting these parameters we 
showed real-time tracking of MESP1-mCherry progenitors during proliferation and further 
differentiation. In future studies we will follow differentiation from day 0 up to day 5, 
where we will study the derivation of MESP1-mCherry expressing progenitors, and quantify 
their proliferative behaviour prior to their further differentiation towards cardiomyocytes. 
In addition, time lapse experiments at later stages of differentiation, in the previously 
developed MESP1mCherry/wNKX-2-5eGFP/w hESC line, will be of interest to perform for a more 
complete understanding of the dynamics of MESP1 expressing progenitors and their further 
differentiation towards specific cardiac lineages. Moreover, time-lapse experiments on cell 
proliferation may also enlighten knowledge on circadian rythms of cardiac progenitors, for 
which evidence grows it is tightly regulating cellular function, such as proliferation and/or 
maturation[25].
For potential future high-throughput screening experiments on proliferation of cardiac 
progenitors or cardiomyocytes, we are currently working on the development of an 
automated quantification method using classifiers that are based on the distinct localizations 
of eGFP-Anillin. Using such an automated system, a large number of combinations of 
growth factors and small molecules can be screened for their enhancing effect on MESP1-
progenitor proliferation. Our automated image analysis system is efficient to identify single 
cells from the image.  However, segmentation of the nucleus with diverse morphology or 
in a highly overlapped region needs further improvement. Nevertheless, after selecting 
the most optimal automated classification method for our set-up, we managed to reach a 
high F-score equalling ±0.85, which exceeds the performance of previous cell segmentation 
studies. In further experiments, we will test our newly developed quantification method in 
the absence and presence of proliferation inhibitors and stimulators, to understand which 
improvements are desired for implementation of this method in large-scale screening 
experiments. Automated image analysis is a critical step for the development of phenotypic 
screens that allow high-speed, reproducible and quantitative analysis.
In order to identify crucial signalling pathways that play a role in cardiac progenitor 
proliferation, which would subsequently be of interest as target pathways in large-scale 
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screening experiments, pilot experiment were performed that included initial screenings on 
our standard monolayer differentiations. At day 2 or day 3 of differentiation, we removed 
the standard cardiac differentiation growth factors, and replaced them for potential growth-
inductive cytokines. However, flow cytometry measurements after 24 hours of induction 
did not result in significant increased levels of MESP1-mCherry expressing progenitors. In 
contrast, previous findings showed that NKX2-5-progenitor proliferation could be enhanced 
by IGF-1 or in combination with SAG (a smoothened agonist), and SB431542 (TGF-β/Activin/
Nodal inhibitor)[9, 19]. The lack of response in our assay may indicate that a combination 
of different factors is required for MESP1 progenitors to proliferate, and possibly in the 
presence of the right microenvironment, such as the specific composition of ECM proteins 
or other cell types[26].
Proliferation of cardiomyocytes in the human heart has been described, although the rate is 
very limited[27]. It is important to understand how, if any, factors may induce cardiomyocyte 
proliferation, which may have an impact on treatment of heart failure by regeneration 
of the damaged heart after infarction[12-15, 28, 29]. Further optimization and technical 
advancement of screening assays, such as the combination of an Anillin reporter with a 
cardiac reporter appropriate for live imaging and automated quantification may prove 
to be very useful for identifying molecules and their underlying mechanisms for specific 
differentiation and differentiation of cardiac cell- (sub)types, which may lead to new 


























Figure 1. A: A schematic representation of Anillin. Localization of Anillin is visualized by fusion to eGFP and can be 
observed  in the nucleus during G1-phase and migrates into the cytoplasm during prophase. During metaphase it 
appears in  the cytoplasmic ring. Eventually, a midbody is formed during ana/telephase. Images are acquired using 
a 40x oil imm. Objective. Figure 1a. is adapted from Hesse et al. Nature Communications 2011. B: eGFP-Anillin lo-
calization in proliferating hESCs. 
Figure 2. A: Overview scheme of how the eGFP-Anillin-MESP1mcherry/w reporter line was generated. hESCs were 
transfected with lentiviral particles containing the CAG-eGFP-Anillin cassette and were incubated for 24 hours. 48 
hours after incubation, cells were sorted on eGFP expression and positive clones were selected for cardiac mono-
layer differentiations and compound screenings. Proliferation of MESP1-mCherry progenitors was assessed through 
live imaging of the eGFP-Anillin localizations. B: Schematic representation of the dual cardiac reporter line.





















DAPI  eGFP-Anillin eGFP-Anillin
Figure 3. A: Picture of the dual reporter eGFP-Anillin-MESP1mcherry/w hESC line expressing eGFP–anillin under 
control of the CAG promoter. eGFP–Anillin (green) localization in the cytoplasm (open arrowhead), and midbody (ar-
row). B: Flow cytometric analysis of eGFP-Anilin hESCs stained for Ki-67 (anti-Ki-67-PE) and control isotype (mIGG1-
PE). C,D,E: Stainings for the proliferation markers PHH3 (red), Aurora B (grey), and Ki-67 (grey) reveals co-expression 


























Figure 4. A: Cardiac monolayer differentiation protocol. MESP1-mCherry  expression starts around day 2, and peaks 
between day 3 and day 4. Proliferation can be studied based on eGFP-Anillin expression. B: Flow cytometric anal-
ysis during cardiac differentiation, every 24 hours, from day 0 until day 5. eGFP-Anillin levels slowly decrease upon 
further differentiation.






























Figure 5. Flow cytometric analysis of Ki-67 co-expression with eGFP-Anillin- MESP1-mCherry expressing progenitors, 
at day 3 and day 5 of differentiation. Ki-67 levels remain high, despite a slight decrease, whereas eGFP-Anillin levels 
have decreased significantly, when compared to day 0 levels (Figure 4). B:  Co-stainings for Ki-67 at day 3 and day 5 
of differentiation revealed a large percentage of Ki-67 positive cells (active cell cycle) that show diminished eGFP-
Anillin levels, indicating silencing of the construct.
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Figure 6. A: Percentage of all cells dividing (eGFP-Anillin M-phase localizations) upon early cardiac differentiation. 
B: Picture of a cardiac monolayer differentiation at day 3 visualizing proliferating (green) MESP1-mCherry 
progenitors (red). Nuclei are stained with DAPI (blue). C: Percentages of MESP1-mCherry progenitors dividing at 
day 2, day 3, and day 4 of differentiation. No significant differences between early and late progenitors were found. 
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Figure 7. A: Schematic overview of proliferation compound screenings upon a monolayer cardiac differentiation. 
Cells were differentiated as described before. At day 2 or day 3, BMP4, Activin A, and Chir were removed, and 
replaced with screening compounds for 48 or 24 hours, respectively. At day 4 of differentiation, the percentage of 
MESP1-mCherry progenitors in the total population was measured by flow cytometry. B,C: Percentages of MESP1-
mCherry progenitors measured by flow cytometry at day 4 of differentiation, after treatment with compounds for 

















SH1 Long R3 IGF-1 SH2 FGF
SU5402 BMP4
DMH-1 Long R3 IGF-1
CR Chir
SH3 BMP4 DM
Long R3 IGF-1 SB431542
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eGFP-Anillin
eGFP-Anillin
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T=40 min T=50 min T=60 min T=70 min
A
B: Cell Tracking on eGFP-Anillin signal
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D: Cell Tracking of MESP1-mCherry expressing progenitors
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Figure 8: A: Settings for live-imaging fluorescent microscopy were optimized to prevent bleaching. 60 Sequential 
images were acquired with 63x glycerine immersion objective at minimised interval. The intensity of the lamp, 
exciting the fluorophores, is of great importance to prevent bleaching. By closing the lamp and microscope light 
shutter, the intensity of the light was reduced which resulted in decreased bleaching. B: A time interval of 10 
minutes allows manual cell tracking of eGFP-Anillin expressing cells. C. Live visualization of dividing cell upon 
cardiac differentiation. A U-shaped nucleus is visible prior to cell division (arrow). Images are 2,5xzoom from original 
acquired image size. C: Manual tracking of MESP1-mCherry progenitors shows minimal migrative behaviour over 
a time span of 15 hours. Cell tracking stopped when cells were out of focus. Time interval of image acquisition: 15 
minutes. D: Live visualization of dividing MESP1-mCherry progenitor (arrow). A U-shaped nucleus is visible prior to 








Figure 9. A: Time-lapse imaging of MESP1-mCherry sorted and replated progenitors. Images were acquired using 
a glycerol immersion 63x objective. T is given in minutes. To be able to track the highly migrative cells, a 10 minute 
interval was set. B: Time-lapse imaging of MESP1-mCherry sorted and replated progenitors. The Anillin-eGFP 
signal gets silenced upon further differentiation. mCherry levels decrease, as MESP1 levels are downregulated 
upon further differentiation. Morphological changes can be observed: cells become elongated and obtain a 
mesenchymal phenotype. T is given in hours.
Figure 10. Automated Segmentation Result. 
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Figure	   11.	   Automated	   annotation	   versus	   manual	   annotation.	   A-­‐D.	   Green	   circles:	   positive	   and	  
selected.	  Yellow	  circles:	  false	  negative.	  Red	  circles:	  false	  positive.	  E.	  Calculation	  of	  F-­‐score.	  TP:	  true	  
positives.	  FP:	  false	  positives.	  FN:	  false	  negatives.	  P:	  Precision.	  R:	  Recall.	  
 
TP: TP + FP: TP + FN: 
Total: 399 490 444 
    
 
Precision: Recall: F-score: 
 
0,814285714 0,898648649 0,854389722	  
Figure 11. Automated Annotation versus Manual Annotation. To identify the degree of errors in the automated 
analysis, we compared the results from manually quantifications of 22 images with their automated quantified 
counterpart. A-D: Green circles: positive and selected. Yellow circles: false negative. Red circles: false positive. 










TP + FN 
Table	  1.	  Minimal	  value	  of	  mean	  weighted	  errors	  for	  each	  feature	  selection	  method.	  
Weighted	  classification	  error:	  the	  sum	  of	  k-­‐th	  class	  error	  divided	  by	  the	  k-­‐th	  class	  size	  multiplying	  the	  
weight	  k	  which	  is	  the	  prior	  probability	  of	  k-­‐th	  class.	  







ek	  is	  the	  number	  of	  misclassified	  training	  examples	  from	  the	  k-­‐th	  class	  and	  nk	  is	  the	  size	  of	  the	  k-­‐th	  class	  in	  the	  
training	  set.	  
	  

















Minimal	  errorw	  calculated	  for	  each	  feature	  selection	  method:	  
	  
	   Individual	   B&B	   Backward	   Forward	  
	   min	   sem	   min	   sem	   min	   sem	   min	   sem	  
LDC	   0.0322	   	  0.0014	   0.0314	   0.0013	   0.0344	   0.0013	   0.0352	   0.0012	  
QDC	   0.0388	   	  0.0017	   0.0336	   0.0014	   0.0406	   0.0014	   0.0426	   0.0013	  
KNNC	   0.0359	   	  0.0014	   0.0256	   0.0011	   0.0317	   0.0013	   0.0320	   0.0013	  
SVC	   0.0355	   	  0.0013	   0.0285	   0.0013	   0.0314	   0.0014	   0.0313	   0.0013	  
	  
Individual:	   best	   individual	   N	   feature	   selection	  method;	   B&B:	   branch	   and	   bound	   feature	   selection	  
method;	   Backward:	   greedy	   backward	   elimination	   method;	   Forward:	   greedy	   forward	   selection	  
method;	  min:	  minimal	  value	  of	  mean	  weighted	  error;	  sem:	  standard	  error	  of	  mean;	  LDC:	  the	  linear	  
classifier;	  QDC:	  the	  quadratic	  classifier;	  KNNC:	  the	  k-­‐nearest	  neighbour	  classifier;	  SVC:	  support	  vector	  











Table 1. Minimal Value of Mean Weighted Errors for each Feature Selection Method.




























Wnt5a (Millipore) 5 ng/mL
50 ng/mL
XAV939 5 uM
Medium FGF (ng/mL) BMP4 (ng/mL) IGF
SH2 1 10 100 ng/mL
2 10 100 ng/mL
1 20 100 ng/mL
2 20 100 ng/mL
3 10 100 ng/mL
3 10 100 ng/mL
SH3 1 10  - 
2 10  - 
1 20  - 
2 20  - 
3 10  - 
3 10  - 
Medium IGF SAG (Millipore) SB431542 (Tocris) SU5402 DMH1 bFGF BMP4
MB1 100 ng/mL 1 uM 5 uM 5 uM 0.5uM  -  - 
MB2 100 ng/mL 1 uM 5 uM  -  - 1 ng/mL 20 ng/mL
Medium Chir DM SB431542
CR 3 uM 2uM 0.5uM
Supplemental Table 1. Microscopy live imaging settings
CHAPTER 76
Supplemental Table 2. Time-lapse imaging settings
Objective: 63x Glyc
Channels; eGFP, mCherry and Brightfield
Image Interval: 10 minutes
Imaging Time: 64 hours
Z-Stack: 3x 5µM
Binning: 2x2
Autofocus: Brightfield, compensated with zstack
Stitching: 3x3 (x: 59.6 y: 35.371)
Channels: Exposure (ms) EM gain Intensity
eGFP 125 1100 4,3
mCherry (txred) 125 1100 4,3
Brightfield 30 1100 5
Supplemental Table 2. Small molecules/Growth factors screened
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It is critical to gain knowledge in the underlying mechanisms that control human cardiovascular 
developm ent, which helps us to understand the onset of congenital cardiovascular diseases, 
and to develop optimal culture methods for efficient in vitro cardiomyocyte differentiation 
from hPSCs, which are of interest for final translational applications including screening 
and efficacy assays for disease modelling, drug discovery and development, personalized 
medicine, and perhaps the regeneration of cardiovascular tissues for therapeutic purposes. 
In this thesis, we show how genetic manipulation of human pluripotent stem cells (hPSCs), 
resulting in the genomic integration of a fluorescent protein encoding sequence at the 
locus of a key cardiac transcription factor, allows us to visualize and isolate early pre-
cardiac progenitors subpopulations, and to study the molecular mechanisms involved in 
their further differentiation to cells of the cardiac lineage, including smooth muscle cells, 
endothelial cells, and cardiomyocyte subtypes. 
IN VITRO MODELLING OF HUMAN CARDIAC DEVELOPMENT AND 
DIFFERENTIATION USING HUMAN PLURIPOTENT STEM CELLS:
HOW DO FLUORESCENT GENE REPORTERS CONTRIBUTE?
Temporal gene expression analysis upon cardiac differentiation
Multiple fluorescent PSC reporter lines have been generated to visualize the derivation 
of cardiomyocytes and to isolate PSC-derived cardiac cells, including cardiac progenitor 
populations and subtypes of cardiomyocytes (reviewed in Chapter 2). Most in vitro 
fluorescent reporter PSC lines described in literature so far, contain a construct that follows 
the expression of a single gene during differentiation, such as cardiomyocyte reporters 
NKX2-5eGFP/w, NCX-1-eGFP, or alpha-MHC-mCherry human embryonic stem cell (hESC) 
lines[1, 2] [3]. These lines allow visualization and isolation of the reporter-expressing cells, 
cardiac progenitors and cardiomyocytes. On the basis of a fluorescent marker, this allows 
screening molecules for their role in cardiomyocyte differentiation or the identification 
of subtype specific cell surface markers. This was used for example to identify SirpA and 
VCAM1 as cell surface markers for early cardiomyocytes[3, 4]. In Chapter 3 we describe 
the generation of a dual fluorescent cardiac reporter MESP1mCherry/wNKX2-5eGFP/w hESC line, 
that allows the derivation of early pre-cardiac mesoderm progenitors to be monitored and 
their further lineage-committed differentiation to the cardiac lineage, marked by NKX2-5-
eGFP expression. Comprehensive gene expression analysis of MESP1 cardiac derivatives 
in Chapter 4 showed how cardiac differentiation of these progenitors recapitulates the 
early steps of in vivo heart development, through the sequential expression of key cardiac 
transcription factors and the expression of functional and structural genes in definitive 
cardiomyocytes, providing evidence of how such a dual fluorescent cardiac reporter line is 
useful for studying early human cardiac differentiation. Several previous studies have shown 
global gene expression patterns upon cardiac differentiation from hPSCs[5, 6]. However, 
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in our study, we could follow the formation of cardiac cells, deriving from an early pre-
cardiac-committed lineage, and decreasing the risk for upregulation of genes that are 
not associated with the cardiac lineage, and thus increasing the predictive value of this 
model. Putative (co)-regulators of cardiac lineage commitment were identified based on 
their temporal enrichment levels compared to MESP1 negative derivatives, their DNA-
binding properties, and their predicted interaction with other established key regulators. 
We identified homeobox domain containing HOXB2 as potential interactive transcriptional 
partner for MEIS1, MEIS2, and PBX3. This was strengthened by a similar expression level 
pattern throughout cardiac differentiation. MEIS1, MEIS2, and PBX3 all share regulating roles 
in either heart looping and chamber septation stages, and cardiac lineage commitment. 
Moreover, MEIS1, MEIS2, HOXB2, and PBX3 were all upregulated upon Mesp1 induction in 
mouse ESCs, indicating that they all act downstream of Mesp1 (REF). Other DNA binding 
transcription factors that showed significant stage-specific expression levels upon cardiac 
differentiation, included zinc finger protein containing transcription factors ZNF503, ZFHX3, 
ZFPM1, and ZFPM2, that may have co-regulatory roles for established cardiac transcription 
factors or repressive roles on transcription of key genes involved in other lineages, such 
as skeletal[7]. Such a repressive role of other lineages could perhaps be of importance for 
enhancing cardiac lineage commitment.
Additionally, in our study, shortly after temporal MESP1 expression, we also identified 
significant enriched temporal expression levels of DNA binding genes with an unknown role 
in heart development at present, including ZBTB16, RUNX1T1, and TSHZ2. The exact role of 
such putative regulators, which may include lineage commitment, but could also govern cell 
cycle regulation, proliferation, and/or survival, has to be determined in functional studies, 
such as in vitro inducible knock down studies in MESP1-lineage specific derivatives, or 
downstream target gene analysis using chip sequencing. Functional studies are a prerequisite 
for definite conclusions about gene function and role. 
In the study of Paige et al.[5], they show how temporally regulated gene expression levels 
are accompanied by programmed temporal alterations in chromatin structure, which 
distinguishes key regulators of cardiovascular development from other genes. Currently, 
further studies are being performed to look into chromatin patterns and dynamics of 
genomic regions of transcription factors that we identified in this thesis, which would 
strengthen their role in cardiac differentiation and/or lineage commitment. This will be 
discussed briefly below.
Future Directions: integrative (epi)genetic analysis upon cardiac lineage 
commitment.
Despite increasing knowledge on key cardiac transcriptional regulators, signalling molecules 
and interacting pathways, the role of epigenetic alterations, such as chromatin dynamics 
and histone modification patterns, are largely unknown, but are proposed to play crucial 
roles in gene regulation during mammalian heart development and differentiation[5, 8]. 
General discussion
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Recent studies have indicated that large-scale reorganization of the genome, and epigenetic 
mark transitions, such as histone modification patterns, coincide with the commitment of 
pluripotent cells to differentiation[5, 8, 9].  A large integrative study on (epi)genetic and 
transcriptional regulation during early cardiac differentiation, dual fluorescent cardiac gene 
reporter MESP1mCherry/w-NKX2-5eGFP/w hESCs would therefore be useful, and is currently being 
performed. It allows the isolation of defined cardiac (progenitor) populations in order to 
study gene- and cell type-specific chromatin dynamics, histone modifications patterns, 
RNA expression levels, and enhancer regions. The increasing development and technical 
improvements of molecular genomic technologies, such as ATAC-sequencing (studying 
chromatin availability), ChiP-sequencing, and Chromosome Conformation Capture Hi-C 
(studying chromatin conformations) will allow us to integrate large genomic and epigenetic 
information at stage-specific cardiac cell types, in order to contribute to the identification of 
stage-specific (distal) enhancer- and/or promoter elements and unidentified (co)-regulators 
of cardiac lineage commitment, and potentially also of cardiac subtype diversification. 
Current pitfalls that require improvement: high costs are made, and high cell numbers are 
required for such studies. Nonetheless, interest into large integrative (epi)genetic studies is 
growing. 
Screening signaling molecules upon cardiac lineage commitment
From a large number of differentiation studies we know that the inhibition of Wnt-pathway 
signalling, using distinct Wnt-pathway inhibiting molecules such as Xav939, is crucial for 
efficient differentiation of pre-cardiac mesoderm towards the cardiac lineage[10-12]. 
MESP1 expressing mesoderm progenitors may differentiate towards distinct lineages, 
including skeletal, hematopoietic, and cardiac lineages[13]. In order to determine how the 
presence and/or absence of distinct signaling molecules may induce pre-cardiac MESP1 
expressing mesoderm stage progenitors to further segregate towards the cardiac lineage, 
dual fluorescent cardiac gene reporter MESP1mCherry/w-NKX2-5eGFP/w hESCs is of excellent 
utility. In Chapter 3, we studied a selection of signaling molecules, which included small 
molecule Wnt-pathway inhibitor Xav939[12], TGF-β/act/Nodal antagonist SB431542, 
and BMP inhibitor Dorsomorphin. Besides the strong role for Wnt-pathway inhibition in 
efficient cardiomyocyte differentiation from mesoderm stage, none of the other inhibitors 
led to an increase in NKX2-5-eGFP expression, where TGF-β/act/Nodal inhibition even 
seemed to decrease cardiomyocyte differentiation, in contrast with previous literature 
describing an inhibitory role for TGF-β/act/Nodal signaling in mesoderm to cardiomyocyte 
differentiation[14, 15]. Such diverse effects could be highly dependent on ligand or small 
molecule concentration and timing, and in the case of growth factors, specific activity, 
which is rarely measured.  In addition, growth factor effects on cardiomyocyte sublineage 
commitment, may depend on the combinatorial presence of other cytokines so that it will 
be necessary to study the effects of a large number of growth factors or small molecules at 
middle- or high-throughput level (in 96-, 384- or 1536 well plates). For in vitro differentiation 
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assays, the additional use of cardiomyocyte subtype reporters, resulting in a multi-color 
differentiation study may be ideal. This would allow us to follow hPSC differentiation to 
mesoderm, followed by cardiac specification, and definite subtype derivation. Examples of 
cardiomyocyte subtype reporters, established in the NKX2-5eGFP/w hESC line, are discussed 
below (Chapter 6 and 7). 
The search for expandable early cardiac progenitor populations for 
translational applications
In order to generate large numbers of cardiomyocyte subtypes for many translational 
purposes, it would be advantageous to have cardiac lineage-committed progenitor 
populations, which can be expanded and further differentiated, under tight control, to large 
pure numbers of the required cardiac subtype. However, only a limited number of studies 
has shown the ability to maintain cardiac progenitors in their self-renewing developmental 
state, most with the limitation of a single expansion (reviewed in Birket et al.)[16].
There is a strong demand for the identification of specific cell surface markers that identify 
and can be used for isolation of hPSC-derived cardiac progenitor populations. In this thesis, 
we have identified the presence of previously described cardiac progenitors, based on 
ROR2, CD13 (ANPEP), PDGFRA and KDR, and SirpA and VCAM1 expression[4, 17]. However, 
the search for additional early cardiac-specific surface markers is still required, since ROR2, 
CD13, PDGFRA, and KDR showed a more broad mesoderm expression (Chapter 3). From 
our micro array analysis of MESP1-lineage derivatives in Chapter 4, we suggest potential 
novel surface marker proteins, based on their temporal-specific upregulated transcript 
levels. It will now be of importance to study their expression dynamics at protein level by 
antibody-binding experiments. Based on current knowledge of cardiac progenitor biology, a 
combinatorial expression of multiple surface markers may identify cardiac-lineage specific 
progenitors[4, 18, 19]. Thus, the exact genes and surface markers identifying critical cardiac 
progenitor populations remain to be defined. The next step will be to study their expandable 
capacity. In Chapter 7, we attempted to study the proliferative capacity of MESP1-mCherry 
expressing progenitors. A previous study described how they could expand an early hPSC-
derived cardiovascular progenitor population (expressing MESP1). Their expansion protocol 
was based on the inhibition of BMP and activin/nodal signalling, and the activation of Wnt 
signalling[20, 21]. Even though both progenitors seem to be at a similar developmental 
stage, we could not reproduce MESP1 progenitor maintenance in our hands. Moreover, we 
attempted a variety of other cytokines, including those that were described to be involved 
in NKX2-5 progenitor maintenance[21].
The expansion capacity of cardiac progenitors may be based on their developmental stage 
and the extracellular niche that they may require. More studies into signals required 




FLUORESCENT GENE REPORTERS FOR CARDIOMYOCYTE SUBTYPE 
DERIVATION
The identification of molecular regulators involved in cardiomyocyte subtype 
derivation.
In chapter 5 and 6, we describe the generation of two separate dual cardiomyocyte 
fluorescent hPSC reporter lines, either for the identification of ventricular or nodal-like 
cardiomyocytes, and to study molecular regulators important for their derivation. Both 
lines were generated in the previously described NKX2-5eGFP/w hESC line[3]. In chapter 6, we 
generated a reporter construct in which an atrioventricular-specific enhancer and a pan-
cardiac enhancer, that were previously identified to synergistically activate TBX3 expression 
in the atrioventricular conduction system of the developing mouse embryo, were coupled to 
a promoter element and fluorescent protein mCherry. This reporter construct was randomly 
integrated into the genome of NKX2-5eGFP/w hESCs through lentiviral delivery. 
The use of gene regulatory elements that have been identified through in vivo studies in 
other organisms, such as rodents, the zebrafish, and chick, is a common strategy for in 
vitro fluorescent reporter studies[22-24]. Likewise used the group of Laflamme, in order to 
identify PSC-derived nodal-like cardiomyocytes, a proximal promoter-enhancer region of 
the chicken GATA6 (cGATA6) gene that was earlier identified to be selectively activated in 
the atrioventricular (AV) node and the bundle of His of the adult mouse heart[24, 25]. hESC-
cardiomyoycte cultures were transduced with a lentiviral vector in which cGATA6 drives 
expression of enhanced green fluorescent protein (EGFP), resulting in the identification 
of cardiomyocytes with a nodal-like phenotype, evidenced by their action potential. 
Furthermore, they showed how ErbB antagonist AG1478 could enhance the differentiation of 
hESC towards nodal-like cardiomyocytes. Therefore, in our study, we exposed dual reporter 
TBX3e-mCherry-NKX2-5eGFP/w hESCs to AG1478, shortly after mesoderm formation. However, 
we failed to identify TBX3e-mCherry expressing cells. Also preliminary screening with a 
variety of other cytokines and small molecules did not show any positive cells. Although we 
think that the combinatorial use of both TBX3 enhancers with cardiomyocyte marker NKX2-5 
is of interest to study molecules involved in the derivation of nodal-like cardiomyocytes, we 
realized that our strategy could be biased by many biological and technical issues, including 
transgene silencing, mouse/human differences, or lack of activity of both enhancers in 
our system (technical issues are described below in more detail). It would be of interest to 
study a variety of other CCS-specific regulatory elements, or to report endogenous TBX3 
expression through a knockin or fusion strategy.
In chapter 6, we aimed to monitor and isolate hESC-derived ventricular cardiomyocytes by 
the generation of dual cardiomyocyte reporter MYL2w/T2A-mCherry-NKX2-5eGFP/w hESCs through 
an endogenous fusion strategy. Although from electrophysiology data on cardiomyocyte 
cultures we know that PSC differentiation often results in a predominantly ventricular fate, 
we could identify MYL2-mCherry expressing cardiomyocytes, only at low levels. This agrees 
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with previous studies using mouse and human MYL2 PSC reporter lines[22, 26] and from 
our microarray analysis of MESP1 derivatives (Chapter 3) we know that MYL2 starts to be 
significantly expressed around day 14 of differentiation. Moreover, as MYL2 levels in the 
adult heart are >2 fold upregulated compared with hPSC-CMs, and as MYL2 levels in hPSC-
CMs increase upon maturation (Ribeiro et al.[27] and Chapter 6), MYL2 may also be an 
interesting marker for measuring the degree of ventricular cardiomyocyte maturation. 
Although recent protocols, based on retinoic acid signalling, have been shown to drive hPSCs 
towards atrial fate[28, 29], fluorescent atrial reporter lines have not yet been developed. 
Genes of interest to target could include atrial-specific sarcolipin or COUPTF genes[29-31]. 
This would allow monitoring of a variety of other molecules possibly involved in atrial fate 
differentiation, and may contribute to optimize growth factor concentration and timing. The 
availability of high numbers of hPSC-derived atrial cardiomyocytes will be of interest for 
assay development for atrial-specific associated disease modelling and drug discovery and/
or toxicity[29].
Another strategy to obtain atrial- or ventricular specific cardiomyocytes could be based on a 
panel of surface markers being expressed, without the requirement of genetic modifications 
of hPSC lines.  The primary use of fluorescent reporter lines allows the isolation of 
cardiomyocyte specific cell types, which then may contribute to the identification of cell 
type specific surface markers that could be used for future subtype isolation.
The optimal strategy for the generation of a cardiac fluorescent reporter 
line should be carefully considered: biological/technical hurdles and new 
perspectives.
As mentioned before, prior to the generation of a fluorescent reporter line in hPSCs, it 
is important to consider the technical and biological hurdles that may be faced upon 
establishment of such a line. Comprehensive details are reviewed in Chapter 2. In this thesis, 
we show the generation of four distinct reporter lines, using different modification strategies. 
In Chapter 3, we generated a MESP1mCherry/w reporter line through the replacement of 
one allele with the coding sequence of fluorescent protein mCherry, allowing reporting 
the activity of the endogenous MESP1 promoter. mCherry is monomeric, has a reasonable 
brightness, and a fast maturing folding efficiency at 37 °C and a high photostability, optimal 
for long-term imaging studies[32]. Targeting was performed in the previously by Elliott et 
al. generated NKX2-5eGFP/w hESC line[3]. MESP1-mCherry expressing progenitors could 
be distinguished from NKX2-5-eGFP cardiac progenitors, due to their non-overlapping 
timing of expression, and the non-overlapping excitation and emission spectra of mCherry 
(excitation at 587 nm) and eGFP (excitation at 488 nm). In a similar matter, we made use of 
these distinguishing spectra when we generated the dual cardiac reporter hESC lines TBX3e-
mCherry-NKX2-5eGFP/w in Chapter 5 and MYL2w/T2A-mCherry-NKX2-5eGFP/w in Chapter 6. 
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Although we could not detect molecular abnormalities upon cardiomyocyte differentiation 
from MESP1mCherry/wNKX2-5eGFP/w hESCs, generating a knockin reporter line through gene 
replacement brings along the risk for haploinsufficiency defects. Therefore, we generated 
the MYL2w/T2A-mCherry-NKX2-5eGFP/w hESC line through a fusion knockin strategy, where we 
made use of the small viral T2A fusion peptide[33], which, upon activation of the MYL2 
promoter, results in the generation of one transcript, containing both MYL2 and mCherry 
coding sequences, and is later translated into two separate proteins. This latter strategy 
seems to have a great potential in stem cell fate reporter technology, especially with the eye 
on the generation of multicolour reporter lines. However, in hPSCs, there are few reports on 
the use of these small fusion peptides, thus technical hurdles may still exist. Although in our 
study, we show the presence of MYL2-mCherry expressing cardiomyocytes, the translation 
efficiency of both proteins was undefined. Another strategy would be to fuse a fluorescent 
protein directly the targeted gene, although this may affect gene function.
A less labour-intensive method to develop fluorescent reporter lines is the lentiviral delivery 
of a reporting construct. In Chapter 5 lentiviral transfection of NKX2-5eGFP/w hESCs, resulted 
in the random integration of the TBX3e-Hsp68-mCherry reporting construct into the hESC 
genome. However, as mentioned before, lentiviral integration into active genome sequences 
is random, and can be highly susceptible to transgene silencing due to surrounding regulatory 
elements or upon cardiac lineage differentiation (shown in Chapter 7). Positive controls to 
select correctly targeted clones is a prerequisite, but also labour-intensive.
Therefore, stem cell reporter technology requires technical improvements, including more 
efficient and less labour-intensive locus-specific targeting strategies  (perhaps through the 
use of the new advances in CRISPR/CAS technology), and through the identification of loci in 
the human genome that are not silenced upon cardiac-specific lineage differentiation[34-36]. 
However, it may not be a guarantee that such a “docking locus” may be active in every 
cardiac sub lineage that will be studied.
HUMAN PLURIPOTENT STEM CELL-DERIVED CARDIAC PROGENITORS 
AND CARDIOMYOCYTES: TRANSLATIONAL APPLICATIONS
The establishment of hPSC technology and advanced cardiomyocyte differentiation 
protocols has opened a new platform for cardiac development, tissue engineering, disease 
modelling, and drug efficacy and toxicity testing. There are still many hurdles that need 
to be taken before stem cell based therapies find its way in the clinic for the treatment 
of heart failure. In recent years the recognition for using hPSC-derived cardiomyocytes 
for disease modelling, drug discovery, and drug toxicity screenings has increased 
significantly. hPSC-technology aims to develop highly reliable animal-free pre-clinical drug 
discovery and safety pharmacology models that closely mimic the physiological human 
environment[37]. In particular, the availability of hiPSC models now makes it possible to 
generate human cardiomyocytes in vitro from both healthy individuals and from patients 
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with cardiac abnormalities[38]. A wide range of scientific studies has shown how in vitro 
hiPSC-cardiomyocyte models closely mimic their in vivo disease phenotype[39-41]. This 
allows the pharmaceutical industry to design and develop compounds on disease-specific 
human in vitro models[38]. Minimal qualifications that are necessary for hiPSC-CMs to be of 
interest for pharmaceutical industry is the high quality of cells, high purity, and high yields; 
all contributing to the high predictability and cost-effectiveness of the screening models to 
be developed. Advanced protocols to yield high numbers of cardiomyocytes are present 
and constantly subject to improvements[10, 11]. Furthermore, current issues that are 
being studied, which may be crucial for reliable prediction of drug efficacy and/or toxicity, 
are the immature nature of these cardiomyocytes[42], the lack of cardiomyocyte subtype 
purity[43], and the physiological conditions of cardiomyocyte models that may not reflect 
the in vivo adult heart. 
The combinatorial use of fluorescent reporters and high-content analysis in 
high-through-put screening assays
For cost-effective drug discovery, safety and toxicity screening assays, high-throughput 
screenings and high content analysis are required. Detailed opportunities for fluorescent 
reporters in such assays are described in Chapter 2. In Chapter 7 we show how a live fluorescent 
proliferation reporter in PSCs may be used to detect cardiac progenitor proliferation, 
available for high-content detection in a cardiomyocyte monolayer differentiation assay. 
Additionally, such an assay could be useful for studying cardiomyocyte proliferation, 
which could for example be of interest for therapies of the damaged heart. To note, the 
development of assay-specific automated imaging analysis software is a prerequisite for 
high-content screenings. The combinatorial use of such technologies may together be a 
powerful opportunity to develop biochemical and cell-based assays for compound efficacy 
and/or toxicity screenings. 
Future physiological relevant cardiac assays
The development of predictive physiological relevant in vitro cardiac assays for drug 
discovery and safety pharmacology is a whole new era to be explored in the short-term, 
especially since legislation to decrease adverse drug reactions  (pharmacovigilance) are 
being strengthened (Pharmacovigilance Legislation EU, effective since 2012), and new 
legislation is being developed to reduce the use of animal research in drug efficacy and risk 
management studies (Directive 2010/63/EU, effective since 2013).
Cardiotoxicity and safety pharmacology remain major concerns during drug development, 
with increased pro-arrhythmic potential being one of the main concerns. The pharmaceutical 
industry is challenged by the growing costs of research and development and cannot afford 
drug attrition in late phases of development or withdrawals of approved drugs[44]. hPSC-
CM based assays are predicted as a new paradigm for assessment of cardiac risk in humans. 
Assays may include action potential analysis, contraction rates and features, specific ion-
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current analysis, cell viability measurements, force of contraction measurements, sarcomeric 
organization, metabolic activity, cell size (e.g. hypertrophy), or activation of specific 
signalling pathways. Moreover, current protocols are mostly developed in a 2-dimensional 
matter. It may be of interest to develop complex 3-dimensional models, mimicking in vivo 
environment, consisting of a combination of multiple cell-types, such as endothelial cells, 
smooth muscle cells, fibroblasts, and cardiomyocyte subtypes. Also physical contraction and 
the presence of a haemodynamic blood flow may be of interest to develop in future assays. 
In addition, disease modelling and drug efficacy and toxicity may also be studied on organ-
system level, in the presence of a blood flow system, with the interplay of important organs, 
including liver, heart, and kidneys.
The FDA CiPA Initiative
One of the factors that currently drives the potential use of hPSC-CMs in drug development, 
is the FDA (U.S. Food and Drug Administration) initiative for a Comprehensive In Vitro 
Pro-arrhythmia Assay (CIPA). Its proposal is to increase the understanding of the 
electrophysiological mechanism behind pro-arrhythmic risk of drugs by the use of hPSC-CMs 
and in silico prediction models[45-48]. hPSC-CM based assays should be a new paradigm for 
assessment of clinical potential of Torsades de Pointes (TdP), a specific type of abnormal 
heart rhythm that can potentially lead to sudden cardiac death. Recent withdrawals of 
prescription drugs from clinical use because of unexpected side effects on the heart have 
highlighted the need for more reliable cardiac safety pharmacology assays. Block of the 
human Ether-a-go go Related Gene (hERG) ion channel in particular is associated with 
life-threatening arrhythmias[45], but assaying concomitant block of multiple ion channels 
appears to improve predictability of TdP arrhythmia, indicating the involvement of more ion 
currents[46]. For standardization, hPSC-CM assays should show a higher specificity and give 
less “false positives” than the current hERG assay (hERG channel overexpression in HEK293 
cells), leading to more sophisticated ECG modeling of drug effects in the future.
CONCLUDING REMARKS AND PERSPECTIVES
In this thesis, we aimed to decipher the molecular mechanisms important for early cardiac 
lineage commitment and further differentiation through the generation of human PSC 
fluorescent reporter lines. Here, the activity of cardiac progenitor and/or cardiomyocyte 
subtype specific genes was visualized and followed through fluorescent reporter proteins.
Knowledge of signals involved in cardiomyocyte differentiation from PSCs is growing 
rapidly, and efficient protocols are being developed. However, an in-depth understanding 
of key cardiac regulators, at epigenetic and genetic level, involved in cardiac (sub) lineage 
commitment is still sparse. The advanced development of new technologies and efficient 
differentiation protocols will allow us to discover how complex networks interrogate to 
form the developing human heart, composed of sublineages of cardiac cells. Cardiac 
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developmental biology is the basis for understanding the onset of congenital heart disease, 
and the development of predictive complex physiologically relevant cell-based assays for 
disease modelling, drug discovery and pharmacokinetics. In the end, the development 
of animal-replacing and highly predictive hPSC-derived cell-based assays is under high 
attention and promise, and currently underway.
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The establishment of human pluripotent stem cell (hPSC) technology and advanced 
cardiomyocyte differentiation protocols has opened a new platform for regenerative 
medicine, cardiac development, and assay development for tissue engineering, disease 
modelling, and drug toxicity testing. The need for these assays will be largely increasing 
in our nearby future, due to strengthened legislations, aiming at decreasing adverse drug 
reactions, and reducing the use of animal research in drug efficacy and risk management 
studies. Moreover, since the ability to generate patient- and disease- specific hiPSC lines, our 
health care system will slowly move towards the idea of personalized medicine, a model that 
aims at patient-specific medical treatments, based on genetic and biomarker information. 
Such a model can both lower costs and increase the quality of health care, and can therefore 
be of high importance for a sustainable health care system in our future.
In this PhD research
For pharmaceutical applications, it is important that cardiomyocyte-based assays are 
of highly predictive value. The use of cardiomyocyte subtypes in such assays could be of 
great importance, which may include atrial or ventricular cardiomyocytes, or cells of the 
cardiac conduction system. Moreover, the combination of different cardiomyocyte subtypes 
could also play a role in successful cellular transplantation therapies of the damaged heart. 
Therefore, it is of great interest to develop differentiation protocols that direct towards the 
generation of specific subtypes of cardiomyocytes. In this thesis, we describe the generation 
of fluorescent stem cell reporter lines to obtain insights into molecular mechanisms that play 
role in the formation of early cardiac progenitors and their commitment to cardiomyocyte 
subtypes. 
A comprehensive overview of existing fluorescent reporter lines and their developmental 
and translational applicability is given in Chapter 2. Further, we describe in Chapter 3 how the 
generation of a dual cardiac reporter MESP1mCherry/w NKX2-5eGFP/w hESC line allows us to study 
the formation of MESP1 expressing pre-cardiac mesoderm progenitors and their further 
commitment towards the cardiac lineage, in which key cardiac transcription factor NKX2-
5 becomes expressed. We show the characteristics of MESP1-expressing progenitors and 
their cardiac derivatives based on gene expression profiling and surface marker expression 
analysis (Chapter 3,4). In Chapter 4, we point towards putative cardiac (co)-regulators, 
based on their temporal expression profile upon cardiac differentiation, and their predicted 
protein-protein interaction with established key cardiac transcription factors. Functional 
experiments are required to identify their definite role. 
In Chapter 5 and 6 we describe the generation of dual cardiac reporters TBX3e-mCherry-
NKX2-5eGFP/w and MYL2-T2A-mCherry-NKX2-5eGFP/w hESC lines, aiming at obtaining either 
human nodal-like or ventricular cardiomyocytes in vitro, respectively. We discuss the 
technical and biological hurdles that we faced upon developing directed differentiaton 
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protcols towards nodal-like cardiomyocytes. Further, we showed how MYL2 expression 
levels in early ventricular cardiomyocytes were low, and did only increase after long-
term culture. Interestingly, we showed how MYL2 levels could be induced upon culture 
in maturation-inducing medium, which could indicate MYL2 as potential cardiomyocyte 
maturation marker.
Further, in Chapter 7, we showed how proliferation reporter Anillin, fused to fluorescent 
protein eGFP, could be used to visualize distinct phases of the cell cyle, including cell division. 
We indicate how the visualization of proliferation using such a marker, in combination with 
automated quantification software, could be of potential use for high-throughput screenings 
of molecules playing a role in cardiac progenitor development and/or cardiomyocyte 
regeneration.
In conclusion (Chapter 8), the innovation of advanced molecular technologies and 
efficient directed cardiomyocyte differentiation protocols will contribute to a better 
understanding of the complexicity of how epigenetics and transcriptional networks play a 
crucial role in cardiac lineage commitment and the onset of disease. In-depth knowledge 
into cardiomyocyte differentiation and development is a prerequisite for translational 




Hoe zit een hart in elkaar?
Het hart is het eerst werkende orgaan tijdens de ontwikkeling van zoogdieren, zoals de mens. 
Al vlak na de vorming brengt het met pulserende bewegingen de bloedstroom op gang, wat 
vervolgens zorgt voor de zuurstof- en voedingsstof voorziening van het gehele embryo. Een 
volwassen hart is complex en bestaat uit vier afzonderlijke hartkamers: twee hartboezems 
(de atria), en twee hartkamers (de ventrikels) (Figuur 1). Zuurstofrijk bloed stroomt vanuit 
de longen via het linkerboezem naar het linker ventrikel. Door de samentrekking van de 
dikke gespierde ventrikelwand, wordt dit bloed het lichaam in gepompt om de organen 
van zuurstof te voorzien. Zuurstofarm bloed komt vervolgens vanuit het lichaam in het 
rechterboezem terecht, en wordt via het rechterventrikel de longen in gepompt, zodat het 
bloed weer voorzien kan worden van zuurstof en terug naar het linkerboezem kan stromen. 
Het hart heeft een gespecialiseerd geleidingssysteem om te zorgen dat de verschillende 
kamers in de juiste volgorde samentrekken. De pacemakercellen van het hart geven de eerste 
prikkel en zorgen dat de twee boezems samentrekken. Dit signaal komt vervolgens binnen in 
de atrioventriculaire knoop (AV-knoop) en wordt na een korte vertraging doorgestuurd naar 
een bundel van vezels, die vertakt, en via Purkinje fibers verbonden is met de hartspiercellen 
van de ventrikels, die dan samentrekken. 
Figuur 1. Het volwassen hart met het bijbehorende geleidingssysteem. SAN: sinoatrial node. 
AVN: Atrioventricular node. CB: Common bundle/His Bundle. RA: right atrium. SCV: superior 
caval vein. LBB/RBB: left/right bundle branches. PF: Purkinje Fiber network. CS: coronary 
sinus. IVC: inferior vena cava. LV: left ventricule. MB: moderator band. PV: pulmonary vein. 
RV: right ventricle. Jongbloed et al. Differentiation 2012.
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Waarom doen we onderzoek naar de ontwikkeling van het hart?
De vorming en ontwikkeling van het hart is complex. Genetische afwijkingen spelen vaak al 
tijdens de vroege ontwikkeling een grote onderliggende rol in het ontstaan van hartziekten. 
Echter, soms komen afwijkingen pas tot uiting in een later stadium van het leven, zoals bij 
hevige inspanning of ouderdom. Daarnaast wordt het ontstaan van ziekten beïnvloed door 
omgevingsfactoren, zoals het gebruik van medicijnen. Om het ontstaan van hartziekten 
te kunnen voorkomen, en te genezen met de juiste medicijnen, is het van belang een 
gedetailleerd begrip te hebben van de ontwikkeling van het menselijk (humane) hart, en de 
reactie van het hart op specifieke fysiologische omstandigheden. Het gebruik van humane 
(ziekte)modellen is hiervoor een pré.
Kloppende hartcellen kweken in een schaaltje
Omdat het gebruik van humane embryo’s beperkt is, en in veel landen ethisch omstreden, 
worden vooral proefdieren en eenvoudige cel modellen gebruikt om deze vraagstukken te 
beantwoorden. Echter, vaak blijkt de stap tussen mens en dier groot. Helaas liggen goede 
humane onderzoeksmodellen niet voor het oprapen. Het kweken van humane hartcellen 
(cardiomyocyten) uit stamcellen biedt daarom een exclusieve oplossing.
Vanuit humane pluripotente stamcellen (hPSCs) zijn we tegenwoordig in staat grote 
hoeveelheden cardiomyocyten te kweken. Onder hPSCs verstaan we  embryonale stamcellen 
(hESCs) en geïnduceerde pluripotente stamcellen (hiPSCs). hESCs worden, sinds 1998, 
geïsoleerd uit een celklompje van een gerijpte bevruchte eicel, blastocyst genaamd, wat 
een overblijfsel is van IVF behandelingen. HiPSCs worden, sinds 2007, verkregen uit menig 
celtype van een volwassen mens door deze te “induceren” met een specifieke combinatie 
van genen, en zijn daarom ethisch minder omstreden. Uit hPSCs kunnen we bijna elke cel 
van het menselijk lichaam vormen door ze in een gecontroleerde omgeving een specifieke 
richting op te sturen met behulp van groeifactoren of chemische moleculen. 
Het kweken van cardiomyocyten uit hPSCs geeft ons een unieke kans om de embryonale 
ontwikkeling van het menselijke hart in een kweekschaal te kunnen bestuderen, en daarbij 
inzicht te krijgen in het ontstaan van aangeboren hartziekten. 
Klinische toepassingen van in vitro gekweekte hartcellen
Sinds we in staat zijn hiPSCs te creëren, bieden deze in vitro verkregen hartcellen ook 
een groot potentieel voor toekomstige klinische en farmaceutische toepassingen, zoals 
celtransplantaties ter vervanging van beschadigd hartweefsel, en het opzetten van 
effectiviteits/toxiciteit-screening-experimenten (assays) voor de ontwikkeling van nieuwe 
medicijnen. 
De ontwikkeling van een nieuw medicijn begint bij de ontdekking van nieuwe stoffen 
in het “drug discovery” stadium in het laboratorium. Na uitvoerige testen op cel- en 
proefdiermodellen, wordt een strenge selectie van medicijnen getest in klinische studies 
op mensen. Echter, juist in dit stadium blijken veel medicijnen niet voor elke patiënt 
effectief te zijn, of voor negatieve bijwerkingen te zorgen, die in het initiële “drug 
discovery” stadium niet zijn opgepikt in de huidige screenings-modellen. Daarnaast zijn er 
momenteel veel medicijnen op de markt met negatieve bijwerkingen voor het hart, zoals 
veel chemotherapeutische middelen, die mogelijk in een goede toxiciteits-screening-assay 
uitgeselecteerd hadden kunnen worden.
De vraag naar betrouwbare assays zal daarom in de toekomst steeds groter worden, mede 
door de aanstelling van nieuwe wetgeving waarbij het gebruik van proefdieren verminderd 
zal moeten worden, en de wetgeving rondom de gevaren voor negatieve bijwerkingen 
van medicijnen steeds strenger wordt. Daarnaast zal de medische wereld zich, dankzij de 
ontwikkeling van patiënt-specifieke iPS modellen, steeds meer gaan richten op patiënt-
specifieke medicatie (personalized medicine), wat zal kunnen leiden tot een hogere kwaliteit 
van zorg en een bijdrage aan de ontwikkeling van een duurzaam zorgsysteem, wat van groot 
toekomstig belang zal zijn in een vergrijzende maatschappij. 
Dit promotieonderzoek
Voor farmaceutische toepassingen is het van belang dat de voorspellende waarde van 
cardiomyocyte assays zo betrouwbaar mogelijk is, waarbij het gebruik van specifieke 
cardiomyocyte subtypes van invloed kan zijn. Voorbeelden van subtypes zijn: hartkamer-
(ventrikel) of hartboezem-(atrium) cellen, of cellen van het geleidingssysteem, zoals 
pacemakercellen (Figuur 1). Daarnaast is gebleken uit cel transplantatie studies in dieren, 
dat de combinatie van de juiste celtypes van groot belang is voor vervanging van beschadigd 
hartweefsel. Om deze redenen is het voor zowel de academische als de farmaceutische 
wereld interessant om uit humane pluripotente stamcellen een zuivere populatie van 
specifieke subtypes hartcellen te verkrijgen. In deze thesis beschrijven we de generatie van 
fluorescente stamcel reporter lijnen als methode om inzicht te verkrijgen in de moleculaire 
signalen die een rol spelen bij de vorming van specifieke voorlopercellen en cardiomyocyte 
subtypes.
Hoofdstuk 1 geeft een korte inleiding in de mogelijkheden van het gebruik van pluripotente 
stamcellen en translationele toepassingen. We geven aan hoe kennis, verkregen uit 
embryonale diermodellen zoals de muis, heeft geleid tot de ontwikkeling van efficiënte 
in vitro kweekprotocollen voor het verkrijgen (differentiëren) van cardiomyocyten uit 
humane pluripotente stamcellen. We beschrijven hoe genetische netwerken* in vivo, 
op een vergelijkbare manier van belang zijn tijdens de vorming van cardiomyocyten in 
vitro, wat aangeeft hoe nauw onze in vitro kweekmodellen overeenkomen met in vivo 
ontwikkelingsbiologie.
*: genetische netwerken bestaan uit een netwerk van eiwitten (de producten van genen), 




Hoofdstuk 2 geeft een uitgebreid overzicht van de tot nu toe beschreven in vitro 
fluorescente pluripotente stamcel reporter lijnen* die gebruikt zijn voor het visualiseren en 
verkrijgen van in vitro hartcellen. Daarnaast beschrijven we de potentie van fluorescente 
reportermodellen voor de ontwikkeling van assays op het gebied van medicijnontwikkeling, 
toxiciteitscreenings, en ziektemodellen, en laten we zien hoe fluorescente reporters gebruikt 
kunnen worden in transplantatiestudies van het hart.
*: in een fluorescente stamcel lijn is het DNA van een stamcel gemodificeerd; we vervangen 
de genetische code van een gen dat we willen volgen, door de genetische codering voor een 
fluorescent eiwit. Wanneer het specifieke gen actief wordt in een specifiek celtype, zal het 
fluorescente eiwit worden aangemaakt en zichtbaar worden in een cel.
Hoofdstuk 3 beschrijft de opbouw van een duale fluorescente reporter lijn: een MESP1mCherry/
wNKX2-5eGFP/w humane embryonale stamcel lijn. Deze lijn maakt het mogelijk om tijdens in 
vitro cardiomyocyte differentiatie, de ontwikkeling van vroege voorlopercellen van het hart 
(en het gen MESP1 tot expressie brengen, nog voordat het hart is gevormd) te volgen, om 
vervolgens  te bestuderen welke moleculaire mechanismen een rol spelen bij hun verdere 
differentiatie naar cardiomyocyten (en het gen NKX2-5 tot expressie brengen, wat aanwezig 
is kort voor de vorming, en in het gehele hart). De expressie van bovengenoemde genen in 
specifieke celtypes kan gevolgd worden doordat ze gekoppeld zijn aan de genetische codes 
voor fluorescente eiwitten, zoals mCherry of eGFP. Deze eiwitten worden bij een specifieke 
lichtlengte aangeslagen (excitatie), en zenden vervolgens een eiwit-specifiek lichtpatroon 
uit (emissie).
In dit hoofdstuk isoleren en karakteriseren we MESP1-mCherry positieve voorloperellen 
op basis van de aanwezigheid van het mCherry eiwit. We kijken naar de expressie van 
celmembraan markers en naar het algehele genexpressie patroon. We identificeren 
specifieke verschillen met eerdere in vitro studies in muis, en geven daarmee het belang 
aan van in vitro studies in menselijke celtypes.
In Hoofdstuk 4 differentiëren we geïsoleerde MESP1 voorlopercellen naar NKX2-5 positieve 
hartcellen en meten we genexpressie profielen op verschillende tijdstippen, waaronder dag 
5, dag 7, dag 10 en dag 14. Op basis van temporale genexpressie patronen, voorspellende 
eiwit-eiwit interacties met huidige belangrijke transcriptionele genen, en hun DNA bindende 
eigenschappen, identificeren we potentiele (co-)regulators van cardiomyocyte differentiatie. 
Functionele experimenten zullen moeten uitwijzen wat de rol van deze potentiele regulators 
zal zijn. 
In Hoofdstuk 5 beschrijven we de opbouw van een duale TBX3e-mCherry-NKX2-5eGFP/w 
hESC reporter line. TBX3 komt in het hart specifiek tot expressie in het geleidingssysteem. 
Voor studies naar afwijkingen binnen dit systeem is het van belang om de moleculaire 
mechanismen die een rol spelen bij het ontstaan van conductiesysteem cardiomyocyten 
te begrijpen. Met behulp van deze duale reporter lijn hoopten we TBX3 positieve 
cardiomyocyten te verkrijgen voor verdere karakterisatie. Echter, het blijkt moeilijk te zijn 
om met de huidige kennis van het ontwikkelende geleidingssystem in vivo, protocollen 
op te zetten om in vitro pluripotente stamcellen te differentiëren naar deze celtypes. Ook 
technische uitdagen kunnen bij de afwezigheid van TBX3 positieve cardiomyocyten een rol 
hebben gespeeld.
Hoofdstuk 6 beschrijft de opbouw van een derde duale cardiale reporter: MYL2-T2A-
mCherry-NKX2-5eGFP/w hESCs. Deze reporter lijn maakt het mogelijk om specifiek ventriculaire 
cardiomyocyten te isoleren, door middel van co-expressie van MYL2 en NKX2-5. In deze 
studie laten we zien dat de ventriculaire marker MYL2 pas laat tijdens differentiatie hoog 
tot expressie komt, en daarom mogelijk een graadmeter is voor cardiomyocyte maturatie. 
Daarnaast laten we zien dat maturatie-gerelateerde factoren als dexamethason, IGF-1, en 
thyroid hormoon MYL2 expressie in cardiomyocyten verhogen.
In Hoofdstuk 7 bestuderen we het delingsvermogen (proliferatie capaciteit) van MESP1 
positieve voorlopercellen van het hart. Het verkrijgen van een oneindige voorraad van 
voorlopercellen kan van grote interesse zijn voor transplantatiestudies of voor grootschalige 
experimentele assays. We laten met time-lapse imaging zien hoe we de proliferatie van deze 
voorlopercellen kunnen visualiseren met behulp van het eiwit Aniline, wat in deze assay 
gekoppeld is aan het fluorescente eiwit eGFP. Daarnaast laten we zien hoe de ontwikkeling 
van automatische kwantificatie software, in combinatie met deze fluorescente proliferatie 
reporter, mogelijk interessant kan zijn voor grootschalige proliferatie-inducerende screening 
assays op hartvoorlopercellen of cardiomyocyten.
Hoofdstuk 8 omvat de algemene discussie van dit proefschrift. We concluderen dat de 
ontwikkeling van nieuwe moleculaire technieken en efficiënte differentiatie protocollen 
gaat bijdragen aan een beter begrip van de complexiteit van epigenetische en genetische 
netwerken die cruciaal zijn voor de embryonale ontwikkeling van het humane hart, 
bestaande uit een groot aantal subtypes hartcellen.  Kennis van humane hartontwikkeling 
is de basis voor het verkrijgen van inzicht in het ontstaan van aangeboren en verkregen 
hartafwijkingen, en de ontwikkeling van voorspellende complexe fysiologisch-relevante 
cardiomyocyte-assays voor menselijke ziektemodellen, medicijn ontwikkeling- en 
testsystemen. De ontwikkeling van proefdiervrije en hoog-voorspellende hPSC-gebaseerde 
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